

Ref. No.: F.02(355)/RMSCL/ED (P) EMPANELMENT/DTL/NIB-12/2022/2277 Dated :-27.07.2022

RAJASTHAN MEDICAL SERVICES CORPORATION LTD. (A Govt. of Rajasthan Undertaking) Gandhi Block, Swasthya Bhawan, Tilak Marg, Jaipur – 302005, India Tel No: 0141-2228066, 2228064, E-mail: edp<u>rmsc@nic.in</u>

E-BID FOR THE RATE CONTRACT CUM EMPANELMENT OF ANALYTICAL TESTING LABORATORIES FOR THE TEST AND ANALYSIS OF DRUGS (Two Years RC ending on 31.08.2024)



!! सर्वे सन्तु निरामयाः!!

LAST DATE OF SUBMISSION OF ONLINE BIDS	16.08.2022 & 6.00 PM
DATE AND TIME OF OPENING OF ONLINE TECHNICAL BIDS	17.08.2022 & 11.00 AM





RAJASTHAN MEDICAL SERVICES CORPORATION LTD.

(A Govt. of Rajasthan Undertaking)

Gandhi Block, Swasthya Bhawan, Tilak Marg, Jaipur – 302005, India

Phone No: 0141-2228066, 2228064 CIN:U24232RJ2011SGC035067 Website: www.rmsc.health.rajasthan.gov.in E-mail : <u>edprmsc@nic.in</u>

Ref. No.: F.02(355)/RMSCL/ED (P) EMPANELMENT/DTL/NIB-12/2022/2277 Dated :-27.07.2022

Notice Inviting E-Bids

e-bids for rate contract cum empanelment for following items are invited from eligible bidders as detaited below:-

S.No	Item Name	Ref.No	UBN	Estimated	Time &
	/Description			Value Rs.	Last date
				in Crore	for bid
					submission
1.	Analysis of Drugs & Medicine	F.02(355)/RMSCL/ED (P) EMPANELMENT/DTL/NIB- 12/2022/2277 Dated :- 27.07.2022	MSC2223SLRC00044	7.13	Upto 6.00 P.M. on 16.08.2022

Other particulars of the bids may be visited on the procurement portal <u>http://eproc.rajasthan.gov.in</u>, <u>http://sppp.rajasthan.gov.in</u> and <u>www.rmsc.health.rajasthan.gov.in</u> and may be downloaded from there.

Executive Director (Procurement) RMSCL



RAJASTHAN MEDICAL SERVICES CORPORATION LTD. RAJASTHAN

e-BID FOR RATE CONTRACT CUM EMPANELMENT OF ANALYTICAL TESTING LABORATORIES FOR THE TEST AND ANALYSIS OF DRUGS

(Rate contract for two years ending on 31.08.2024)

Bid Reference	:	F.02(355)/RMSCL/ED (P) EMPANELMENT/DTL/NIB-12/2022/2277 Dated :- 27.07.2022
Pre- bid conference	:	29.07.2022 at 12.30 P.M.
Date and time for downloading bid document	:	27.07.2022 from 06.00 PM
Last date and time of submission of online bids	:	16.08.2022 at 6.00 PM
Date and time of opening of Online technical bids	:	17.08.2022 at 11.00 PM
Cost of the Bid Document	:	Rs. 2360/- (Including GST@ 18%)
RISL Processing Fees	:	Rs. 1180/- (Including GST @ 18%)
Bid Security	:	Rs. 20000/-



RAJASTHAN MEDICAL SERVICES CORPORATION LTD. RAJASTHAN

E-BID FOR RATE CONTRACT CUM EMPANELMENT OF ANALYTICAL TESTING LABORATORIES FOR THE TEST AND ANALYSIS OF DRUGS (Rate contract for two years ending on 31.08.2024)

"CONFIDENTIALITY IS THE ESSENCE OF THIS BID" 1. LAST DATE FOR RECEIPT OF BIDS, BID FORM FEES, BID SECURITY & RISL PROCESSING FEES

- a) E-Bids [In Two Separate Bids (Technical Bid & Price Bid)] Shall Be Received Till 06.00 PM on 16.08.2022 By The Rajasthan Medical Services Corporation Ltd, For The Rate contract cum Empanelment Of Analytical Testing Laboratories For The Test And Analysis Of DRUGS (Rate contract for two years ending on **31.08.2024**) in English language. Proposal received after the closing date and time shall not be considered.
- b) The bids shall be valid for a Period of 120 days from the date of opening of Technical Bid and prior to the expiration of the bid validity the Bid Inviting Authority may request the Bidders to extend the bid validity for another period of 30 days. The Bidder may refuse extension of bid validity without forfeiting the Bid Security deposit. No refund of tender fee is claimable under any circumstances to any of the bidder.
- c) The e-Bids will be received on web-portal of e-procurement of GoR i.e. http://eproc.rajasthan.gov.in. Every Bidder will be required to pay the Bid form fee Rs. 2360/- (Including GST@ 18%) for downloaded forms from the website, Bid Security as applicable in Bid condition no. 6 and processing fee of Rs. 1180/- (Including GST@ 18%) of R.I.S.L. through three separate prescribed challans (*format enclosed in Annexure- I*) in any branch of the Punjab National Bank into Account no. 2246002100024414 throughout the country upto 16.08.2022 or through D.D. / Bankers Cheque in favour of M.D. RMSCL (tender fees and Bid Security) and MD, RISL (tender processing fees) physically in the office of RMSCL by 6.00 PM on 16.08.2022 The bidders shall submit/upload scanned copy of all the challans in Technical Bid. Bids will be opened only after ensuring receipt of Bid fees, processing fees and Bid Security. In the absence of Bid fees, processing fees and Bid Security the Bids shall be rejected and shall not be opened.



2. Eligibility Criteria for Empanelment :-

- (1) Drug Testing Laboratories should have valid Approval for carrying out test on drugs under the Drugs and Cosmetics Act, 1940 and Rules there under. Three years standing in the test & analysis of drugs/chemicals or food items and the lab shall be entitled for empanelment for the categories of items for which lab has bidded and having approval. Bid is invited from approved Drugs Testing Laboratories situated in India.
- (2) The laboratory should be GLP compliant under the provisions of Drugs and Cosmetics Act, 1940 and Rules there under and should hold schedule L-1 certificate or should have approval from Drug Control Department and NABL accreditation with proper scope of accreditation to undertake testing of drugs, surgical and sutures.
- (3) The laboratory should have an average annual turnover of not less than Rs.
 50 Lakh for past preceding three years (2018-19, 2019-20 & 2020-21 or 2019-20, 2020-21 & 2021-22).

Only audited accounts would be considered provisional accounts would not be considered in any case.

- (4) The lab should have undertaken test and analysis of drugs and supplies of similar nature of drugs for at least three government institutions/corporation/reputed manufacturers of drug formulations.
- (5) The lab should not stand banned / debarred or blacklisted by any State or Central Government or its Organizations or its procurement agencies on the due date of bid submission. If a bidder or an approved bidder will be found defaulter for concealing this fact, then following actions may be taken.
 - (i) Bid rejection
 - (ii) Bid Security forfeiture
 - (iii) Agreement rejection
 - (iv) Performance Security forfeiture
 - (v) Blacklisting
- (6) The laboratory and its responsible persons should not have been convicted under the provisions of applicable laws with regard to the activities and



conduct of the laboratory.

(7) The laboratory should have all necessary instruments/equipments/machines for testing of drugs with minimum three functional HPLC's.

3 TECHNICAL BID

The Bidder must furnish the following in technical bid.

- Bidders are allowed the option to quote for anyone item or more items as mentioned in bid (list of medicines proposed to be analyzed tested as at Annexure-VII).
- b. The bidders shall submit/upload in Technical Bid scanned copies of all the challans / DD/ BC of deposits of Bid form fees, RISL processing fee and Bid Security Money.
- c. Attested Photocopy of Analytical approval duly renewed up to date, issued by the State Licensing Authority.
- d. Compliance of Schedule L-1 of Drugs & Cosmetics Rules, 1945 (GLP certificate) and Copy of NABL accreditation with scope for testing of drug formulations.
- Documentary evidence of having analysed Drugs, <u>chemicals</u>, foods and other <u>items</u> for last three years with a statement in the proforma as given in Annexure III.
- f. Attested copy of certificate of GST registration.
- g. GST return 31.03.2022 or latest Months
- h. Non- Conviction Certificate by the State Licensing Authority/ competent authority.
- Annual turnover statement for 3 year i.e. (2018-19, 2019-20 & 2020-21 or 2019-20, 2020-21 & 2021-22) certified by the practicing Chartered Accountant with UDIN No.
- j. Copies of the Balance Sheet and Profit and Loss Account for three years i.e. (2018-19, 2019-20 & 2020-21 or 2019-20, 2020-21 & 2021-22) duly audited or certified by the practicing Chartered Accountant. No provisional balance sheet or Profit and Loss account would be entertained.
- k. The following information in the form given in Annexure IV (a) to IV (d).
 - a) The list of permanent technical qualified personnel employed in the laboratory with proof of their qualifications and relevant approvals.



- b) The list of sophisticated instruments available in the laboratory.
- c) Micro Biological facilities available in the laboratory.
- d. List of Reference Samples along with their date of procurement and quantities.
- e. In the case of Non- Pharmacopoeial Products the Method of Analysis Should be appended to the Report, especially if the sample is declared as "Not of the Standard Quality".
- 1. A declaration in the proforma given in Annexure V duly signed and Notarized.
- m. Details of Laboratory in Annexure VI.
- n. A copy of PAN issued by Income Tax Department.
- o. Documentary evidence for the constitution of the company / concern.
- p. At any time prior to opening of price bid, RMSC either at their own initiate or in response to clarification requested by prospective tender, may modify tender by issuing an amendment. Such amendments shall be uploaded on e-Proc site and will be part of the tender.
- q. A bidder has to fill up the checklist enclosed at Annexure VIII indicating the infrastructure and testing facilities available in the lab.

4 **PRICE BID:**

The price bid shall also be known as financial document and every bidder will be required to submit its price in excel format attached to the bid document (BOQ). **BOQ template must not be modified/ replaced by the bidder and the same should be uploaded after filling the relevant** columns, else the bid is liable to be rejected for the particular item. Bidders are allowed to enter the bidder name and values only. The bidder should quote rate for the complete tests as applicable to the item. The rate for sterility test for sterile products should also be quoted separately at last entry of BOQ. Any type of uncalled clarifications on prices or rebates shall not be accepted.

5 <u>OPENING OF TECHNICAL BID AND FINANCIAL BID</u> <u>EVALUATION</u>

The technical bids would be opened on scheduled date and time on eproc website i.e. <u>https://eproc.rajasthan.gov.in</u>. After technical evaluation physical inspection of the laboratories may be carried out by the designated team. Thereafter financial bids would be opened of those bidders who are found



finally responsive on technical criteria. The acceptable rates for analysis will be decided and communicated accordingly.

6 <u>BID SECURITY</u>

The Bid Security Money Deposit shall be Rs. 20,000/- (Rs Twenty Thousand only) The Earnest Money Deposit shall be paid in through separate prescribed challans (format enclosed in Annexure-I) in any branch of the Punjab National Bank Account no. 2246002100024414 throughout country up to 16.08.2022 or through D.D. / bankers cheque in favour of M.D. RMSCL physically in the office of RMSC by 6.00 PM on 16.08.2022 Bid Security Deposit in any other form will not be accepted

The Bids submitted without sufficient Bid Security will be summarily rejected. The Bid Security will be forfeited, if the Bidder withdraws its Bid after last time & date fixed for receiving bids or in the case of a successful Bidder, if the Bidder fails to sign the contract agreement or fails to furnish the security deposit within the stipulated time.

Government undertaking PSU are exempted from Bid Security deposition on producing the certificate issued by the competent authority.

7 GENERAL CONDITIONS

- 1. The details of the Drugs, to be analysed shall be given in Annexure VII.
- 2. The Bidder should quote the rates for complete analysis of each product and name of test to be performed, methodology to be used for each test. However wherever rates for individual test are demanded, they should be furnished accordingly in BOQ.
- 3. The rates quoted should be exclusive of taxes, though the applicable taxes are to be mentioned separately.
- 4. The rates quoted and accepted will be binding on the Bidder for the stipulated period and on no account any revision will be entertained till the completion of the rate contract period including extensions, if any given.
- 5. Analytical Laboratory, which also has its manufacturing activity, if empanelled by RMSC, then Samples of its own manufacturing unit shall not be sent to its empanelled laboratory for testing.
- 6. The laboratory will not be permitted to outsource any test to any other laboratory.
- 7. RMSCL shall have the right to cause inspection of the laboratory by the members of its technical committee before opening of price bid and subsequently as and when considered appropriate and based on the finding, the Bidder may be disqualified or de-empanelled, as the case may be.
- 8. Conditional tender will not be accepted and rejected immediately.
- 9. GST at applicable rate should be mentioned by the bidder where evere applicable.



8. ACCEPTANCE OF BID

- The Bid evaluation committee formed by Managing Director, Rajasthan Medical Services Corporation Ltd. will evaluate the Bid with reference to various criteria specified in bid document.
- 2. The Managing Director, Rajasthan Medical Services Corporation Limited reserves the right to accept or reject any BID for any one or more of the items Bided for, without assigning any reason.
- 3. The Managing Director, Rajasthan Medical Services Corporation Limited has the right to accept one or more bids depending on the volume of analytical work.

9. AGREEMENT

- 1. The agreement with empanelled laboratories shall remain valid up to 31.08.2024. If Required period of contract can be extended upto 3 months on same rate, terms and condition without any prior consent of the bidder and shall be binding on approved bidder.
- 2. RMSCL will issue letters of Intent (LOIs) to successful bidders and bidders who are empanelled will have to execute an agreement on a nonjudicial stamp paper of value **Rs. 500** /- (Stamp duty to be paid by the Bidder), in favour of Managing Director, Rajasthan Medical Services Corporation Limited Jaipur within 15 days from the date of receipt of the intimation to them informing that their BIDs have been accepted. The format of agreement will be issued by RMSCL. (Annexure IX)
- **3.** The Bidder shall not, at any time, assign, sub-let or make over the contract or the benefit therefore or any part thereof to any other person or persons whatsoever.
- 4. All notices or communication relating to, or arising out of this agreement or any of the terms thereof shall be considered duly served on or given to the Bidder if delivered to him or emailed on its email address or left at the premises, places of business or abode.

10. PERFORMANCE SECURITY

The successful Bidders shall be required to pay a Performance Security of Rs.
 50,000/- (Rs Fifty Thousand only) in the form of demand draft at the time of



execution of the agreement. Performance security will be refunded three month after expiry of rate contract subject to successful completion of services.

11. COMPLETE ANALYSIS & REPORTING CONDITIONS

1. (a) On empanelment and entrustment of the job, the Analytical Laboratory should furnish the test reports within:

- i. 10 days from the receipt of the sample in case of Tablets, Capsules, Pessaries, Ointments, Powder and Liquid Oral Preparations (non – sterile products)
- ii. 21 days from the receipt of the sample in the case of I.V. Fluids and injectables and other items requiring test for sterility.
- b) All the tests mentioned in IP/BP/USP/Drugs & Cosmetics Act. etc. including addendus, (as the case may be) should be carried out for each and every sample. The results obtained in the test should be mentioned in numerical value (wherever possible). However this condition will not apply when only specific testing is called for/desired on any particular sample. If any drug is not included in the pharmacopeia at the time of bid opening and letter on it is including in any pharmacopeia the drug should be tested as per pharmacopeia specification.
- c) Mentioning only "COMPLIES" or "PASSES" in the result column of the report would be treated as incomplete report, if the result has some numerical value.
- d) Every test report must have remarks either as "Standard Quality" or "Not of Standard Quality". Any ambiguity/cutting in reports will not be accepted (clear mention of "standard quality or not of standard quality" should be stated in bold letters and crossing/cutting of one of these will not be accepted).
- e) Reports should be in A4 size (8.27" X 11.69") paper of good quality.
- f) Report should be issued on form 39 A and should have S. no., name of drug sample, code no., batch no., mfg. date, exp. date, description of tests, protocol of test specified & applied, findings & results obtained and should be signed by person-in-charge of testing. In case of Not of Standard Quality Reports the reports shall be release on Pink/Red colored paper for easy identification of NOSQ drugs.
- g) Reports should be attached along with Spectra / Chromatography data



sheets, if applicable and it will be considered incomplete if spectra or chromatograms are not attached.

- All test reports of each batch of sample should be submitted to the RMSC in triplicate. In case of failure of a sample, the result should be communicated immediately to the Executive Director (Q.C.) through phone / e-mail and the report should be sent along with protocol.
- 3. If in any circumstances (like break down of instrument, non-availability of reference standard etc.) the Analytical Laboratory is unable to undertake analysis for a sample, the same should be reported within 24 hours of receipt of such a sample by phone or E-mail and the sample should be returned to the Executive Director (Quality Control), Rajasthan Medical Services Corporation Limited, Jaipur after taking necessary telephonic or mail consent. In case of inability of laboratory to undertake the testing, a penalty of 25% of testing charges applicable for that product / products will be recovered.
- 4. If placebo or standard test procedure of any product is required the same should be demanded within 48 hours with return request. Period lapsed/taken in providing placebo or standard testing procedure will be condoned from prescribed time limit for that sample.
- 5. If any sample is received in a damaged condition by the laboratory, the sample should not be analyzed and the information should be sent immediately to the E.D. (Quality Control), Services Rajasthan Medical Corporation Limited Jaipur by Fax or E-mail.
- 6. The Managing Director, Rajasthan Medical Services Corporation Limited or his authorized representative(s) has / have the right to inspect the laboratories of the Bidders who have submitted BIDs, before taking any decision regarding empanelment. Similarly, the Managing Director, Rajasthan Medical Services Corporation Limited or his authorized representatives may also inspect any empanelled laboratory, at any point of time during the continuance of the BID and terminate / cancel its empanelment or any orders issued to the laboratory, not to entrust any further testing job to the laboratory based on facts brought out during such inspections.
- The successful lab shall have to make own arrangement for collection of sample, from RMSC Headquarters.



8. It will be sole discretion of RMSC to allot the samples to any empanelled lab in case when there are more than one lab approved for an item. (One or more Laboratories may be empanelled by this tender.)

12. PAYM ENT PROVISIONS

- 1. No advance payment towards any analysis will be made to the empanelled Bidder.
- 2. No payment will be made for the incomplete analysis or incomplete report. Deliberate omission of any critical test will be viewed seriously and shall invite action against the laboratory as deemed fit by RMSCL.
- 3. Payments towards the analysis of Drugs will be made as per approved rate plus tax on it will be along with Tax at the prevailing rate as applicable at the time of payment.
- 4. GST shall be applicable as per prevailing rates notified by the Government.

13. PENALTIES

- 1. If the successful Bidder fails to execute the agreement and deposit security amount within the time specified or withdraws the BID after intimation of the acceptance of the BID or owing to any other reasons, is unable to undertake the contract, the empanelment will be cancelled and the Earnest Money amount deposited by the Bidder shall stand forfeited in favour of the Rajasthan Medical Services Corporation Limited. Such Bidder(s) will also be liable for all damages sustained by the Rajasthan Medical Services Corporation Limited due to breach of BID conditions. Such damages shall be assessed by the Managing Director, Rajasthan Medical Services Corporation Limited whose decision shall be final and binding.
- 2. After entering into Rate contract, if the laboratory does not as per the terms and conditions, it may be disqualified to participate in the BID for the period as decided by RMSCL.
- 3. To assess the correctness of the test results being given by the Empanelled laboratories, samples at random, would also be sent to the Government Analyst for testing and if any variation is found the result would be informed to empanelled laboratories. If there is any gross variation in the analytical reports furnished by the empanelled laboratories (either pass or fail) with Government



Lab for 3 times in assay test and 4 times for any other specification, in a year, the empanelled laboratory shall be considered for blacklisting for a period as considered proper after following the due process.

- 4. If it is revealed that the analytical Laboratory is involved in any form of fraud and collusion with the suppliers of Rajasthan Medical Services Corporation Limited, the Analytical Laboratory will be black listed for a period considered suitable. The Bidders shall also be liable for action under criminal law and the matter will be notified to the concerned Director of Drugs Control for suitable action against them under Drugs & Cosmetics Act & Rules.
- 5. The Managing Director, Rajasthan Medical Services Corporation Limited will be at liberty to terminate, the empanelment of any laboratory either wholly or in part at one month's notice without assigning any reasons. The Bidder will not be entitled for any compensation whatsoever in respect of such termination.
- 6. In all matters pertaining to the BID, the decision of the Managing Director, Rajasthan Medical Services Corporation Limited shall be final and binding.
- 7. (i)If the laboratory requires an extension in time for submission of test report, on account of occurrence of any hindrance it shall apply in writing for extension on occurrence of hindrance but not after the stipulated date of *furnishing the test report*.
 - (ii)The Executive Director (QC)/ Drug Controller/ADC (QC) may extend the testing period with or without liquidated damages in case they are satisfied that the delay in the submission of test reports is on account of any hindrances, he shall apply in writing for extension on occurrence of hindrance but not after the stipulated date of submission of report. Reasons shall be recorded.
 - (iii)Extension in testing period:- In case of extension in the testing period with liquidated damages the recovery shall be made on the basis of following percentages of *testing charges* which the Bidder has failed to submit:-
 - (a) Delay upto one fourth period of the prescribed testing period; 2.5%



- (b) Delay exceeding one fourth but not exceeding half of the prescribed testing period; 5%
- (c) Delay exceeding half but not exceeding three fourth of the prescribed testing period; 7.5%

(d) Delay exceeding three fourth of the prescribed testing period; 10%Note: Fraction of a day in reckoning period of delay in *furnish the test report* shall be eliminated if it is less than half a day. The maximum amount of liquidated damages shall be 10%.

iv. If, at any time during the continuance of this Agreement, the *laboratory* has, in the opinion of the Purchaser, delayed in submitting any test report, by the reasons of any riots, mutinies, wars, fire, storm, earthquakes, tempest or other exceptional cause, on a specific request made by the laboratory, the time for submitting test report may be extended by the *RMSCL* purely at his discretion for such period as may be considered reasonable. No further representation from the *laboratory* will be entertained on this account.

14. <u>CORRECTION OF ARITHMETIC ERRORS:</u>

Provided that a financial bid is substantially responsive, the procuring Entity will correct arithmetical errors during evaluation of Financial Bids on the following basis:

- (i) If there is a discrepancy between the unit price and the total price that is obtained by multiplying the unit price and quantity, the unit price shall prevail and the total price shall be corrected, unless in the opinion of the Procuring Entity there is an obvious misplacement of the decimal point in the unit price, in which case the total price as quoted shall govern and the unit price shall be corrected;
- (ii) If there is an error in a total corresponding to the addition or subtraction of subtotals, the subtotals shall prevail and the total shall be corrected; and.
- (iii) If there is a discrepancy between words and figures, the amount in words shall prevail, unless the amount expressed in words is related to an arithmetic error, in which case the amount in figures shall prevail subject to clause (a) and (b) above.



If the Bidder that submitted the lowest evaluated bid does not accept the correction of errors, its Bid shall be disqualified and its Bid Security shall be forfeited or its Bid Securing Declaration shall be executed.

15. <u>GRIEVANCE REDRESSAL DURING EMPANELMENT PROCESS:</u>

The Designation and address of the First Appellate Authority is MD, NRHM.

The Designation and address of the Second Appellate Authority is Secretary to Government, Medical & Health and Family Welfare, Govt. of Rajasthan.

i. Filling an appeal

If any Bidder or prospective bidder is aggrieved that any decision, action or omission of the Procuring Entity is in contravention to the provisions of the Act or the Rules of the Guidelines issued there under, he may file an appeal to First Appellate Authority, as specified in the Bidding Document within a period of ten days from the date of such decision or action, omission, as the case may be, clearly giving the specific ground or ground on which he feels aggrieved:

Provided that after the declaration of a Bidder as successful the appeal may be filed only by a Bidder who has participated in procurement proceedings: Provided further that in case a Procuring Entity evaluates the Technical Bids before the opening of the Financial Bids, an appeal related to the matter of Financial Bids may be filed only by a Bidder whose Technical Bid is found to be acceptable.

- **ii.** The Officer to whom an appeal is filed under Para (1) shall deal with the appeal as expeditiously as possible and shall Endeavour to dispose it of within thirty days from the date of the appeal.
- **iii.** If the officer designated under Para (1) fails to dispose of the appeal filed within the period specified in Para (2), or if the Bidder or prospective bidder or the Procuring Entity is aggrieved by the order passed by the First Appellate Authority, the Bidder or prospective bidder or the Procuring Entity, as the case may be, may file a second appeal to second Appellate Authority specified in the Bidding Document in this behalf within fifteen days from the expiry of the period specified in Para (2) or of the date of



receipt of the order passed by the First Appellate Authority, as the case may be.

iv. Appeal not to lie in certain cases

No appeal shall lie against any decision of the Procuring Entity relating to the following matters, namely:-

(a) Determination of need of empanelment;

(b) Provision limiting participation of Bidders in the Bid process; (c) The decision of whether or not to enter into negotiations;

(d) Cancellation of a empanelment process;

(e) Applicability of the provisions of confidentiality.

v. Form of Appeal

(a) An appeal under Para (1) or (3) above shall be in the annexed Form along with as many copies as there are respondents in the appeal.

(b) Every appeal shall be accompanied by an order appealed against, if any, affidavit verifying the facts stated in the appeal and proof of payment of fee.

(c) Every appeal may be presented to First Appellate Authority or Second Appellate Authority, as the case may be, in person or through registered post or authorised representative.

vi. Fee for filling appeal

(a) Fee for first appeal shall be rupees two thousand five hundred and for second appeal shall be rupees ten thousand, which shall be non-refundable.

(b) The fee shall be paid in the form of bank demand draft or banker's cheque of a Scheduled Bank in India payable in the name of Appellate Authority concerned.

vii. Procedure for disposal of appeal

(a) The First Appellate Authority or Second Appellate Authority, as the case may be, upon filling of appeal, shall issue notice accompanied by copy of appeal, affidavit and documents, if any, to the respondents and fix date of hearing.

(b) On the date fixed for hearing, the First Appellate Authority or Second Appellate

Authority, as the case may be, shall,-

(i) Hear all the parties to appeal present before him; and



(ii) Peruse or inspect documents, relevant records or copies thereof relating to the matter.

(c) After hearing the parties, perusal or inspection of documents and relevant records or copies thereof relating to the matter, the Appellate Authority concerned shall pass an order in writing and provide the copy of order to the parties free of cost.

(d) The order passed under sub-clause (c) above shall be placed on the State Public procurement Portal.

16. <u>COMPLIANCE WITH THE CODE OF INTEGRITY AND NO</u> <u>CONFLICT OF INTEREST:</u>

Any person participating in a empanelment process shall-

- a) Not offer any bribe, reward or gift or any material benefit either directly or indirectly in exchange for an unfair advantage in procurement process or to otherwise influence the procurement process;
- b) Not misrepresent or omit misleads or attempts to mislead so as to obtain a financial or other benefit or avoid an obligation;
- c) Not indulge in any collusion, Bid rigging or any-competitive behaviour to impair the transparency, fairness and progress of the procurement process;
- d) Not misuse any information shared between the procuring Entity and the Bidders with an intent to gain unfair advantage in the procurement process;
- e) Not indulge in any coercion including impairing or harming or threatening to do the same, directly or indirectly, to any part or to its property to influence the procurement process;
- f) Not obstruct any investigation or audit of a procurement process;
- g) Disclose conflict of interest, if any; and
- h) Disclose any previous transgressions with any Entity in India or any other country during the last three years or any debarment by any other procuring entity.

17. Conflict of interest:-

The Bidder participating in a bidding process must not have a Conflict of Interest.

A Conflict of interest is considered to be a situation in which a party has interests that could improperly influence that party's performance of official duties or responsibilities, contractual obligations, or compliance with applicable laws and regulations.



I. A Bidder may be considered to be in Conflict of interest with one or more parties in bidding process if, including but not limited to:

a. Have controlling partners/shareholders in common; or

b. Receive or have received any direct or indirect subsidy from any of them; or

c. Have the same legal representative for purposes of the Bid; or

d. Have a relationship with each other, directly or through common third parties, that puts them in a position to have access to information about or influence on the Bid of another Bidder, or influence the decisions of the Procuring Entity regarding the bidding process; or

e. The Bidder participates in more than one Bid in a bidding process. Participation by a Bidder in more than one Bid will result in the disqualification of all Bids in which the Bidder is involved. However, this does not limit the inclusion of the same subcontractor, not otherwise participating as a Bidder, in more than one Bid; or

f. The Bidder or any of its affiliates participated as a consultant in the preparation of the design or technical specification of the Goods, Works or Services that are the subject of the Bid; or

g. Bidder or any of its affiliates has been hired (or is proposed to be hired by the Procuring Entity as engineer-in-charge/ consultant for the contract.

18. JURISDICTION

 In the event of any legal dispute arising out of the BID such dispute would be subject to the jurisdiction of the Civil courts within the city of Jaipur only.+

19. <u>APPLICABILITY OF RULES</u>

Besides above conditions all the provisions of RTPP Act 2012 & RTPP Rules 2013 shall be applicable.

Managing Director Rajasthan Medical Services Corporation



Acknowledgement	Q. Cashier/Officer	Acknowledgement
For Bank use only	For Bank use only	
Address for communication	Di	Address for communication
Signature		Signature
Name of the Depositor		Name of the Depositor
Ainouni (in woras). x		Amount (in words): ₹
A second (in monda), 3		
Total		Total
Total amount		* 1
	Commission ₹ 0 0 0 0 0 - 0 0	10*
t	Total fee pavable ₹	20 *
50*		50 *
		100 *
500 *		* 000
1000 *		1000 *
Denomination ₹ Ps Chq No Date of Chq Name of Bank ₹ Ps	Ps Chq No Date of Chq Name of Bank ₹ Ps	iomination ₹
	Cheque Deposit:	Cash Deposit:
Mobile No.		Mobile No.
Type of Deposit Select any one out of - J ender Pees/EMID/SD/ Telloet Processing lecs/Others	Select any one out of - 1 ender rees/EMID/SD/1 ender 1 rocessing fees/Others	posit
		Lender Ket. No.
		Supplier Name
Sum lier Name		DETAILS OF THE SUPPLIER
	DD MM YY	
	Date of Deposit	
Institute ID RMSCJ - AC NO. 224000210002411	RMSCJ - A/c No. 2246002100024414	Institute ID RM
U	Rajasthan Medical bervices corporation, surpri-	Institute Name Raj
Institute Name Rajasthan Medical Services Corporation, Jaipur	atten Modical Convince Corporation Jainur	
Branch		Branch
punjab national bank Dist. No.	punjab national bank DIST. NO.	
	Bank Copy	
	AUTION: USE "FORIDIK MENO OF ITOM IN FRANCES AND THE TOP OF THE PROPERTY OF TH	TON : ODE TOTAL



ANNEXURE- II Ref. Clause No. 2 (3),

3(h)

ANNUAL TURN OVER STATEMENT

Т	he Annual		Turnover	of
M/s	M/s		for the past three	years are
given bel	ow and certified that the statem	ent is true an	d correct.	
S.No.	Years		Turnover in Lacs (Rs)
1	2018-19			
2	2019-20			
3	2020-21			
	Total	Rs.		Lacs
Ave	erage turnover per annual	Rs.		Lacs
		Or		
S.No.	Years		Turnover in Lacs (Rs)
1	2019-20			
2	2020-21			
3	2021-22			
Total		Rs.		Lacs
Average turnover per annual		Rs.		Lacs

Date:

Siganture of Auditor/ Chartered Accountant

Seal: UDIN No.

(Name in Capital)



ANNEXURE III Ref. Clause No: 3 (e) PROFORMA FOR PERFORMANCE STATE MENT (for a period of last 3 years)

Name	of	the	Laboratory
Address:			
Types of Samples	Analysed	No. of Samples A	Analysed during
	(2018-1	9, 2019-20 and 2020	0-21 or 2019-20, 2020-21, 2021-22
01. Tablets / Caps	ules / Pessari	es/Dry Powders	
02. Injectables			
03. Liquid Prepara	ations		
04. Ointments / Cr	reams / Gels		
05. Others (Specif	y)		
06. Surgicals (Spe	cify item nar	nes)	
07. Sutures (Speci	fy types)		
08. Implants			
09. Devices			
			Signature : Date : Name of the Lab :

Office Seal :



ANNEXURE – IV (a) Ref. Clause No: 3 (j) (a) PERSONNEL IN QC DEPARTM ENT

Name of the Technical Staff approved by State Licensing Authority along with his Designation, Highest Qualification, Experience (Experience relevant to analysis of drugs/surgical/sutures)

Signature :

Date :

Nam e of the Lab :

Office Seal :



LIST OF SOPHISTICATED EQUIPMENT/INSTRUMENT/APPARATUS AVAILABLE IN THE LAB

S.No.	Name of the Equipme	nt Make &	Date of	Date of
Approv	ved			
	Instruments / Apparatus	Description	Installation last Validation	for testing of drugs from
State				
1:				

licensing

Authority

since.....

Signature :

Name of the Lab :

Date :

Official Seal:



ANNEXURE – IV (C) Ref. Clause No: 3(j) (c)

FACILITIES IN THE MICROBIOLOGICAL SECTION

I. LIST OF STOCK CULTURES AVAILABLE

II. LIST OF EQUIPMENT / APPARATUS AVAILABLE WITH DATE OF INSTALLATION, make and approval from State Licensing Authority to permit microbiological testing in the Lab.

Signature :

Name of the Lab :

Date :

Official Seal:



ANNEXURE – IV (d) Ref. Clause No: 3(j) (d)

LISTOF REFERENCES SAMPLES ALONG WITH THEIR DATE OF PROCUREMETN AND QUANTITIES

Signature :

Name of the Lab :

Date :

Official Seal:



Affidavit

(on Non Judicial Stamp of Rs.500/-)

ANNEXURE – V Ref. Clause No: 3(k)

DECLARATION FORM

1.	I (Name of the Bidder) S/O	, Age	_, resident of	f, am
	proprietor /Partner/Director	r havin	g our	office
	at	and the appro	oved drug tes	ting laboratory
	at	do hereby	declare that I	have carefully
	read all the conditions of BID of Ra	ajasthan Medic	al Services Co	prporation Ltd.,
	Jaipur, for the BIDs floated for	empanelment	of approved	drugs testing
	laboratories for analysis of drugs.	(Rate contra	nct for two ye	ears ending on
	31.08.2024) and shall abide by all the	he conditions se	et forth thereir	1.

- 2. I further declare that I possess valid approval for testing of all the drugs/surgicals & sutures for which Price Bid have been submitted by me/us in Cover B and permission on Form 37 have been obtained for testing of these items from State Licensing Authority where ever applicable.
- That the approval to test drugs/surgical & sutures have been obtained on Form
 37 bearing No.______which is valid/renewed up to______.
- 4. That the Bidder firm is a proprietorship/Partnership/Pvt. Ltd./ltd. firm and following are the other partners/directors:-

S.No. Name of Partner/Director Age Present & Permanent Address

 That our laboratory/Firm/Company does not stand blacklisted /debarred or banned on any ground either by Bid Inviting Authority or Govt. of Rajasthan on the date of bid submission.

Our laboratory/Firm/Company also does not stand blacklisted, debarred or banned on the ground of **wrong reporting of test results** or on the ground of submission of fake or forged documents or false information / facts, by any State or Central Government or by its central drug procurement agencies, on the date of bid submission for supply of drugs/medicines in India.



That I/We have carefully read all the conditions of bid in Ref. No.: F.02(355)/RMSCL/ED (P) EMPANELMENT/DTL/NIB-12/2022/2277 Dated :-27.07.2022

6. That we have testing facilities as per testing parameters mentioned in Annexure VII and quoted for products as given below:-

Sr No.	Quoted item Code No. (as per mention in Annexure-VII)
1.	For Example NRD-1
2.	
3.	

- 7. For the empanelment of analytical testing laboratories for the test and analysis of DRUGS (Rate contract for two years ending on **31.08.2024**) for Rajasthan medical services corporation and accept all conditions of bid, including amendments if any.
- 8. I/ we hereby declare under Section 7 of Rajasthan Transparency in Public Procurement Act, 2012. that:
 - a. I/we possess the necessary professional, technical, financial and managerial resources and competence required by the Bidding Document issued by the Procuring Entity;
 - b. I/we have fulfilled my/our obligation to pay such of the taxes payable to the Union and the State Government or any local authority as specified in the Bidding Document;
 - c. I/we are not insolvent, in receivership, bankrupt or being wound up. not have my/our affairs administered by a court or a judicial officer, not have my/our business activities suspended and not the subject of legal proceedings for any of the foregoing reasons;
 - d. I/we do not have, and our directors and officers not have, been convicted of any criminal offence related to my/our professional conduct or the making of false statements or misrepresentations as to my/our qualifications to enter into a procurement contract within a period of three years preceding the commencement of this procurement process, or not have been otherwise disqualified pursuant to debarment proceedings;
 - e. l/we do not have a conflict of interest as specified in the Act, Rules and the Bidding Document, which materially affects fair competition;
- 9. Our complete address for communication with phone no.:- -----



10.	E mail address :
11.	Bank detail for e banking :-
	Name of account holder
	Full name of Bank with Branch
	A/c no. with full digits
	IFSC code

(Deponent)

Signature :

Date :

Name of the Lab :

Office Seal :

Verification

IDesignation)
Affirm on oath that the contents/information from para 1 to 10 as mentioned above,
are true & correct to the best of my knowledge and nothing is hidden. I also declare
on oath, that if any information furnished by me as above is found wrong, false,
forged or fabricated; the Corporation will be at liberty to cancel the Bid and forfeiting
the Bid Security deposit and or performance security, for which I shall be solely
responsible and the laboratory / firm may be Debarred/Banned/ prosecuted for the
same

(Name of Deponent & Signature)

ATTESTED BY NOTARY PUBLIC



DETAILS OF LABORATORY

1.	Name of the Laboratory & Full Address :	
	Phone No (landline)	:
	Fax	:
	E-mail	:
2.	Other Branches & their Address (if any) :	
3.	Whether the firm has it own manufacturing unit?	:
	If yes give details of address, license number etc.	
4.	Date of Inception :	
5.	Approval No. & Date	:
6.	Issued by :	
7.	Valid up to :	
8.	Schedule L-1 certificate its no. and date of issue (GLP) or	:
9.	(i) NABL Accreditation no. & date(ii) Scope of Accreditation(iii) Its validity.	
10.	Name of the authorized signatory :	
11.	Specimen Signature of the authorized Signatory	:
12.	Names & Specimen Signatures of the Approved technical Staff who are authorized to sign the test reports	:



ANNEXURE –VII Ref: Clause no. 3 (a),7(1)

NOTE:-

- Bidders have to mention quoted item code in annexure V for which have testing facility as per testing parameters.
- Bidders are advised to carefully go through the testing parameters and in case of any suggestion for change in parameters it may be submitted at least one day in advance to pre-bid meeting. No suggestion for change in parameters would be entertained after pre-bid meeting.
- Test parameters to be carried out for analysis of each item are mentioned below:-

C Ma	Dung Call	Itom Nomo		Test nonemptons to be serviced out
S.No	Drug Code	Item Name		Test parameters to be carried out
1.	NRD-4	Glucosamine 750mg and	1	Description
		Methylsulfonylmethane 200mg	2	Identification (by HPLC)
		Capsule/Tablet		Glucosamine
				Methylsulfonylmethane
			3	Average net content
			4	Disintegration or Dissolution (by HPLC)
				Glucosamine HCL/Methylsulfonylmethane
			5	Uniformity of Weight
			6	0 0
			7	Assay (by HPLC)
				Glucosamine
				Methylsulfonylmethane
2.	NRD-5	Racecadotril Cap. IP 100mg	1	Description
		8	2	Identification (by HPLC)
			3	Average net content
			4	Dissolution (by HPLC)
			5	Related substances (by HPLC)
			6	Uniformity of Weight
			7	Contents of Packaged Dosage Forms
			8	
3.	NRD-6	Rabeprazole 20mg Enteric Coated	1	Description
5.	INIXD-0		2	Identification (by HPLC)
		+Levosulpiride 75 mg SR Cap.		Rabeprazole
				Levosulpiride
			3	Average net content
			4	Dissolution (by HPLC)
			4	
				Rabeprazole Acid Medium
				Phosphate Buffer
				Levosulpiride
				1st Point
				2nd Point
				3rd Point
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Rabeprazole
				Levosulpiride
4.	NRD-7	Acitretin 10 mg Cap. IP	1	Description
			2	Identification A (by UV)
				Identification B (by HPLC)
			3	Average net content
			4	Dissolution (by UV)
			5	Related substances (by HPLC)
			6	Uniformity of Content (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	Assay (by HPLC)
5.	NRD-8	Acitretin 25 mg Cap. IP	1	Description
5.		rational 20 mg cup. II	2	Identification A (by UV)
				Identification B (by HPLC)
			3	Average net content
			4	Dissolution (by UV)
			5	Related substances (by HPLC)
			6	Uniformity of Weight
	L	1	0	Chirofinity of Weight



			7	Contents of Packaged Dosage Forms
			8	Assay (by HPLC)
б.	NRD-9	Alectinib 150 mg Cap.	1	Description
			2	Identification (by HPLC)
			3	Average net content Disintegration or Dissolution (by HPLC)
			4 5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
7.	NRD-11	Anti-Oxidants Cap. (Beta Carotene-10	1	Description
<i>.</i> .		mg,Vit-E 25mg,Vit-C 100 mg,Copper 1.5	2	Identification
		mg, Managanese 1.5 mg,Zinc 7.5	3	Beta Carotene (by UV)
		mg,Selenium 150 microgram)		Vitamin E (by UV)
		ing, Selemun 150 iniciogram)	4	
			5	Vitamin C (by Chemical)
			6	Copper (by ICP MS)
			7	Manganese (by ICP MS)
			8	Zinc (by ICP MS)
			9	Selenium (by ICP MS)
			10	Average Fill
			10	Uniformity of weight
				Disintegration time
			12	
			13	Contents of Packaged Dosage Forms
			14	Assay:
			15	Beta Carotene (by UV)
			16	Vitamin E (by UV)
			17	Vitamin C (byChemical)
			18	Copper (by ICP MS)
			19	Manganese (by ICP MS)
			20	Zinc (by ICP MS)
				-
			21	Selenium (by ICP MS)
8.	NRD-12	Aprepitant Cap. IP 125/80mg	1	Description
		Capsule/Tablet Kit (each kit contains 1 capsule/Tablet of 125mg & 2 capsule/Tablet of 80mg)	2	Identification A (by UV) Identification B (by HPLC)
			3	Average net content
			4	Dissolution (by UV)
			5	
			6	Uniformity of Weight
			7	Contents of Packaged Dosage Forms
			8	
9.	NRD-14	Calcium Dobesilate Cap. 500MG	1	Description Identification (by HPLC)
			2	Average net content
			4	Disintegration or Dissolution (by HPLC)
			5	
			6	
			7	Assay (by HPLC)
10.	NRD-18	Ceritinib Cap. 150mg	1	Description
			2	Identification (by HPLC)
			3	Average net content
			4	
			5	Uniformity of Weight Contents of Packaged Dosage Forms
			7	
11.	NRD-19	Clomipramine Cap./Tab. IP 25 mg	1	Description
11.		ciompranine cap., rab. ii 25 iig	2	
			3	Average net content
			4	Related substances (by HPLC)
			5	<u> </u>
			6	Uniformity of Weight
			7	Contents of Packaged Dosage Forms
10	NDD 20	Customering Cont ID 100	8	Assay (by UV)
12.	NRD-20	Cyclosporine Cap. IP 100 mg	1	Description Identification (by HPLC)
				Water
			3	Average net content
			5	Dissolution (by HPLC)
	1		6	
			0	Contents of Packaged Dosage Forms



				1
10	NDD 01		8	Assay (by HPLC)
13.	NRD-21	Dacarbazine Inj. USP 200 mg (DTIC)	1	Description
			2	Identification A by UV
			3	Identification B by HPLC
				Identification c
			4	рН
			5	5-Aminoimidazole-4-carboxamide hydrochloride
			6	by HPLC Related Substances (by HPLC)
			6	Bacterial Endotoxins
			7	
			8	Sterlity
			9	Particulate Matter
			10	Assay by UV
14.	NRD-22	Danazol cap. IP 100mg	1	Description
			2	Identification A (by IR)
			3	Average net content
			4	Uniformity of weight
			5	Dissolution (by UV)
			6	Contents of Packaged Dosage Forms
			7	Assay: (by HPLC)
15.	NRD-24	Formetrol 12mcg + Budesonide 400 mcg.	1	Description
10.	11112 21	Powder for Inhalation	2	Identification (by HPLC)
			2	Formetrol
				Budesonide
			3	Acceptance Criteria
				Average Fill
			4	
			_	Disintegration Time
			5	Number of deliveries per container
			6	
			7	Contents of Packaged Dosage Forms
			8	Assay: (by HPLC)
				Formetrol
				Budesonide
			9	Microbial Contamination
				Total aerobic count
				Total fungal count
				E. coli
1.0	NIDD 05		1	
16.	NRD-25	Indacaterol and Glycopyronium inhalation	1	Description
		powder 110/50 mcg Hard Capsules	2	Identification (by HPLC)
				Indacaterol
				Glycopyronium
			3	Acceptance Criteria
			4	Average Fill
				Disintegration Time
			5	Number of deliveries per container
			6	Uniformity of delivered dose
			7	Contents of Packaged Dosage Forms
			8	Assay: (by HPLC)
	1			Indacaterol
				Glycopyronium
			9	
			9	Glycopyronium Microbial Contamination
			9	Glycopyronium Microbial Contamination Total aerobic count
			9	Glycopyronium Microbial Contamination Total aerobic count E. coli
			9	Glycopyronium Microbial Contamination Total aerobic count E. coli S. Aureus
			9	Glycopyronium Microbial Contamination Total aerobic count E. coli S. Aureus P. Aeruginosa
17.	NRD-26	Isotretinoin Cap. IP 10mg	9	Glycopyronium Microbial Contamination Total aerobic count E. coli S. Aureus
17.	NRD-26	Isotretinoin Cap. IP 10mg		Glycopyronium Microbial Contamination Total aerobic count E. coli S. Aureus P. Aeruginosa
17.	NRD-26	Isotretinoin Cap. IP 10mg	1	Glycopyronium Microbial Contamination Total aerobic count E. coli S. Aureus P. Aeruginosa Description



			5	Uniformity of Content (by UV)
			6	Dissolution (by UV)
			7	Related substances (by HPLC)
			8	Contents of Packaged Dosage Forms
			9	Assay: (by HPLC)
18.	NRD-27	Isotretinoin Cap. IP 20 mg	1	Description
			2	Identification A (by HPLC)
			3	Identification B (by UV)
			4	Average net content
			5	Uniformity of Content (by UV)
			6	Dissolution (by UV)
			7	Related substances (by HPLC)
			8	Contents of Packaged Dosage Forms
			9	Assay: (by HPLC)
19.	NRD-28	Lomustine Capsule BP 40 mg	1	Description
			2	Identification A (IR)
			3	Identification B (Melting Point)
			4	Related Substances(by TLC)
			5	Average net content
			6	Uniformity of weight
			7	Disintegration time
			8	Contents of Packaged Dosage Forms
			9	Assay (by UV)
20.	NRD-29	Minocycline Capsule/Tablet BP 100mg.	1	Description
20.			2	Identification (IR)
			3	Related Substances(by HPLC)
			4	Average net content
			5	Uniformity of weight
			6	Dissolution (by UV)
			7	Loss on drying
			8	Contents of Packaged Dosage Forms
			9	Impurity
			10	Assay (by HPLC)
21.	NRD-30	Mycophenolate Mofetil Cap. /Tablet IP	10	Description
21.	111LD 50	500MG	2	Identification A (by UV)
		500110	2	Identification A (by HPLC)
			3	Average net content
			4	Uniformity of weight
			5	Dissolution (by UV)
			5	Related substances (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay: (by HPLC)
22.	NRD-31	Netupitant + Palonosetron 300 mg + 0.5	1	Description
22.	INKD-51	mg Cap./Tablet	2	Identification (by HPLC)
		Ing Cap./ I abici		Netupitant
				Palonosetron
			3	Average net content Disintegration or Dissolution (by HPLC)
			4	Netupitant HCL/Palonosetron
			5	Uniformity of Weight
				Uniformity of Content(by HPLC) Palonosetron
			6	0.5mg Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
			,	Netupitant
				Palonosetron
23.	NRD-32	Ramipril Cap./Tablet IP 5 mg	1	Description
23.	INKD-32	Kampin Cap./ rablet if 5 mg	2	Identification (by IR)
			3	Average net Content
			4	Uniformity of content (by HPLC)
			4	Dissolution (by HPLC)



			6	Contents of Packaged Dosage Forms
			7	Assay: (by HPLC)
24	NDD 22	Ducenerih Con. 200 mer	1	Description
24.	NRD-33	Rucaparib Cap. 200 mg	2	Identification (by HPLC)
			3	Average net content
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
25	NDD 04	D 11 C 200	7	Assay (by HPLC)
25.	NRD-34	Rucaparib Cap. 300 mg	1	Description Identification (by HPLC)
			3	Average net content
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
26.	NRD-35	Silodosin Cap./Tablet 4 mg	1	Description
			2	Identification (by HPLC) Average net content
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	
			7	Assay (by HPLC)
27.	NRD-36	Silodosin Cap./Tablet 8 mg	1	Description
			2	Identification (by HPLC)
			3	Average net content Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
28.	NRD-37	Temozolamide Cap. IP 250 mg	1	Description
			2	Identification (by HPLC)
			3	Average net content
			4	Uniformity of weight
			6	Disintegration test Contents of Packaged Dosage Forms
			7	Assay: (by HPLC)
29.	NRD-38	Vitamin A Cap. IP 25000 IU	1	Description
_/.	THE SO		2	Identification A (by TLC)
				Identification B (by Chemical)
			3	Average net content
			4	Uniformity of weight
			6	Disintegration test Contents of Packaged Dosage Forms
			7	Assay: (by HPLC)
30.	NRD-39	Carbolic Acid Crystal 100gm		As per STP of firm
31.	NRD-40	Carbolic Acid Crystal 400gm		As per STP of firm
			1	Description
32.	NRD-46	Amorolfine 0.25% Cream	1	*
			2	Identification (by HPLC)
			3	Contents of Packaged Dosage Forms
			4	Assay: (by HPLC)
33.	NRD-47	Azelaic acid 20% Cream	1	Description
			2	Identification (by HPLC)
			3	Contents of Packaged Dosage Forms
			4	Assay: (by HPLC)
34.	NRD-48	Benzoyl Peroxide Gel 2.5 % IP	1	Description
			2	Identification (by TLC)
			3	Related Substances (by HPLC)
			4	Contents of Packaged Dosage Forms
				Assay: (by Chemical)
25	NDD 10		5	
35.	NRD-49	Desonide 0.05% Cream	1	Description
			2	Identification (by HPLC)
			3	Contents of Packaged Dosage Forms
			4	Assay: (by HPLC)
			1	Description
36.	NRD-51	Glycolic Acid 6% Cream	1	Description
36.	NRD-51	Glycolic Acid 6% Cream	2	Identification (by HPLC)



		1		
27	NDD 52		4	Assay: (by HPLC)
37.	NRD-52	Hydrocortisone 1% Cream IP	1	Description
			2	Identification A (by HPLC) Identification B (by TLC)
			3	
			4	Contents of Packaged Dosage Forms
			5	Assay: (by HPLC)
38.	NRD-53	Hydroquinone Cream USP 2%	1	Description
			2	Identification A (by TLC)
			3	Minimum Fill
			4	Contents of Packaged Dosage Forms
			5	Assay: (by UV)
39.	NRD-55	Luliconazole 1% Cream IP	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Related Substances (by HPLC)
			5	Contents of Packaged Dosage Forms
				Assay: (by HPLC)
			6	
40.	NRD-56	Mometasone 0.1 % Cream IP	1	Description
			2	Identification A (by TLC)
			3	Identification B (by HPLC)
			4	Contents of Packaged Dosage Forms
			5	Assay: (by HPLC)
41.	NRD-58	Neomycin Sulphate 0.5% Cream USP	1	Description
			2	Identification A (by TLC)
			3	Minimum Fill
			4	Contents of Packaged Dosage Forms
			5	Assay: (by Chemical)
40	NRD-60	Adamlana (0, 10/ W/W) Cal		Description
42.	NKD-00	Adaplene (0.1% W/W) Gel	1	Identification (by HPLC)
			2	
			3	Contents of Packaged Dosage Forms
			4	Assay: (by HPLC)
43.	NRD-62	Dextrose 5% with Sod.Chloride 0.9%	1	Description
		Injection 500ml glass Bottle	2	Identification A (Chemical)
			3	Identification B (Chemical)
			4	pH
			5	5-Hydroxymethylfurfural and related substances
				(by UV)
			6	Particulate contamination (by particle counter)
			7	Extractable volume
			8	Bacterial endotoxins
			9	Assay:
			10	For sodium chloride (Chemical)
			11	For dextrose (by optical rotation)
			12	Sterility
44.	NRD-65 a	Salmetrol 50mcg+Fluticasone 500 mcg	1	Description
-		DPI IP	2	Identification (by HPLC)
				Salmetrol
				Fluticasone
			3	Average weight
				Content of Active Ingredient delivered per
			4	actuation
			5	Uniformity of delivered dose
			6	Particle Size
	1		7	Number of deliveries per container
			-	
			0	leak test
			8	leak test
			9	deposition of the emitted dose
			9 10	deposition of the emitted dose Contents of Packaged Dosage Forms
			9	deposition of the emitted dose Contents of Packaged Dosage Forms Assay: (by HPLC)
			9 10	deposition of the emitted dose Contents of Packaged Dosage Forms



4.5	NDD (71		-	Description
45.	NRD-65 b	Salmetrol 50mcg+Fluticasone powder for	1	Description
		Inhalation IP 500 mcg	2	Identification (by HPLC)
				Salmetrol
				Fluticasone
			3	Acceptance Criteria
			4	Average Fill
			5	Number of deliveries per container
			6	-
			7	Contents of Packaged Dosage Forms
			8	Assay: (by HPLC)
				Salmetrol
				Fluticasone
			9	Microbial Contamination
				Total aerobic count
				E. coli
				S. Aureus
				P. Aeruginosa
16			1	Description
46.	NRD-66	Budesonide 400 mcg DPI IP	1	Identification A (by UV)
			2	· · ·
			3	Identification B (by HPLC)
			4	Average weight
			5	
			6	
			7	Content of Active Ingredient delivered per actuation
			8	Uniformity of delivered dose
			9	Particle Size
			10	Number of deliveries per container
			10	leak test
			11	deposition of the emitted dose
			12	Contents of Packaged Dosage Forms
			13	Assay: (by HPLC)
47.	NRD-70	Levosalbutamol 100mcg+ Ipratropium	14	Description
47.	INKD-70			Identification (by HPLC)
		Bromide 40mcg DPI	2	Glycopyrronium
				Formoterol
			3	Acceptance Criteria
			4	Average Fill
			5	Number of deliveries per container
			6	Uniformity of delivered dose
			7	Contents of Packaged Dosage Forms
			8	Assay: (by HPLC)
				Glycopyrronium
				Formoterol
			9	Microbial Contamination
				Total aerobic count
				E. coli
				S. Aureus
				P. Aeruginosa
48.	NRD-71	Diastasa Dansin with simethicans 15m1	1	Description
40.	INKD-/1	Diastase, Pepsin with simethicone 15ml	2	Identification (by HPLC)
		Drop Each ml contains Diastase (1:1200)		Diastase
		33.33mg, Pepsin (1:3000) 5mg, Simethicone emulsion 40mg		Pepsin
		Simethicone emulsion 40mg	<u> </u>	simethicone
			3	Water
			4 5	pH Stability of Suspension (by HPLC) (if
			5	formulation is in suspension form)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC) Diastase



				Pepsin
				simethicone
			8	Identification of colour
			9	Microbial Examination
				Total aerobic count Total fungal count
				E. coli
49.	NRD-76	Hydroxyzine HCL Oral Solution IP 15 ml	1	Description
47.	INKD-70	Trydroxyzine TICL Ofai Solution IF 15 III	2	Identification A (by HPLC)
			3	Identification B (by TLC)
			4	pH
			5	Related substances (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
			8	Identification of colour
			9	Microbial Examination
				Total aerobic count
				Total fungal count
				E. coli
50.	NRD-77	Ambroxol drop 7.5mg/ml 15ml	1	Description
			2	Identification (by HPLC)
			3	Water
			4	pH
			5	Stability of Suspension (by HPLC)(if formulation
			1	is in suspension form) Contents of Packaged Dosage Forms
			6 7	Assay (by HPLC)
			8	Identification of colour
			9	Microbial Examination
			,	Total aerobic count
				Total fungal count
				E. coli
51.	NRD-78	Anticold Drop (Each ml contains	1	Description
51.	THE TO	Paracetamol 125mg, Chlorpheniramine	2	Identification (by HPLC)
				Paracetamol
		Maleate 1mg, Phenylephrine HCL 2.5mg)		Chlorpheniramine Maleate
		15 ml		Phenylephrine HCL
			3	Water
			4	рН
			5	Stability of Suspension (by HPLC)(if formulation
				is in suspension form)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Paracetamol Chlombaning Malasta
				Chlorpheniramine Maleate Phenylephrine HCL
			8	Identification of colour
			9	Microbial Examination
			,	Total aerobic count
				Total fungal count
				E. coli
52.	NRD-81	Ferrous Ascorbate and Folic Acid Drops 15	1	Description
		mi each mi confaine Berrolle Accorbate	2	Identification A (by HPLC)
		ml each ml contains Ferrous Ascorbate	23	Identification B
		10mg and Folic Acid 100mcg)	3	
			3 4 5	Identification B Identification C pH
			3 4 5 6	Identification B Identification C pH Contents of Packaged Dosage Forms
			3 4 5 6 7	Identification B Identification C pH Contents of Packaged Dosage Forms Assay (by HPLC)
			3 4 5 6 7 8	Identification B Identification C pH Contents of Packaged Dosage Forms Assay (by HPLC) For Ferrous Iron (by Chemical)
			3 4 5 6 7 8 9	Identification B Identification C pH Contents of Packaged Dosage Forms Assay (by HPLC) For Ferrous Iron (by Chemical) Folic Acid (by HPLC)
			3 4 5 6 7 8 9 10	Identification B Identification C pH Contents of Packaged Dosage Forms Assay (by HPLC) For Ferrous Iron (by Chemical) Folic Acid (by HPLC) Identification of colour
			3 4 5 6 7 8 9	Identification B Identification C pH Contents of Packaged Dosage Forms Assay (by HPLC) For Ferrous Iron (by Chemical) Folic Acid (by HPLC) Identification of colour Microbial Examination
			3 4 5 6 7 8 9 10	Identification B Identification C pH Contents of Packaged Dosage Forms Assay (by HPLC) For Ferrous Iron (by Chemical) Folic Acid (by HPLC) Identification of colour Microbial Examination Total aerobic count
			3 4 5 6 7 8 9 10	Identification B Identification C pH Contents of Packaged Dosage Forms Assay (by HPLC) For Ferrous Iron (by Chemical) Folic Acid (by HPLC) Identification of colour Microbial Examination Total aerobic count Total fungal count
			3 4 5 6 7 8 9 10	Identification B Identification C pH Contents of Packaged Dosage Forms Assay (by HPLC) For Ferrous Iron (by Chemical) Folic Acid (by HPLC) Identification of colour Microbial Examination Total aerobic count Total fungal count E. coli
			3 4 5 6 7 8 9 10	Identification B Identification C pH Contents of Packaged Dosage Forms Assay (by HPLC) For Ferrous Iron (by Chemical) Folic Acid (by HPLC) Identification of colour Microbial Examination Total aerobic count Total fungal count
			3 4 5 6 7 8 9 10	Identification B Identification C pH Contents of Packaged Dosage Forms Assay (by HPLC) For Ferrous Iron (by Chemical) Folic Acid (by HPLC) Identification of colour Microbial Examination Total aerobic count Total fungal count E. coli
			3 4 5 6 7 8 9 10	Identification B Identification C pH Contents of Packaged Dosage Forms Assay (by HPLC) For Ferrous Iron (by Chemical) Folic Acid (by HPLC) Identification of colour Microbial Examination Total aerobic count Total aerobic count Total fungal count E. coli Staphylococcus Aureus Pseudomonas Aeruginosa
		10mg and Folic Acid 100mcg)	3 4 5 6 7 8 9 10 11	Identification B Identification C pH Contents of Packaged Dosage Forms Assay (by HPLC) For Ferrous Iron (by Chemical) Folic Acid (by HPLC) Identification of colour Microbial Examination Total aerobic count Total aerobic count Total fungal count E. coli Staphylococcus Aureus Pseudomonas Aeruginosa Salmonella
53.	NRD-83		3 4 5 6 7 8 9 10 11	Identification B Identification C pH Contents of Packaged Dosage Forms Assay (by HPLC) For Ferrous Iron (by Chemical) Folic Acid (by HPLC) Identification of colour Microbial Examination Total aerobic count Total fungal count E. coli Staphylococcus Aureus Pseudomonas Aeruginosa Salmonella Description
53.	NRD-83	10mg and Folic Acid 100mcg)	3 4 5 6 7 8 9 10 11	Identification B Identification C pH Contents of Packaged Dosage Forms Assay (by HPLC) For Ferrous Iron (by Chemical) Folic Acid (by HPLC) Identification of colour Microbial Examination Total aerobic count Total aerobic count Total fungal count E. coli Staphylococcus Aureus Pseudomonas Aeruginosa Salmonella Description Identification (by HPLC)
53.	NRD-83	10mg and Folic Acid 100mcg)	3 4 5 6 7 8 9 10 11	Identification B Identification C pH Contents of Packaged Dosage Forms Assay (by HPLC) For Ferrous Iron (by Chemical) Folic Acid (by HPLC) Identification of colour Microbial Examination Total aerobic count Total fungal count E. coli Staphylococcus Aureus Pseudomonas Aeruginosa Salmonella Description



			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
			8	Identification of colour
			9	Microbial Examination Total aerobic count
				Total fungal count
				E. coli
54.	NRD-84	Vitamin D3 Oral Drop 400IU/ml	1	Description
5	THE OT		2	Identification (by HPLC)
			3	
			4	рН
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC) Identification of colour
			<u> </u>	Microbial Examination
			7	Total aerobic count
				Total fungal count
				E. coli
55.	NRD-85	Vitamin D3 Oral Drop 800IU/ml	1	Description
		· · · · · · · · · · · · · · · · · · ·	2	Identification (by HPLC)
			3	Water
			4	рН
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
			8	Identification of colour Microbial Examination
			9	Total aerobic count
				Total fungal count
				E. coli
56.	NRD-86	Cefpodoxime Oral Suspension IP 25mg/ml	1	Description
20.	THE OU	corporoninio oral puspension il 2011g/ili	2	Identification (by HPLC)
			3	Water
			4	pH
			5	Contents of Packaged Dosage Forms
				Stability of Suspension (by HPLC)
			6	Assay (by HPLC) Identification of colour
			7	Microbial Examination
			0	Total aerobic count
				Total fungal count
				E. coli
57.	NRD-87	Lactulose Enema 20%`	1	Description
57.	INKD-07	Lactulose Ellellia 20%	2	Identification (by HPLC)
			3	pH
			4	Net content
			5	Assay (by HPLC)
= 0				Clarity of colour of solution
58.	NRD-94	Natamycin Opthalmic Suspension IP 5%	5	Clarity of colour of solution Description
58.	NRD-94	Natamycin Opthalmic Suspension IP 5%	5 6	Clarity of colour of solution
58.	NRD-94	Natamycin Opthalmic Suspension IP 5%	5 6 1	Clarity of colour of solution Description
58.	NRD-94	Natamycin Opthalmic Suspension IP 5%	5 6 1 2 3	Clarity of colour of solution Description Identification (by UV)
58.	NRD-94	Natamycin Opthalmic Suspension IP 5%	5 6 1 2 3 4	Clarity of colour of solution Description Identification (by UV) pH Particle Size
58.	NRD-94	Natamycin Opthalmic Suspension IP 5%	5 6 1 2 3 4 5	Clarity of colour of solution Description Identification (by UV) pH Particle Size Contents of Packaged Dosage Forms
58.	NRD-94	Natamycin Opthalmic Suspension IP 5%	5 6 1 2 3 4 5 6	Clarity of colour of solution Description Identification (by UV) pH Particle Size Contents of Packaged Dosage Forms Assay: (by HPLC)
			5 6 1 2 3 4 5 6 7	Clarity of colour of solution Description Identification (by UV) pH Particle Size Contents of Packaged Dosage Forms Assay: (by HPLC) Sterility
58. 59.	NRD-94 NRD-95	Olaptadine 0.1% & Ketorolac 0.4%	5 6 1 2 3 4 5 6 7 1	Clarity of colour of solution Description Identification (by UV) pH Particle Size Contents of Packaged Dosage Forms Assay: (by HPLC) Sterility Description
			5 6 1 2 3 4 5 6 7	Clarity of colour of solution Description Identification (by UV) pH Particle Size Contents of Packaged Dosage Forms Assay: (by HPLC) Sterility Description Identification (by HPLC)
		Olaptadine 0.1% & Ketorolac 0.4%	5 6 1 2 3 4 5 6 7 1	Clarity of colour of solution Description Identification (by UV) pH Particle Size Contents of Packaged Dosage Forms Assay: (by HPLC) Sterility Description Identification (by HPLC) Olaptadine
		Olaptadine 0.1% & Ketorolac 0.4%	5 6 1 2 3 4 5 6 7 1	Clarity of colour of solution Description Identification (by UV) pH Particle Size Contents of Packaged Dosage Forms Assay: (by HPLC) Sterility Description Identification (by HPLC)
		Olaptadine 0.1% & Ketorolac 0.4%	5 6 1 2 3 4 5 6 7 1	Clarity of colour of solution Description Identification (by UV) pH Particle Size Contents of Packaged Dosage Forms Assay: (by HPLC) Sterility Description Identification (by HPLC) Olaptadine
		Olaptadine 0.1% & Ketorolac 0.4%	5 6 1 2 3 4 5 6 7 7 1 2	Clarity of colour of solution Description Identification (by UV) pH Particle Size Contents of Packaged Dosage Forms Assay: (by HPLC) Sterility Description Identification (by HPLC) Olaptadine Ketorolac pH
		Olaptadine 0.1% & Ketorolac 0.4%		Clarity of colour of solution Description Identification (by UV) pH Particle Size Contents of Packaged Dosage Forms Assay: (by HPLC) Sterility Description Identification (by HPLC) Olaptadine Ketorolac pH Contents of Packaged Dosage Forms
		Olaptadine 0.1% & Ketorolac 0.4%	5 6 1 2 3 4 5 6 7 7 1 2 2 3	Clarity of colour of solution Description Identification (by UV) pH Particle Size Contents of Packaged Dosage Forms Assay: (by HPLC) Sterility Description Identification (by HPLC) Olaptadine Ketorolac pH Contents of Packaged Dosage Forms Assay: (by HPLC)
		Olaptadine 0.1% & Ketorolac 0.4%		Clarity of colour of solution Description Identification (by UV) pH Particle Size Contents of Packaged Dosage Forms Assay: (by HPLC) Sterility Description Identification (by HPLC) Olaptadine Ketorolac pH Contents of Packaged Dosage Forms Assay: (by HPLC) Olaptadine
		Olaptadine 0.1% & Ketorolac 0.4%		Clarity of colour of solution Description Identification (by UV) pH Particle Size Contents of Packaged Dosage Forms Assay: (by HPLC) Sterility Description Identification (by HPLC) Olaptadine Ketorolac pH Contents of Packaged Dosage Forms Assay: (by HPLC) Olaptadine Ketorolac
59.	NRD-95	Olaptadine 0.1% & Ketorolac 0.4% Opthalmic Suspension		Clarity of colour of solution Description Identification (by UV) pH Particle Size Contents of Packaged Dosage Forms Assay: (by HPLC) Sterility Description Identification (by HPLC) Olaptadine Ketorolac pH Contents of Packaged Dosage Forms Assay: (by HPLC) Olaptadine Ketorolac Sterility
		Olaptadine 0.1% & Ketorolac 0.4%		Clarity of colour of solution Description Identification (by UV) pH Particle Size Contents of Packaged Dosage Forms Assay: (by HPLC) Sterility Description Identification (by HPLC) Olaptadine Ketorolac pH Contents of Packaged Dosage Forms Assay: (by HPLC) Olaptadine Ketorolac Sterility Description
59.	NRD-95	Olaptadine 0.1% & Ketorolac 0.4% Opthalmic Suspension	$ \begin{array}{r} 5 \\ 6 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ \hline 3 \\ 4 \\ 5 \\ \hline 6 \\ 6 \\ 6 \\ 6 \\ 6 \\ 6 \\ 6 \\ 6 \\ 6 \\ 6 \\ 6 \\ 6 \\ 6 \\ 6 \\ 6 \\ 6 \\ 6 \\ 6 \\ 6 \\ 6 \\ 6 \\ 6 \\ 6 \\ 6 \\ 6 \\ 6 \\ 6 \\ 6 \\ 6 \\ 6 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 $	Clarity of colour of solution Description Identification (by UV) pH Particle Size Contents of Packaged Dosage Forms Assay: (by HPLC) Sterility Description Identification (by HPLC) Olaptadine Ketorolac pH Contents of Packaged Dosage Forms Assay: (by HPLC) Olaptadine Ketorolac Sterility
59.	NRD-95	Olaptadine 0.1% & Ketorolac 0.4% Opthalmic Suspension Brinozolamide 1% w/v +Brimonidine	$ \begin{array}{r} 5 \\ 6 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 5 \\ \hline 3 \\ 4 \\ 5 \\ \hline 6 \\ 1 \\ \hline 6 \\ 1 \\ \hline 6 \\ 1 \end{array} $	Clarity of colour of solution Description Identification (by UV) pH Particle Size Contents of Packaged Dosage Forms Assay: (by HPLC) Sterility Description Identification (by HPLC) Olaptadine Ketorolac pH Contents of Packaged Dosage Forms Assay: (by HPLC) Olaptadine Ketorolac Sterility Description



			3	pH
			4	Contents of Packaged Dosage Forms
			•	Particle Size
			5	Assay: (by HPLC)
			5	Brinozolamide
				Brimonidine
			6	Sterility
61.	NRD-99	Chlorpheniramine maleate 0.01%	1	Description
51.	NKD-33	+Carboxymethylcellulose 0.02%	2	
		+Nephazoline 0.1% Eye Drop	Z	Chlorpheniramine
				Carboxymethylcellulose
		-		Nephazoline
		-	2	pH
		-	3	Contents of Packaged Dosage Forms
		-	4	
			5	
				Chlorpheniramine
				Carboxymethylcellulose
				Nephazoline
			6	Sterility
52.	NRD-100	Cyclopentolate 1% Eye Drop IP	1	Description
			2	Identification (by IR)
			3	pH
			4	Related substances (by TLC)
			5	Contents of Packaged Dosage Forms
			6	Assay: (by HPLC)
			7	Sterility
53.	NRD-101	Dorzolamide 2% Eye Drop IP	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Related substances (by HPLC)
			5	Contents of Packaged Dosage Forms
			6	Assay: (by HPLC)
			7	Sterility
54.	NRD-102	Fluromethalone 0.1% Eye Drop	1	Description
511	102		2	Identification (by HPLC)
			3	pH
			4	Contents of Packaged Dosage Forms
			5	Assay: (by HPLC)
			6	Sterility
55.	NRD-103	Gatifloxacin 0.30% +Prednisolone Acetate	1	Description
55.	NKD-103	1% Opthalmic Suspension	2	Identification (by HPLC)
		170 Optimine Suspension	Z	Gatifloxacin
		-		Prednisolone
		-	2	
			3	pH Contents of Packaged Dosage Forms
			4	Particle Size
			5	
			6	
				Gatifloxacin
				Prednisolone
			7	Sterility
66.	NRD-104	HPMC 0.3% Eye Drop	1	Description
			2	Identification (by HPLC)
		[3	pH
			4	Contents of Packaged Dosage Forms
			5	Assay: (by HPLC)
			6	Sterility
57.	NRD-105	Itraconazole 1% Eye Drop	1	Description
			2	Identification (by HPLC)
	1	1	3	pH



		1	4	Contents of Packaged Dosage Forms
			5	Assay: (by HPLC)
			6	Sterility
-0	NDD 106	Latara da al 0.25% Essa Dara		Description
58.	NRD-106	Loteprednol 0.25% Eye Drop	1	Identification (by HPLC)
			2	-
			3	pH
			4	Contents of Packaged Dosage Forms
			5	Assay: (by HPLC)
			6	Sterility
i9.	NRD-107	Moxifloxacin 0.5%+Ketorolac	1	Description
		Tromethamine 0.5% Eye Drop	2	Identification (by HPLC)
				Moxifloxacin
				Ketorolac Tromethamine
			3	pH
			4	Contents of Packaged Dosage Forms
			5	Assay: (by HPLC)
				Moxifloxacin
				Ketorolac Tromethamine
			6	Sterility
0.	NRD-108	Moxifloxacin 0.5% and Dexamethasone	1	Description
0.		0.1% Eye Drop	2	Identification (by HPLC)
			2	Moxifloxacin
				Dexamethasone
			2	pH
			3	Contents of Packaged Dosage Forms
			4	Assay: (by HPLC)
			5	Moxifloxacin
				Dexamethasone
			6	Sterility
1.	NRD-109	Moxifloxacin 0.5% and Prednisolone 1%	1	Description
		Opthalmic Solution	2	Identification (by HPLC)
				Moxifloxacin
				Prednisolone
			3	рН
			4	Contents of Packaged Dosage Forms
			5	Assay: (by HPLC)
				Moxifloxacin
				Prednisolone
			6	Sterility
2.	NRD-110	Nepafenac 0.1% Eye Drop	1	Description
2.		Tepatenae 0.170 Eye Brop	2	Identification (by HPLC)
			3	pH
			4	Contents of Packaged Dosage Forms
			6	Assay: (by HPLC)
			7	Sterility
2	NRD-113	Prednisolone Sodium Phosphate Ear/Eye Drop BP		Description
3.	IND-113	1%	1	Identification A (by TLC)
			2	
			3	Identification B (by HPLC)
			4	Identification C (by Chemical)
			5	Acidity and Alkanility
			6	Free Prednisolone (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	Assay: (by HPLC)
			9	Sterility
4.	NRD-114	Proparacaine Eye Drop USP 0.5% W/v	1	Description
			2	Identification (by chemical)
			3	рН
			4	Uniformity of dosage units
				childring of dosage ands



		T		Constitue
	NDD 115		6	Sterility
75.	NRD-115	Sodium Chloride Eye Drop BP 5 %	1	Description
			2	Identification A (by Chemical)
			3	Identification B (by Chemical)
			4	Contents of Packaged Dosage Forms
			5	Assay (by Chemical)
			6	Sterility
76.	NRD-117	Travapost 0.004% and Timolol 0.5% Eye	1	Description
		Drop	2	Identification (by HPLC)
				Travapost
				Timolol
			3	pН
			4	Contents of Packaged Dosage Forms
			5	Assay: (by HPLC)
				Travapost
				Timolol
			6	Sterility
77	NDD 110	Tranicamida 0.80// Dhanalamhanina	-	Description
77.	NRD-118	Tropicamide 0.8% w/v+Phenylepherine	1	Identification (by HPLC)
		HCL 5% w/v Eye Drop	2	
				Travapost
				Timolol
			3	pH
			4	Contents of Packaged Dosage Forms
			5	Assay: (by HPLC)
				Travapost
				Timolol
			6	Sterility
78.	NRD-119	Voriconazole 1% w/v (Lyophilized) 30mg	1	Description
		Eye Drop	2	Identification (by HPLC)
			3	pH
			4	Contents of Packaged Dosage Forms
			5	Assay: (by HPLC)
			6	Sterility
79.	NRD-120	Azithromycin Eye Ointment 1%	1	Description
1).	100-120	Azitinomychi Lyc Omtinent 170	2	Identification (by HPLC)
			3	Particle size
			-	Contents of Packaged Dosage Forms
			4	
			5	Assay: (by HPLC)
			6	Sterility
80.	NRD-121	Chloramphenicol Eye Ointment IP 0.5%	1 2	Description Identification A (by IR)
			3	Identification B (Chemical)
			4	Minimun fill
			5	Contents of Packaged Dosage Forms
			6	Assay: (by HPLC)
0.1			7	Sterility
81.	NRD-123	Chloramphenicol 1%, Polymyxin B	1	Description
		Sulphate 10000 units + Dexamethasone	2	Identification (by HPLC)
		0.1% Sodium phosphate Eye Ointment		Chloramphenicol
				Polymyxin B Sulphate
				Dexamethasone
			3	pH
			4	Contents of Packaged Dosage Forms
			5	Assay: (by HPLC)
			5	Chloramphenicol
				Polymycin
				Dexamethasone
			-	Particle Size
			6	
02			7	Sterility
82.	NRD-124	Ganciclovir Eye Ointment 0.15%	1	Description



	•	1		
			2	Identification (by HPLC)
			3	Particle size
			4	Contents of Packaged Dosage Forms
			5	Assay: (by HPLC)
			6	Sterility
83.	NRD-125	Itraconazole Eye Ointment 1%	1	Description
			2	Identification (by HPLC)
			3	Particle size
			4	Contents of Packaged Dosage Forms
			5	Assay: (by HPLC)
			6	Sterility
84.	NRD-126	Moxifloxacin Eye Ointment 0.5%	1	Description
0	11120 120		2	Identification (by HPLC)
			3	Particle size
			4	Contents of Packaged Dosage Forms
			5	Assay: (by HPLC)
			6	Sterility
05	NDD 127	Sedium Chleride (0/ Err Ointment USD	1	Description
85.	NRD-127	Sodium Chloride 6% Eye Ointment USP	2	Identification A (by Chemical)
			3	Identification B (Chemical)
			4	Particulate matter
			5	foreign matter
			6	Container content
			7	Assay: (by Chemical) Sterility
86.	NRD-128	Povidone iodine Gargle 0.5% w/v	<u> </u>	Description
ð0.	INKD-120	Fovidone loune Gargie 0.5% w/v		Identification (by HPLC)
			2	Contents of Packaged Dosage Forms
			3	
~-			4	Assay: (by HPLC)
87.	NRD-129	Gatifloxacin 0.3% Eye Drop	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Contents of Packaged Dosage Forms
			5	Assay: (by HPLC)
			6	Sterility
88.	NRD-132	Glycine Irrigation Solution 1.5% 3LTR IP	1	Description
			2	Identification A (by IR)
			2	Identification B (by TLC)
			3	pH Average net Content
			5	Uniformity Of weight
			6	Extractable Vollume
			7	Particulate matter
			8	Bacterial endotoxins
			9	Assay: (by Chemical)
00	NDD 120	$\mathbf{H}_{\text{reduction}} = 110/1002 \mathbf{N}_{\text{red}} + 010/1002 \mathbf{N}_{\text{red}} + 00002 \mathbf{N}_{\text{red}} + 000002 \mathbf{N}_{\text{red}} + 0$	10	Sterility
89.	NRD-139	Hydrogen 11% + Silver Nitrate .01%	10	As per STP of firm
89.		Solution		As per STP of firm
89. 90.	NRD-139 NRD-141		1	As per STP of firm Description
		Solution	1 2	As per STP of firm Description Identification B (by HPLC)
		Solution	1 2 3	As per STP of firm Description Identification B (by HPLC) Identification C (by HPLC)
		Solution	$ \begin{array}{r} 1\\ 2\\ 3\\ 4 \end{array} $	As per STP of firm Description Identification B (by HPLC) Identification C (by HPLC) Identification D (by IR)
		Solution	1 2 3	As per STP of firm Description Identification B (by HPLC) Identification C (by HPLC) Identification D (by IR) pH
		Solution	$ \begin{array}{r} 1\\ 2\\ 3\\ 4 \end{array} $	As per STP of firm Description Identification B (by HPLC) Identification C (by HPLC) Identification D (by IR) pH Average net Content
		Solution	$ \begin{array}{r} 1\\ 2\\ 3\\ 4\\ 5 \end{array} $	As per STP of firm Description Identification B (by HPLC) Identification C (by HPLC) Identification D (by IR) pH Average net Content Uniformity Of weight
		Solution	$ \begin{array}{r} 1\\ 2\\ 3\\ 4\\ 5\\ 6\\ \end{array} $	As per STP of firm Description Identification B (by HPLC) Identification C (by HPLC) Identification D (by IR) pH Average net Content
		Solution	$ \begin{array}{r} 1\\ 2\\ 3\\ 4\\ 5\\ 6\\ 7\\ \end{array} $	As per STP of firm Description Identification B (by HPLC) Identification C (by HPLC) Identification D (by IR) pH Average net Content Uniformity Of weight
		Solution	$ \begin{array}{r} 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 9 \end{array} $	As per STP of firm Description Identification B (by HPLC) Identification C (by HPLC) Identification D (by IR) pH Average net Content Uniformity Of weight Related substances (by HPLC)
		Solution	$ \begin{array}{r} 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ \end{array} $	As per STP of firm Description Identification B (by HPLC) Identification C (by HPLC) Identification D (by IR) pH Average net Content Uniformity Of weight Related substances (by HPLC) Extractable volume Particulate matter
		Solution	$ \begin{array}{r} 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ \end{array} $	As per STP of firm Description Identification B (by HPLC) Identification C (by HPLC) Identification D (by IR) pH Average net Content Uniformity Of weight Related substances (by HPLC) Extractable volume Particulate matter Assay: (by UV)
90.	NRD-141	Solution Metoprolol Inj. IP 1mg/ml l vial	$ \begin{array}{r} 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ 12 \\ \end{array} $	As per STP of firm Description Identification B (by HPLC) Identification C (by HPLC) Identification D (by IR) pH Average net Content Uniformity Of weight Related substances (by HPLC) Extractable volume Particulate matter Assay: (by UV) Sterility
		Solution	$ \begin{array}{r} 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ \end{array} $	As per STP of firm Description Identification B (by HPLC) Identification C (by HPLC) Identification D (by IR) pH Average net Content Uniformity Of weight Related substances (by HPLC) Extractable volume Particulate matter Assay: (by UV)



	1		1	
			4	Average net Content
			5	Uniformity Of weight
			6	Extractable volume
			7	Particulate matter
			8	Assay: (by HPLC)
			9	Sterility
92.	NRD-145	Sodium Chloride Inj. IP 3% 100ml	1	Description
			2	Identification (Chemical)
			3	Heavy metals
			4	pH
			5	Particulate contamination (by particle counter)
			6	Extractable volume
			7	Bacterial endotoxins
			8	Assay: Sodium chloride (Chemical)
			9	Sterility
93.	NRD-156	Artesunate Inj. IP 120 mg (Each Combo	1	Description
13.	INKD-130	Pack contains Artesunate Injection 120 mg		Identification A (by IR)
		Vial, Sodium Bicarbonate Injection IP 5%	2	Identification B (by TLC)
		w/v (2 ml ampoule), Sodium chloride	3	Average net content
		Injection IP 0.9% w/v (10 ml ampoule)	4	Uniformity of weight
			5	Related substances (by HPLC)
			6	Bacterial endotoxins
			7	Water
			8	Clarity of solution test a and b
			9	Particulate matter
			10	Assay: (by HPLC)
			11	Sterility
			B	Sodium Bicarbonate Injection IP
			1	Description
			2	Identification A
			3	Identification B
				pH
			4	Extractable volume
			5	
			6	Particulate matter
			7	Bacterial endotoxins
			8	Assay: Sodium bicarbonate
			9	Sterility
			C	Sodium chloride Injection IP
			1	Description
			2	Identification
			3	Heavy metals
			4	pH
			5	Extractable volume
	1		6	Bacterial endotoxins
			7	Particle Matter (Particle Counter)
			8	Assay: Sodium chloride
	1		-	Sterility
1	NDD 160	A - a sidiling Ini. 100	9 1	
94.	NRD-160	Azacitidine Inj. 100mg	2	Description Identification (by HPLC)
	1		3	pH
			4	Average net Content
			5	Uniformity Of weight
	1		6	,
			7	Particulate matter
			8	
	1		9 10	Assay: (by HPLC) Sterility
5.	NRD-161	Azithromycin Inj. 10 ml vial equaivelent	10	Description
5.	101-101	to 500 mg	2	Identification (by HPLC)
	1	10 500 mg	3	pH
			_	1
			4 5	Average net Content Uniformity Of weight



			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			<u>9</u> 10	Assay: (by HPLC) Sterility
96.	NRD-169	Caffeine Cirate Injection BP 20mg/ml	10	Description
90.	1000	Currente Cirate injection Dr Zonig in	2	Identification A (TLC)
				Identification B (HPLC)
			3	
			4	Identification C (Chemical)
			5	Related Susbstances (by HPLC)
			6	Average net content
			7	Uniformity of Weight
			8	pH
			9	Particulate matter
			10	Extractable volume
			11	Impurity
			12	Assay(by HPLC)
			12	Sterility
07	NDD 172			Description
97.	NRD-173	Carfilzomib Inj. 30 mg	2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	
			7	Particulate matter
			8	Bacterial endotoxins Assay: (by HPLC)
			10	
98.	NRD-174	Carfilzomib Inj. 60 mg	10	Description
70.	111D-174	Carnizonno nij. 00 nig	2	Identification (by HPLC)
			3	рН
			4	Average net Content
			5	
			6	
			7	Particulate matter Bacterial endotoxins
			9	Assay: (by HPLC)
			10	Sterility
99.	NRD-175	Carmustine Inj. IP 100 mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by HPLC)
			4	pH
			5	Average net Content
			6	Uniformity Of weight
			7	Bacterial endotoxins
			8	Water
			9	Related Substances (by HPLC)
			10	Clarity of solution test a and b
			11	Particulate matter
			12	Assay: (by HPLC)
			13	Sterility
100.	NRD-176	Caspofungin Inj. 50 mg	1	Description
100.	110 170	Casporangin inj. 50 ing	2	Identification (by HPLC)
			3	рН
			4	Average net Content
			5	Uniformity Of weight
			6	
			7	Particulate matter Bacterial endotoxins
			8	
			10	Sterility
101.	NRD-177	Caspofungin Inj. 70 mg	1	Description
101.	1,120 177	carporangin inj. / v ing	2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight Clarity of solution test a and b



			7	Particulate matter
			8	Bacterial endotoxins
			10	
102.	NRD-178	Cefipime 1000MG + Tazobactum Inj.	10	Description
102.	IND-170	125MG	2	Identification (by HPLC)
		1251010		Cefipime
				Tazobactum
			3	pH
			4	Bacterial Endotoxins
			5	Average net content
			6	Uniformity of weight
			7	Clarity of solution test a and b
			8	Particulate matter
			9	
			9	Cefipime
				Tazobactum
			10	Sterility
103.	NRD-179	Cefoperazone 1gm+Tazobactum Inj.	1	Description
		125mg	2	Identification (by HPLC)
				Cefipime
				Tazobactum
			3	pH
			-	Bacterial Endotoxins
			4	
			5	
			6	Uniformity of weight
			7	Clarity of solution test a and b
			8	Particulate matter
			9	Assay: (by HPLC)
				Cefipime
				Tazobactum
			10	Sterility
104	NBD 100		10	
104.	NRD-180	Cefoperazone Inj. IP 500mg	1	Description
			2	Identification A (by HPLC)
			3	Identification B
			4	pH
			5	Average net Content
			6	Uniformity Of weight
			7	Bacterial endotoxins
			8	Water
				Clarity of solution test a and b
			9	
			10	Particulate matter
			11	Assay: (by HPLC)
			12	Sterility
105.	NRD-181	Ceftazidime 1gm+Sulbactam Inj. 500 mg	1	Description
			2	Identification (by HPLC)
			-	Ceftazidime
				Sulbactam
			3	pH
				-
			4	Bacterial Endotoxins
			5	Average net content
			6	Uniformity of weight
			7	Clarity of solution test a and b
			8	Particulate matter
			9	Assay: (by HPLC)
			⊢́	Ceftazidime
			10	Sulbactam
			10	Sulbactam Sterility
106.	NRD-182	Ceftazidime+ Avibactum Inj. 2gm+500mg	10 1 2	Sulbactam



			3	Identification B pH
			5	Average net Content
			6	Uniformity Of weight
			7	Bacterial endotoxins
			8	Water
			9	Clarity of solution test a and b
			10	Particulate matter
			11	Assay: (by HPLC) Sterility
109	NDD 104	Cofficience Lai ID 125 ma	12	Description
108.	NRD-184	Ceftriaxone Inj. IP 125 mg	1 2	Identification A (by IR)
			3	Identification B (by HPLC)
			4	Identification C
			5	Appearance of solution
			6	pH
			7	Related substances (by HPLC)
			8	Bacterial endotoxins
			9	Water
			10	Average weight
			11	Uniformity of weight
			12	Particulate matter
			13	Clarity of solution A and B
			14	Assay: (by HPLC)
			15	Sterility
109.	NRD-185	Ceftriaxone 1000mg +Salbactum 500mg +	1	Description
		disodium EDTA 37mg Inj.	2	Identification (by HPLC)
				Ceftriaxone
				Salbactum
				1' 1' EDEA
				disodium EDTA
			3	pH
			4	pH Bacterial Endotoxins
			45	pH Bacterial Endotoxins Average net content
			4 5 6	pH Bacterial Endotoxins Average net content Uniformity of weight
			4 5 6 7	pH Bacterial Endotoxins Average net content Uniformity of weight Clarity of solution test a and b
			4 5 6 7 8	pH Bacterial Endotoxins Average net content Uniformity of weight Clarity of solution test a and b Particulate matter
			4 5 6 7	pH Bacterial Endotoxins Average net content Uniformity of weight Clarity of solution test a and b Particulate matter Assay: (by HPLC)
			4 5 6 7 8	pH Bacterial Endotoxins Average net content Uniformity of weight Clarity of solution test a and b Particulate matter Assay: (by HPLC) Ceftriaxone
			4 5 6 7 8	pH Bacterial Endotoxins Average net content Uniformity of weight Clarity of solution test a and b Particulate matter Assay: (by HPLC) Ceftriaxone Salbactum
			4 5 6 7 8 9	pH Bacterial Endotoxins Average net content Uniformity of weight Clarity of solution test a and b Particulate matter Assay: (by HPLC) Ceftriaxone Salbactum disodium EDTA
110	NDD 107	Cofining 1000-rest Track of 125	4 5 7 8 9 10	pH Bacterial Endotoxins Average net content Uniformity of weight Clarity of solution test a and b Particulate matter Assay: (by HPLC) Ceftriaxone Salbactum disodium EDTA Sterility
110.	NRD-187	Ceftriaxone1000mg+ Tazobactom125mg	4 5 7 8 9 	pH Bacterial Endotoxins Average net content Uniformity of weight Clarity of solution test a and b Particulate matter Assay: (by HPLC) Ceftriaxone Salbactum disodium EDTA Sterility Description
110.	NRD-187	Ceftriaxone1000mg+ Tazobactom125mg Inj.	4 5 7 8 9 10	pH Bacterial Endotoxins Average net content Uniformity of weight Clarity of solution test a and b Particulate matter Assay: (by HPLC) Ceftriaxone Salbactum disodium EDTA Sterility



			3	pH
			4	Bacterial Endotoxins
			5	Average net content
			6	Uniformity of weight
			7	Clarity of solution test a and b
			8	Particulate matter
			9	Assay: (by HPLC)
			-	Ceftriaxone
				Tazobactom
			10	Sterility
111.	NRD-188	Cefuroxime Inj. IP 1Gm	10	Description
111.	100-100	Ceruroxinie inj. ir Tolii	2	Identification A (by HPLC)
			3	Identification B
			4	pH
			5	Related substances (by HPLC)
				Bacterial endotoxins
			6	Water
			7	
			8	Average weight
			9	Uniformity of weight
			10	Particulate matter
			11	Clarity of solution A and B
			12	Assay: (by HPLC)
			13	
112.	NRD-189	Cetrorelix Acetate Inj. 0.25 mg	1	Description
			2	Identification (by HPLC) pH
			4	Average net Content
			5	
			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	Assay: (by HPLC) Sterility
113.	NRD-192	Chloramphenicol Sodium Succinate Inj.	1	Description
115.	100 172	IP 1gm/vial	2	Identification A (by TLC)
			3	Identification B
			4	Identification C
			5	pH
				Specific optical rotation
			6	Free Chloramphenicol (by TLC)
			7	Bacterial endotoxins
			8	
			9	Water
			10	Average weight
			11	Uniformity of weight
			12	Particulate matter
			13	Clarity of solution A and B
			14	Assay: (by UV)
			15	Sterility
114.	NRD-193	Cladrabine Inj. 10 mg	1	Description
			2	Identification (by HPLC)
			3	pH Average net Content
			5	
			6	
			7	Particulate matter
			8	Bacterial endotoxins
			9	
115.	NRD-194	Clarithromycin for Infusion BP 500mg/vial	10	Sterility Description
113.	111112-174	Chartenoniyen for infusion Dr 500ing/viai	2	Identification A (by IR)
			3	
			4	pH Clarity of solution test a and b
			1 /1	LA DALLY OF SOUTION TEST & AND D
			5	Particulate matter



	r	1	1	<u>I</u>
			6	Average net content
			7	Uniformity of Weight
			8	Related Substances (by HPLC)
			9	Sterility
			10	Assay(by HPLC)
116.	NRD-199	Cytarabine Inj. IP 1000 mg	1	Description
		- j	2	Identification (by IR)
			5	pH
			-	Related Substances (by TLC)
			7	
			8	Bacterial endotoxins
			9	Water
			10	Average weight
			11	Uniformity of weight
			12	Particulate matter
			13	Clarity of solution A and B
			14	Assay: (by Titration)
			15	Sterility
117.	NRD-201	Dextrose Inj. IP 5% 500 ml Glass Bottle	13	Description
11/.	INKD-201	Dexuose IIIJ. IF 5% 500 IIII Glass Boule	-	Identification A
			2	
			3	Identification B (by optical rotation)
			4	pH
			5	5-Hydroxymethylfurfural and related substances
				(by UV)
			6	Heavy metals
			7	Particulate contamination (by particle counter)
			8	Extractable volume
			9	Bacterial endotoxins
			10	Assay: (by optical rotation)
			11	Sterility
118.	NRD-207	Decitabine Inj. 50 mg	1	Description
110.	NRD-207	Decitablic inj. 50 ing	2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	, , , , , , , , , , , , , , , , , , , ,
			6	2
			7 8	Particulate matter Bacterial endotoxins
			9	Assay: (by HPLC)
				Sterility
119.	NRD-209	Degarelix Inj.80 mg	1	Description
	11112 200		2	Identification (by HPLC)
			3	рН
			4	Average net Content
			5	Uniformity Of weight
			6	
			7 8	Particulate matter Bacterial endotoxins
			9	Assay: (by HPLC)
			10	Sterility
120.	NRD-210	Degarelix Inj. 120 mg	1	Description
	1.112 210	0m + mj. 120 mg	2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	
			7 8	Particulate matter Bacterial endotoxins
			8	Assay: (by HPLC)
			10	Sterility
121.	NRD-220	Docetaxel Inj. IP 120 mg	1	Description
1	11110 220		2	Identification A (by HPLC)
				Related substances (by HPLC)
			3	-
			4	Average net Content
				Linitormity ()t woight
			5	Uniformity Of weight Extractable volume



			7	Particulate matter
			8	Assay: (by HPLC)
			9	Sterility
122.	NRD-221	Doxycycline for Injection USP 100 mg	1	Description
122.	NKD-221	Doxycycline for nijection OST 100 nig	2	Identification A (by UV)
			3	Identification B (by HPLC)
			4	Organic Impurities (by HPLC)
			5	pH
			6	Average net Content
			7	Loss on drying
			8	Uniformity Of dosage unit
			9	Clarity of solution test a and b
			10	Particulate matter
			11	Bacterial endotoxins
			12	Assay: (by HPLC)
			13	,
123.	NRD-228	Eribulin Inj. 0.5mg	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	
			6	5
			7	Particulate matter Bacterial endotoxins
			8	
			10	Assay: (by HPLC) Sterility
124	NDD 220	Esibulia Isi, 1 suc	10	Description
124.	NRD-229	Eribulin Inj. 1 mg	2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	
			6	
			7	Particulate matter
			8	Bacterial endotoxins
			9	Assay: (by HPLC)
			10	Sterility
125.	NRD-230	Ertapenem sodium Inj. 1gm = Ertapenem	1	Description
		1.046 gm	2	Identification (by HPLC)
		1.010 511	3	рН
			4	Average net Content
			5	Uniformity Of weight
			5	
			6	, ,
			6 7	Particulate matter
			6 7 8	Particulate matter Bacterial endotoxins
			6 7 8 9	Particulate matter Bacterial endotoxins Assay: (by HPLC)
125			6 7 8 9 10	Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility
126.	NRD-231	Etomidate Inj. USP 20 mg	6 7 8 9 10 1	Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description
126.	NRD-231	Etomidate Inj. USP 20 mg	$ \begin{array}{r} 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 1 \\ 2 \end{array} $	Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description Identification A (by UV)
126.	NRD-231	Etomidate Inj. USP 20 mg	$ \begin{array}{r} 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 1 \\ 2 \\ 3 3 \end{array} $	Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description Identification A (by UV) Identification B (by HPLC)
126.	NRD-231	Etomidate Inj. USP 20 mg	$ \begin{array}{r} 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 1 \\ 2 \end{array} $	Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description Identification A (by UV) Identification B (by HPLC) Organic Impurities (by HPLC) Related
126.	NRD-231	Etomidate Inj. USP 20 mg	$ \begin{array}{r} 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 1 \\ 2 \\ 3 \\ 4 \\ \end{array} $	Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description Identification A (by UV) Identification B (by HPLC) Organic Impurities (by HPLC) Related compound
126.	NRD-231	Etomidate Inj. USP 20 mg	$ \begin{array}{r} 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 5 \\ \end{array} $	Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description Identification A (by UV) Identification B (by HPLC) Organic Impurities (by HPLC) Related compound Total propylene glycol ester (by HPLC)
126.	NRD-231	Etomidate Inj. USP 20 mg	$ \begin{array}{r} 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ \end{array} $	Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description Identification A (by UV) Identification B (by HPLC) Organic Impurities (by HPLC) Related compound Total propylene glycol ester (by HPLC) pH
126.	NRD-231	Etomidate Inj. USP 20 mg	$ \begin{array}{r} 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ \end{array} $	Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description Identification A (by UV) Identification B (by HPLC) Organic Impurities (by HPLC) Related compound Total propylene glycol ester (by HPLC) pH Average net Content
126.	NRD-231	Etomidate Inj. USP 20 mg	$ \begin{array}{r} 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ \end{array} $	Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description Identification A (by UV) Identification B (by HPLC) Organic Impurities (by HPLC) Related compound Total propylene glycol ester (by HPLC) pH Average net Content Uniformity Of dosage unit
126.	NRD-231	Etomidate Inj. USP 20 mg	$ \begin{array}{r} 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ \end{array} $	Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description Identification A (by UV) Identification B (by HPLC) Organic Impurities (by HPLC) Related compound Total propylene glycol ester (by HPLC) pH Average net Content Uniformity Of dosage unit Extractable volume
126.	NRD-231	Etomidate Inj. USP 20 mg	$ \begin{array}{r} 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 9 \\ \end{array} $	Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description Identification A (by UV) Identification B (by HPLC) Organic Impurities (by HPLC) Related compound Total propylene glycol ester (by HPLC) pH Average net Content Uniformity Of dosage unit Extractable volume Particulate matter
126.	NRD-231	Etomidate Inj. USP 20 mg	$ \begin{array}{r} 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ \end{array} $	Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description Identification A (by UV) Identification B (by HPLC) Organic Impurities (by HPLC) Related compound Total propylene glycol ester (by HPLC) pH Average net Content Uniformity Of dosage unit Extractable volume Particulate matter Bacterial endotoxins
126.	NRD-231	Etomidate Inj. USP 20 mg	$ \begin{array}{r} 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ \end{array} $	Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description Identification A (by UV) Identification B (by HPLC) Organic Impurities (by HPLC) Related compound Total propylene glycol ester (by HPLC) pH Average net Content Uniformity Of dosage unit Extractable volume Particulate matter
			$ \begin{array}{r} 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ 12 \\ \end{array} $	Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description Identification A (by UV) Identification B (by HPLC) Organic Impurities (by HPLC) Related compound Total propylene glycol ester (by HPLC) pH Average net Content Uniformity Of dosage unit Extractable volume Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description
126.	NRD-231 NRD-236	Etomidate Inj. USP 20 mg Fluconazole Inj. USP 200 mg	$ \begin{array}{r} 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ 12 \\ 13 \\ \end{array} $	Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description Identification A (by UV) Identification B (by HPLC) Organic Impurities (by HPLC) Related compound Total propylene glycol ester (by HPLC) pH Average net Content Uniformity Of dosage unit Extractable volume Particulate matter Bacterial endotoxins Assay: (by HPLC)
			$ \begin{array}{r} 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ 12 \\ 13 \\ 1 \end{array} $	Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description Identification A (by UV) Identification B (by HPLC) Organic Impurities (by HPLC) Related compound Total propylene glycol ester (by HPLC) pH Average net Content Uniformity Of dosage unit Extractable volume Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description
			$ \begin{array}{r} 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ 12 \\ 13 \\ 1 \\ 2 \\ \end{array} $	Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description Identification A (by UV) Identification B (by HPLC) Organic Impurities (by HPLC) Related compound Total propylene glycol ester (by HPLC) pH Average net Content Uniformity Of dosage unit Extractable volume Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description Identification (by HPLC)
			$ \begin{array}{r} 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ 12 \\ 13 \\ 1 \\ 2 \\ 3 \\ 3 \\ 1 \end{array} $	Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description Identification A (by UV) Identification B (by HPLC) Organic Impurities (by HPLC) Related compound Total propylene glycol ester (by HPLC) pH Average net Content Uniformity Of dosage unit Extractable volume Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description Identification (by HPLC) Sodium Chloride Content (chemical) Organic Impurities (by HPLC) for Non Polar Impurities
			$ \begin{array}{r} 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ 12 \\ 13 \\ 1 \\ 2 \\ 3 \\ 3 \\ 1 \end{array} $	Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description Identification A (by UV) Identification B (by HPLC) Organic Impurities (by HPLC) Related compound Total propylene glycol ester (by HPLC) pH Average net Content Uniformity Of dosage unit Extractable volume Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description Identification (by HPLC) Sodium Chloride Content (chemical) Organic Impurities (by HPLC) for Non Polar
			$ \begin{array}{r} 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ 12 \\ 13 \\ 1 \\ 2 \\ 3 \\ 4 \\ 4 \\ \end{array} $	Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description Identification A (by UV) Identification B (by HPLC) Organic Impurities (by HPLC) Related compound Total propylene glycol ester (by HPLC) pH Average net Content Uniformity Of dosage unit Extractable volume Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description Identification (by HPLC) Sodium Chloride Content (chemical) Organic Impurities (by HPLC) procedure-3
			$ \begin{array}{r} 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ 12 \\ 13 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ \end{array} $	Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description Identification A (by UV) Identification B (by HPLC) Organic Impurities (by HPLC) Related compound Total propylene glycol ester (by HPLC) pH Average net Content Uniformity Of dosage unit Extractable volume Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description Identification (by HPLC) Sodium Chloride Content (chemical) Organic Impurities (by HPLC) procedure-3 Organic Impurities (by HPLC) procedure-4
			$ \begin{array}{r} 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ 12 \\ 13 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 6 \\ \end{array} $	Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description Identification A (by UV) Identification B (by HPLC) Organic Impurities (by HPLC) Related compound Total propylene glycol ester (by HPLC) pH Average net Content Uniformity Of dosage unit Extractable volume Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description Identification (by HPLC) Sodium Chloride Content (chemical) Organic Impurities (by HPLC) Organic Impurities (by HPLC) Organic Impurities (by HPLC) Organic Impurities (by HPLC) Organic Impurities (by HPLC) procedure-3 Organic Impurities (by HPLC) procedure-4 Average net Content
			$\begin{array}{c} 6\\ 7\\ 8\\ 9\\ 10\\ 1\\ 2\\ 3\\ 4\\ 5\\ 6\\ 7\\ 8\\ 9\\ 10\\ 11\\ 12\\ 13\\ 1\\ 1\\ 12\\ 3\\ 4\\ 4\\ 5\\ 6\\ 7\\ 8\\ 9\\ 9\\ 9\\ 9\\ 9\\ 9\\ 9\\ 9\\ 9\\ 9\\ 9\\ 9\\ 9\\$	Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description Identification A (by UV) Identification B (by HPLC) Organic Impurities (by HPLC) Related compound Total propylene glycol ester (by HPLC) pH Average net Content Uniformity Of dosage unit Extractable volume Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description Identification (by HPLC) Sodium Chloride Content (chemical) Organic Impurities (by HPLC) Organic Impurities (by HPLC) procedure-3 Organic Impurities (by HPLC) procedure-4 Average net Content
			$\begin{array}{c} 6\\ \hline 7\\ 8\\ 9\\ \hline 10\\ 1\\ 2\\ 3\\ 4\\ \hline 5\\ 6\\ 7\\ 8\\ 9\\ 10\\ 11\\ 12\\ 13\\ 1\\ 1\\ 2\\ 3\\ 4\\ \hline 5\\ 6\\ 7\\ 8\\ 9\\ 10\\ \hline 8\\ 9\\ 10\\ \hline 8\\ 9\\ 10\\ \hline \end{array}$	Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description Identification A (by UV) Identification B (by HPLC) Organic Impurities (by HPLC) Related compound Total propylene glycol ester (by HPLC) pH Average net Content Uniformity Of dosage unit Extractable volume Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description Identification (by HPLC) Sodium Chloride Content (chemical) Organic Impurities (by HPLC) Organic Impurities (by HPLC) procedure-4 Average net Content Uniformity Of dosage unit Extractable volume
			$\begin{array}{c} 6\\ 7\\ 8\\ 9\\ 10\\ 1\\ 2\\ 3\\ 4\\ 5\\ 6\\ 7\\ 8\\ 9\\ 10\\ 11\\ 12\\ 13\\ 1\\ 1\\ 12\\ 3\\ 4\\ 4\\ 5\\ 6\\ 7\\ 8\\ 9\\ 9\\ 9\\ 9\\ 9\\ 9\\ 9\\ 9\\ 9\\ 9\\ 9\\ 9\\ 9\\$	Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description Identification A (by UV) Identification B (by HPLC) Organic Impurities (by HPLC) Related compound Total propylene glycol ester (by HPLC) pH Average net Content Uniformity Of dosage unit Extractable volume Particulate matter Bacterial endotoxins Assay: (by HPLC) Sterility Description Identification (by HPLC) Sodium Chloride Content (chemical) Organic Impurities (by HPLC) Organic Impurities (by HPLC) procedure-3 Organic Impurities (by HPLC) procedure-4 Average net Content

	r		10	
			13 14	Assay: (by HPLC) Sterility
128.	NRD-237	Fludarabine Phosphate Injection IP 100mg	14	Description
120.	NKD-237	Filderabilie Filosphate injection if Tooling	2	Identification A (by UV)
			3	Identification B (by HPLC)
			4	pH
			5	Average net Content
			6	Uniformity Of weight
			7	Related substances (by HPLC) Becterial endotoxins
			8	Particulate matter
			10	Extractable volume
			11	Assay: (by HPLC)
			12	Sterility
129.	NRD-238	Fludarabine Phosphate Injection IP 50mg	1	Description
			2	Identification A (by UV)
			3	Identification B (by HPLC)
			4	pH
			5	Average net Content Uniformity Of weight
			7	Related substances (by HPLC)
			8	Becterial endotoxins
			9	Particulate matter
			10	Extractable volume
			11	Assay: (by HPLC)
			12	Sterility
130.	NRD-242	Fondaparinux Sodium Inj. USP 2.5mg	1	Description
			2	Identification A (by HPLC)
			3	Identification B
			4	Organic Impurities (by HPLC)
			6	Free Sulphate Determination (by HPLC) pH
			7	Average net Content
			8	Uniformity Of dosage unit
			9	Extractable volume
			10	Particulate matter
			11	Bacterial endotoxins
			12	Assay: (by HPLC)
			13	Sterility
131.	NRD-246	Fulvestrant Inj. 250mg	1	Description
			2	Identification (by HPLC)
			3	pH Assessment Content
			4	Average net Content Uniformity Of weight
			6	
			7	Particulate matter
			8	Bacterial endotoxins
			9	Assay: (by HPLC)
			10	Sterility
132.	NRD-249	Injection Goserelin Acetate implant 3.6 mg BP	1	Description
			2	Identification A (HPLC)
			3	Identification B: Size exclusion Chromatography
			4	Drug Release
			5	Related Substances (by HPLC)
				-
			6	Acetic Acid(by GLC)
			7	Water
			8	Bacterial endotoxins
			9	Uniformity of Content (HPLC)
			10	Average Fill Volume
			11	Extractable volume
			11	Particulate matter
				Impurity
			13	· ·
			14	Assay: by Size exclusion Chromatography
			15	Sterility
133.	NRD-263	Intralipds 10% Injection 10gm/100ml	1	Description
			2	Nominal Volume
			3	Extractable volume
			4	рН
	1		5	Globule Size (by Microscope)



			6	Peroxide Value
			7	Free Acid Value
			8	Bacterial endotoxins
			9	Assay
			10	Content of Long chain Triglycerides
			11	Content of Medium chain Triglycerides
			12	Glycerol
			13	Sterility
134.	NRD-264	Invert Sugar 10% Inj. IP	1	Description
			2	Identification
			4	pH Assessment Contant
			5	Average net Content Uniformity Of weight
			7	5-Hydroxymethylfurfural and Related substances
				(by UV)
			8	Bacterial endotoxins
			9	Particulate matter
			10	Extractable volume
				Heavy metals Chloride
				Completeness of inversion(by HPLC)
			11	Assay:
			12	Sterility
135.	NRD-265	Iohexol USP (solution for Injection) non	1	Description
		Ionic contrast medium in sterile aqueous	2	Identification (by HPLC)
		solution, 300 mg lodine/ml non ionic 50 ml	3	Organic impurities (by HPLC)
			4	Bacterial endotixins
			5	pH
			6	Particulate matter (by Liquid particle size
			0	analyzer)
			8	Free Iodide
			9	Uniformity Of dosage unit
			10	Sterility
			10	Extractable volume
			12	Assay (by chemical)
136.	NRD-271	Laggemide Infusion 200mg	12	Description
130.	INKD-2/1	Lacosamide Infusion 200mg	2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	•
			7	Particulate matter Pactorial and to vinc
			9	Bacterial endotoxins Assay: (by HPLC)
			10	Sterility
137.	NRD-274	Levosulpride Inj. 12.5 MG/ML 2ml	1	Description
1071	1,112 271		2	Identification (by HPLC)
			3	рН
			4	Average net Content
			5	Uniformity Of weight Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	Assay: (by HPLC)
			10	Sterility
138.	NRD-278	Lignocaine Hydrochloride Inj. IP 2% 50ml	1	Description
		vial	2	Identification A (Chemical)
			3	Identification B: Melting Point
			4	Identification C (Chemical)
			5	pH
			6	2,6-Dimethylaniline
			7	Bacterial endotoxins
				Nominal Volume
			8	
			9	Average Fill Volume
	1		10	Uniformity of Volume
			11	Particulate matter

			12	Assay: Lignocaine hydrochloride (by titration)
			13	Sterility
139.	NRD-285	Mephentermine 30mg/ml Inj. 10ml Vial IP	1	Description
			2	Identification A
			3	Identification B
				Identification C pH
			4	Average net Content
			5	Uniformity Of weight
			8	Particulate matter
			9	Extractable volume
			10	Assay: (by Chemical)
1.40			11	Sterility
140.	NRD-286	Meropenem Inj.IP 2gm	1	Description
			2	Identification (by HPLC)
			3	Average net content
			4	Uniformity of weight
			5	pH
			6	Related Substances (by HPLC)
			7	Content of Sodium (by FP/AAS)
			8	Bacterial endotoxins
			9	Loss on drying
			10	Clarity of solution test a and b
			11	Particulate matter
			12	Assay: (by HPLC)
			13	Sterility
141.	NRD-288	Methotrexate Inj. IP 250 mg	1	Description
		3 6	2	Identification (by UV)
			3	pH
			4	Average net Content
			5	Uniformity Of weight Related substances (by HPLC)
			7	Bacterial endotoxins
			8	Particulate matter
			9	Extractable volume
			10	Assay: (by HPLC)
			11	Sterility
142.	NRD-289	Methotrexate Inj. IP 1000 mg	1	Description
			2	Identification (by UV)
			3	pH America and Content
			4 5	Average net Content Uniformity Of weight
			6	Related substances (by HPLC)
			7	Bacterial endotoxins
			8	Particulate matter
			9	Extractable volume
			10	
			11	Sterility
43.	NRD-290	Methylene Blue Inj. USP 10mg/ml	1	Description
			2	Identification A (by UV) Identification B (by HPLC)
			3	Organic Impurities (by HPLC)
			5	
			6	pH
			7	Average net Content
			8	Uniformity Of dosage unit
		[9	Extractable volume
			10	Particulate matter
			11	Bacterial endotoxins
			12	Assay: (by HPLC)
11	NDD 201	Mathulnradnigalan Asstata In: ID 40m	13	Sterility Description
44.	NRD-291	Methylprednisolon Acetate Inj. IP 40mg	2	Identification A (by IR)
			3	Identification B (by TLC)
			4	pH
			5	Average net Content
			6	Uniformity Of weight
		[7	Particulate matter
			8	Extractable volume
			9	Assay: (by HPLC)



			-	
1.1.7			10	Sterility
145.	NRD-292	Methylprednisolon Acetate Inj. IP 125mg	1	Description Identification A (by IR)
			2	Identification B (by TLC)
			4	pH
			5	Average net Content
			6	Uniformity Of weight
			7	Particulate matter
			8	Extractable volume
			9	Assay: (by HPLC)
			10	Sterility
146.	NRD-294	Midazolam Inj. IP 5mg/ml 1 ml	1	Description
			2	Identification (by IR)
			3	рН
			4	Average net Content
			5	Uniformity Of weight
			6	Related substances (by HPLC) Bacterial endotoxins
			8	Particulate matter
			9	Extractable volume
			10	Assay: (by HPLC)
			11	Sterility
147.	NRD-295	Milrinone Lactate Inj. USP 10 MG	1	Description
		J	2	Identification A (by HPLC)
			3	Identification B (by UV)
			4	Organic Impurities (by HPLC)
			5	Content of Lactic Acid (by HPLC)
			6	pH
			7	Average net Content
			8	Uniformity Of dosage unit Extractable volume
			10	Particulate matter
			10	Bacterial endotoxins
			11	Assay: (by HPLC)
			13	Sterility
148.	NRD-296	Mitomycin Inj. IP 2 mg	1	Description
110.	100 290	Mitomyem nj. n 2 mg	2	Identification (by TLC)
			3	pH
			4	Water
			5	Average net Content
			6	Uniformity Of weight
			7	Clarity of solution test a and b
			8	Particulate matter
				Bacterial endotoxins Assay: (by HPLC)
			10	Sterility
149.	NRD-297	Mitomycin Inj. IP 40 mg	1	Description
149.	NKD-297	Wittomyem mj. nº 40 mg	2	Identification (by TLC)
			3	pH
			4	Water
			5	Average net Content
			6	Uniformity Of weight
			7	Clarity of solution test a and b
			8	Particulate matter
			9	Bacterial endotoxins
			10	Assay: (by HPLC)
1.50	NDD 201	M. '0. '. L' 400 /100 1	11	Sterility Description
150.	NRD-301	Moxifloxin Inj. 400mg/100ml	1 2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	Assay: (by HPLC)
			10	Sterility
151.	NRD-303	Nabpaclitaxel Inj. (Paclitaxel Nano	1	Description
		Particle)100 mg	2	Identification (by HPLC)
			3	pH
			. 4	a second second distance of the second
			4	Average net Content Uniformity Of weight



			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins Assay: (by HPLC)
			10	Sterility
152.	NRD-304	Nandrolone Decanoate Inj. IP 100mg	1	Description
132.	NRD-304	Nandrololie Decalloate Inj. If Tooling	2	Identification (by TLC)
			3	Average net Content
			4	Uniformity Of weight
			5	Particulate matter
			6	Extractable volume
			7	Assay: (by HPLC)
			8	Sterility
153.	NRD-305	Nandrolone Decanoate Inj. IP 50 mg	1	Description
			2	Identification (by TLC)
			4	Average net Content Uniformity Of weight
			5	Particulate matter
			6	Extractable volume
			7	Assay: (by HPLC)
			8	Sterility
154.	NRD-317	Octreotide Inj. 100mg	1	Description
			2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b Particulate matter
			8	Bacterial endotoxins
			9	Assay: (by HPLC)
			10	Sterility
155.	NRD-318	Octreotide-LAR Inj. (long Acting	1	Description
155.	111LD 510	Release) 20 mg	2	Identification (by HPLC)
		Release) 20 mg	3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	, ,
			7	Particulate matter
			8	Bacterial endotoxins
			9	Assay: (by HPLC)
150	NDD 210		10	Sterility
156.	NRD-319	Octreotide-LAR Inj. (long Acting	1	Description
		Release) 30 mg	3	Identification (by HPLC) pH
			4	Average net Content
			5	Uniformity Of weight
			6	• •
			7	Particulate matter
			8	Bacterial endotoxins
			9	Assay: (by HPLC)
			10	Sterility
157.	NRD-322	Ornidazole Inj. IP 500mg	1	Description
			2	Identification (by HPLC)
			3	Appearance of Solution
			4	Related substances (by HPLC)
			5	Average net Content
			6	Uniformity Of weight Bacterial endotoxins
			8	Particulate matter
			9	Extractable volume
			10	Assay: (by HPLC)
			11	Sterility
158.	NRD-323	Palonosetron Inj. 0.25mg	1	Description
	1.12 525		2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	
			7	Particulate matter
	1		8	Bacterial endotoxins
			9	Assay: (by HPLC)



		1	-	
			10	Sterility
159.	NRD-326	Peg Asparaginase Inj. 3750 IU 5 ml	1	Description
			2	Identification A by Fermentive activity
			3	Identification B by chemical test
			4	Constituted solution
			5	Completeness of solution
			6	Clarity of solution
			7	Colour of solution (UV)
			8	Uniformity of dosage unit (weight variation)
			9	Uniformity of weight
			10	Particulate matter by liquid particle size analyser
				By Visual inspection
			11	By light obscuration Particle Count test
			12	
			13	Average Net Content
			14	рН
			15	Bacterial endotoxins
			16	Sterility
			17	Water
			18	Reconstitution time
			19	Content of Amino acetic acid
			20	Content of Protein
			21	Fermentive activity
			21	Specific gravity
160.	NRD-330	Pemetrexed Inj.IP 100mg	1	Description
100.	NKD-330	remettexed inj.ir tooling	2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	,
			7	Particulate matter Assay: (by HPLC)
			9	Sterility
161.	NRD-331	Pemetrexed Inj.IP 500 mg	1	Description
101.	1000 331	remetered inj.ir 500 mg	2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b Particulate matter
			8	
			9	Sterility
162.	NRD-335	Piperacillin 1 gm + Tazobactum 125 mg	1	Description
		Inj. IP	2	Identification (by HPLC)
				Piperacillin
				Tazobactum
			3	pH
			4	Water
			5	Related Substances (by HPLC)
			6	Bacterial Endotoxins
			-	Average net content
			7	
			8	Uniformity of weight
			9	Clarity of solution test a and b
			10	Particulate matter
			11	Assay: (by HPLC)
				Piperacillin
				Tazobactum
			12	Sterility
163.	NRD-336	Piracetam 200mg Inj.	1	Description
105.	1.1.12 330	- maccuuit 200mg mj.	2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b Particulate matter
			/	



			8	Bacterial endotoxins
			9	Assay: (by HPLC)
			10	Sterility
164.	NRD-338	Plerixafor Inj. 24 mg	1	Description
			2	Identification (by HPLC)
			3	pH Assessment Content
			4 5	Average net Content Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	Assay: (by HPLC)
			10	Sterility
165.	NRD-340	Potassium Chloride 10% Injection IP	1	Description
105.	11112 510	roussium emoride 1070 mjection n	2	Identification
			2	
				Potassium
				Chloride
			3	pH
			4	Average net Content
			5	Uniformity Of weight
				Extractable volume
			6	
			7	Particulate matter
			8	Bacterial endotoxins
			9	Assay:(Atomic absorption Spectrometery)
			10	Sterility
	NDD 252	D'	10	Description
66.	NRD-353	Risperidone prolonged released	2	Identification (by HPLC)
		Depot/Suspernsion 25 mg Inj.	3	pH
			4	Average net Content
			5	
			6	
			7	Particulate matter
			8	Bacterial endotoxins
			9	Assay: (by HPLC)
			10	
167.	NRD-354	Risperidone prolonged released	1	Description
		Depot/Suspension 50mg Inj.	2	Identification (by HPLC)
		Depot Suspension Sonig nij.	3	рН
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	Assay: (by HPLC)
			10	Sterility
68.	NRD-361	Ropivacaine Inj. IP 0.75% 20ml vial	1	Description
			2	Identification A (by HPLC)
			3	Identification B (by HPLC)
			4	Limit of Ropivacaine Related Compound (by
				HPLC)
			5	pH
			6	Enantiomeric Purity (by HPLC)
				Average net Content
			7	-
			8	Uniformity Of weight
			9	Extractable volume
			10	Particulate matter
			11	Bacterial endotoxins
				Assay:(by HPLC)
			12	
			13	Sterility
69.	NRD-364	Sildenafil Injection BP 0.8mg	1	Description
			2	Identification A (by TLC)
				Identification B: by HPLC
			4	Related substances (by HPLC)
				-
			5	Average net content
			6	Uniformity of weight
				Particulate matter



			8	Extractable volume
			9	Assay: (by HPLC)
			10	Sterility
170.	NRD-365	Sodium Bicarbonate Inj. 7.5% IP Injection	1	Description
			2	Identification A (Chemical)
			3	Identification B (Chemical)
			4	PH
			-	
			5	Average net content
			6	Uniformity of weight
			7	Bacterial endotoxins
			8	Extractable volume
			9	Particulate matter
			10	Assay: (Chemical)
			11	Sterility
171.	NRD-367	Sodium Hyaluronate Inj. 1.4mg	1	Description
1/1.	INKD-307	Sourum Hyaruronate Inj. 1.4mg	2	Identification (by HPLC)
			3	pH
			4	Average net Content
			5	Uniformity Of weight
			6	Clarity of solution test a and b
			7	Particulate matter
			8	
			9	Assay: (by HPLC)
152			10	
172.	NRD-371	Teicoplanin Inj. IP 200 mg	1	Description
			2	Identification A (by IR)
			4	Identification B (by HPLC) Appearance of Solution
			5	
			6	Composition and Related Substances (by HPLC)
			7	Average net Content
			8	Impurity -A (by HPLC)
			9	Chlorides
			10	Heavy metals
			11	Water
			12	Bacterial endotoxins
			13	, , , , , , , , , , , , , , , , , , , ,
			14	Clarity of solution test a and b
			15	Particulate matter
			16 17	Assay: (by Microbiological) Sterility
173.	NRD-372	Teicoplanin Inj. IP 400 mg	1	Description
175.	INKD-572	Teleoplanni inj. ir 400 mg	2	Identification A (by IR)
			3	Identification B (by HPLC)
			4	
			5	11
			6	
			7	Average net Content
			8	Impurity -A (by HPLC)
			9	
			10	Heavy metals
			11	Water
			12	Bacterial endotoxins
			13 14	Uniformity Of weight Clarity of solution test a and b
			14	Particulate matter
			15	Assay: (by Microbiological)
			10	
174.	NRD-379	Tigecycline for injection USP 50mg	1	Description
1, 1.	1.1.2 577		2	Identification A (by HPLC)
			3	
			4	рН
			5	
			6	Average net Content
			6 7	Average net Content Bacterial Endotoxins
			6 7 8	Average net Content Bacterial Endotoxins Uniformity Of dosage unit
			6 7 8 9	Average net Content Bacterial Endotoxins Uniformity Of dosage unit Clarity of solution test a and b
			6 7 8 9 10	Average net Content Bacterial Endotoxins Uniformity Of dosage unit Clarity of solution test a and b Particulate matter
			6 7 8 9	Average net Content Bacterial Endotoxins Uniformity Of dosage unit Clarity of solution test a and b



175.	NRD-380	Tigecycline for injection USP 100mg	1	Description Identification A (by HPLC)
			2	Identification A (by HPLC) Identification B (by UV)
			4	pH
			5	Organic Impurities (by HPLC)
			6	Average net Content
			7	Bacterial Endotoxins
			8	
			9	Clarity of solution test a and b
			10	Particulate matter
			11	Assay: (by HPLC) Sterility
176.	NRD-381	Tobaramycin Inj. IP 80mg	12	Description
170.	NKD-301	robaraniyeni nij. ir oonig	2	Identification A (by TLC)
			-	Identification B (Chemical)
			3	
			4	РН
				Related substances (by HPLC)
			5	Average net content
			6	Uniformity of weight
			7	Bacterial endotoxins
			8	Extractable volume
			9	Particulate matter
				Assay: (by Microbiological)
			10	
			11	Sterility
177.	NRD-382	Topotecan Inj. IP 1 mg	1	Description
			2	Identification A (by HPLC)
			3	Identification B (Chemical)
			4	PH
			5	Average net content
			6	Uniformity of weight
			7	Bacterial endotoxins
			8	Extractable volume
				Particulate matter
			9	
			10	Assay: (by HPLC)
			11	Sterility
178.	NRD-383	Topotecan Inj. IP 2.5 mg	1	Description
			2	Identification A (by HPLC)
			3	Identification B (Chemical)
			4	РН
			5	Average net content
				Uniformity of weight
			6	Bacterial endotoxins
			7	
			8	Extractable volume
			9	Particulate matter
			10	Assay: (by HPLC)
			11	Sterility
179.	NRD-384	Topotecan Inj. IP 4 mg	1	Description
			2	Identification A (by HPLC)
			3	Identification B (Chemical)
			-	PH
			4	
			5	Average net content
			6	Uniformity of weight
			7	Bacterial endotoxins
			8	Extractable volume
			9	Particulate matter
			10	Assay: (by HPLC)
			10	Sterility
180.	NDD 207	Trobatadin 1 mg Ini	11	Description
100.	NRD-387	Trabectedin 1 mg Inj.	2	Identification (by HPLC)
			3	pH
			4	Average net Content
			4 5	Average net Content Uniformity Of weight Clarity of solution test a and b



NRD-393 Trypan Blue 0.06% w/v Inj. Image: http://doi.org/10.1000/000000000000000000000000000000					
9 Assu: 0: µPIC? 10 Schilay 1181. NRD-393 Trypan Blue 0.06% w/v Inj. 1 Description 12 Menfication (by 1PIC?) 1 Description 131 NRD-393 Trypan Blue 0.06% w/v Inj. 1 Description 14 Definition (by 1PIC?) 1 Description 15 Unformity Of weight 1 Description 16 Schilay Rescription (by 1PIC) 1 182 NRD-394 Triptorelin Inj. 0.1 mg 1 Description 183 NRD-395 Triptorelin Inj.3.75 mg 1 Description 183 NRD-395 Triptorelin Inj.3.75 mg 2 Mentification ofly PIPC?) 184 NRD-396 Triptorelin Inj.11.25 mg 2 Mentification ofly PIPC?) 185 NRD-400 Vinorelbine Inj. IP 10mg 1 Description 185 NRD-400 Vinorelbine Inj. IP 10mg 1 Description 186 NRD-4001 Vinorelbine Inj. IP 10mg 1 Description				7	Particulate matter
181. NRD-393 Trypan Blue 0.06% w/v Inj. 1 Description 181. NRD-393 Trypan Blue 0.06% w/v Inj. 1 Description 182. NRD-394 Triptorelin Inj. Description 1 182. NRD-394 Triptorelin Inj. 0.1 mg 1 Description Set and Description 182. NRD-394 Triptorelin Inj. 0.1 mg 1 Description 1 183. NRD-394 Triptorelin Inj. 0.1 mg 1 Description 1 184. NRD-395 Triptorelin Inj. 3.75 mg 1 Description 1 183. NRD-395 Triptorelin Inj. 3.75 mg 1 Description 1 184. NRD-395 Triptorelin Inj. 11.25 mg 1 Description 1 184. NRD-400 Triptorelin Inj. 11.25 mg 1 Description 1 184. NRD-400 Triptorelin Inj. 11.25 mg 1 Description 1 184. NRD-400 Triptorelin Inj. 11.25 mg 1 Description 1				-	
NRD-393 Trypan Blue 0.06% w/v Inj. Image: Content imag					
1 2 Hemification thy HPLC) 3 pH 4 Average net Content 5 Uniformity Of weight 6 Clarity of solution test and b 7 Particulate matter 8 Basicility 182. NRD-394 Triptorelin Inj. 0.1 mg 1 Description 1 Description 2 Userification matter 3 pH 4 Average net Content 4 Average net Content 5 Uniformity Of veight 6 Clarity of solution test and b 7 Particulate matter 8 Bascription 183. NRD-395 7 Triptorelin Inj.3.75 mg 184. NRD-396 7 Particulate matter 6 Clarity of solution test and b 7 Particulate matter 8 Bascription 184. NRD-396 7 Triptorelin Inj. 11.25 mg 1 <td></td> <td></td> <td></td> <td>10</td> <td>Sterility</td>				10	Sterility
1 2 Hemification thy HPLC) 3 pH 4 Average net Content 5 Uniformity Of weight 6 Clarity of solution test and b 7 Particulate matter 8 Basicility 182. NRD-394 Triptorelin Inj. 0.1 mg 1 Description 1 Description 2 Userification matter 3 pH 4 Average net Content 4 Average net Content 5 Uniformity Of veight 6 Clarity of solution test and b 7 Particulate matter 8 Bascription 183. NRD-395 7 Triptorelin Inj.3.75 mg 184. NRD-396 7 Particulate matter 6 Clarity of solution test and b 7 Particulate matter 8 Bascription 184. NRD-396 7 Triptorelin Inj. 11.25 mg 1 <td>181</td> <td>NRD-393</td> <td>Trypan Blue 0.06% w/y Ini</td> <td>1</td> <td>Description</td>	181	NRD-393	Trypan Blue 0.06% w/y Ini	1	Description
183. NRD-394 Triptorelin Inj. 0.1 mg	101.	100 575	Trypan Dide 0.0070 w/v trij.	2	
182. NRD-394 Triptorelin Inj. 0.1 mg 1 Description 182. NRD-394 Triptorelin Inj. 0.1 mg 1 Description 183. NRD-394 Triptorelin Inj. 0.1 mg 1 Description 184. NRD-395 Triptorelin Inj. 3.75 mg 1 Description 185. NRD-395 Triptorelin Inj. 3.75 mg 1 Description 184. NRD-396 Triptorelin Inj. 3.75 mg 1 Description 184. NRD-396 Triptorelin Inj. 3.75 mg 1 Description 184. NRD-396 Triptorelin Inj. 11.25 mg 1 Description 184. NRD-396 Triptorelin Inj. 11.25 mg 1 Description 185. NRD-400 Vinorelbine Inj. IP 10mg 1 Description 185. NRD-400 Vinorelbine Inj. IP 10mg 1 Description 186. NRD-400 Vinorelbine Inj. IP 10mg 1 Description 186. NRD-401 Vinorelbine Inj. IP 50mg 1 Description				3	
6 Clarity of solution text and b 7 Particulate nature 8 Bacterial endotoxins 8 Assay: (b) IPLC) 10 Sterility 11 Sterility 12 MRD-394 Triptorclin Inj. 0.1 mg 13 Description 14 Average net Content 15 Identification (b) IPLC) 16 Clarity of solution text and b 7 Particulate nuter 16 Sterility 17 Particulate nuter 183 NRD-395 Triptorelin Inj.3.75 mg 184 NRD-396 Triptorelin Inj.3.75 mg 19 Sterility 10 Sterility 10 Sterility 1183 NRD-396 Triptorelin Inj. 11.25 mg 1184 NRD-396 Triptorelin Inj. 11.25 mg 1185 NRD-400 Vinorelbine Inj. IP 10mg 1185 NRD-400 Vinorelbine Inj. IP 10mg 1185 NRD-401 Vinorelbine Inj. IP 10mg 1				4	
8 -7 Particulate matter 8 Basterial endotoxins -9 Assay: (by IPLC) 182. NRD-394 Triptorelin Inj. 0.1 mg 1 Description 182. NRD-395 Triptorelin Inj. 0.1 mg 1 Description 183. NRD-395 Triptorelin Inj. 3.75 mg 1 Clarity of solution test a and b 183. NRD-395 Triptorelin Inj. 3.75 mg 2 Identification (by HPLC) 184. NRD-396 Triptorelin Inj. 11.25 mg 2 Identification (by HPLC) 184. NRD-396 Triptorelin Inj. 11.25 mg 1 Description 184. NRD-396 Triptorelin Inj. 11.25 mg 1 Description 184. NRD-396 Triptorelin Inj. 11.25 mg 1 Description 185. NRD-400 Vinorelbine Inj. IP 10mg 1 Description 185. NRD-400 Vinorelbine Inj. IP 10mg 1 Description 186. NRD-401 Vinorelbine Inj. IP 50mg 1 Description 186. NRD-401				5	
8 Baserial endocoms 9 Assay: (by IH 2C) 10 Steinity 1182. NRD-394 Triptorelin Inj. 0.1 mg 11 Description 12 Identification (by IHPLC) 13 H 14 Average net Content 15 Uniformity Of weight 16 Clarity of Solution test and b 7 Particulate matter 8 Bacterial endocoms 9 Assay: (by IHPC) 10 Steinity 1183. NRD-395 Triptorelin Inj.3.75 mg 1 12 Identification (by IHPLC) 13 pH 4 Average net Content 5 Uniformity Of weight 6 Clarity of Solution test and b 7 Particulate matter is 8 Average net Content 9 Assay: (by IHPLC) 10 Steinity 1185. NRD-400 Vinorelbine Inj. IP 10mg 1 1185.					
9 Asay: (b) IPLC) 182. NRD-394 Triptorelin lnj. 0.1 mg 1 Description 183. NRD-395 Triptorelin lnj. 0.1 mg 1 Description 184. NRD-395 Triptorelin lnj. 3.75 mg 1 Ottormity Of weight 183. NRD-395 Triptorelin lnj. 3.75 mg 1 Description 184. NRD-395 Triptorelin lnj. 3.75 mg 1 Description 184. NRD-396 Triptorelin lnj. 3.75 mg 1 Description 184. NRD-396 Triptorelin lnj. 11.25 mg 1 Description 184. NRD-396 Triptorelin lnj. 11.25 mg 1 Description 184. NRD-400 Vinorelbine lnj. IP 10mg 1 Description 185. NRD-401 Vinorelbine lnj. IP 10mg 1 Description 186. NRD-401 Vinorelbine lnj. IP 50mg 1 Description top UV) 186. NRD-401 Vinorelbine lnj. IP 50mg 1 Description top UV) 187. NRD-401 Vinorelbi					
182. NRD-394 Triptorelin lnj. 0.1 mg 10 Ibecription 182. NRD-394 Triptorelin lnj. 0.1 mg 2 Identification (by IPLC) 183. NRD-395 Triptorelin lnj. 3.75 mg 10 Netrity of weight 183. NRD-395 Triptorelin lnj. 3.75 mg 1 Description 183. NRD-396 Triptorelin lnj. 3.75 mg 1 Description 184. NRD-396 Triptorelin lnj. 11.25 mg 1 Description 185. NRD-400 Vinorelbine lnj. IP 10mg 1 Description 186. NRD-400 Vinorelbine lnj. IP 10mg 1 Description 186. NRD-401 Vinorelbine lnj. IP 50mg 1 Description 186. NRD-401 Vinorelbine lnj. IP 50mg 1 Description				-	
182. NRD-394 Triptorelin Inj. 0.1 mg 1 Description 183. NRD-395 Triptorelin Inj. 0.1 mg 1 Description 184. NRD-395 Triptorelin Inj. 3.75 mg 1 Description 183. NRD-395 Triptorelin Inj. 3.75 mg 1 Description 184. NRD-396 Triptorelin Inj. 3.75 mg 1 Description 184. NRD-396 Triptorelin Inj. 11.25 mg 1 Description 184. NRD-396 Triptorelin Inj. 11.25 mg 1 Description 184. NRD-400 Triptorelin Inj. 11.25 mg 1 Description 185. NRD-400 Vinorelbine Inj. IP 10mg 1 Description 185. NRD-401 Vinorelbine Inj. IP 10mg 1 Description 186. NRD-401 Vinorelbine Inj. IP 50mg 1 Description 186. NRD-401 Vinorelbine Inj. IP 50mg 1 Description 187. NRD-402 Vinorelbine Inj. IP 50mg 1 Description 188. NRD-401 Vinorelbine Inj. IP 50mg 1 Description					
183. NRD-395 Triptorelin Inj.3.75 mg 2 Identification (by HPLC) 183. NRD-395 Triptorelin Inj.3.75 mg 1 Description 184. NRD-396 Triptorelin Inj.3.75 mg 1 Description 183. NRD-397 Triptorelin Inj.3.75 mg 1 Description 184. NRD-396 Triptorelin Inj. 11.25 mg 1 Description 184. NRD-396 Triptorelin Inj. 11.25 mg 1 Description 184. NRD-396 Triptorelin Inj. 11.25 mg 1 Description 184. NRD-400 Vinorelbine Inj. IP 10mg 1 Description 185. NRD-400 Vinorelbine Inj. IP 10mg 1 Description 186. NRD-401 Vinorelbine Inj. IP 50mg 1 Description 186. NRD-401 Vinorelbine Inj. IP 50mg 1 Description 187. NRD-402 Vinorelbine Inj. IP 50mg 1 Description 186. NRD-401 Vinorelbine Inj. IP 50mg 1 Description	182	NRD-39/	Triptorelin Ini 0.1 mg		
183. NRD-395 Triptorelin Inj.3.75 mg	102.	NKD-394	Imptorenni mj. 0.1 mg		
4 Average net Content 6 Clarity of solution tests and b 7 Particulare matter 8 Bacterial endotoxins 9 Assay: (b) HPLC) 10 Sterility 11 Description 12 Magnity (b) HPLC) 13 NRD-395 Triptorelin lnj.3.75 mg 1 14 Average net Content 15 Uniformity Of weight 16 Clarity of solution test and b 17 Particulare matter 184 NRD-396 Triptorelin lnj. 11.25 mg 1 184 NRD-396 Triptorelin lnj. 11.25 mg 1 184 NRD-400 Vinorelbine lnj. IP 10mg 1 185 NRD-400 Vinorelbine lnj. IP 10mg 1 186 Clarity of solution test and b 19 Assay: (by HPLC) 10 Sterility 185 NRD-400 Vinorelbine lnj. IP 10mg 1 10 <td< td=""><td></td><td></td><td></td><td></td><td></td></td<>					
6 Clarity of solution test a and b 7 Particulate matter 8 Bacterial endotoxias 10 Sterility 110 Sterility 110 Sterility 111 Sterility 112 Sterility 1138 NRD-396 1138 NRD-400 1148 NRD-400 1159 NRD-400 1150 Sterility 1160 Sterility				4	Average net Content
7 Particulate matter 9 Assay: (by IPLC) 183. NRD-395 Triptorelin Inj.3.75 mg 1 183. NRD-395 Triptorelin Inj.3.75 mg 1 Description 184. NRD-396 Triptorelin Inj. 11.25 mg 1 Description 185. NRD-400 Vinorelbine Inj. IP 10mg 1 Description 185. NRD-400 Vinorelbine Inj. IP 10mg 1 Description 186. NRD-401 Vinorelbine Inj. IP 50mg 1 Description 186. NRD-401 Vinorelbine Inj. IP 50mg 1 Description 187. NRD-402 Vinorelbine Inj. IP 50mg 1 Description 188. NRD-401 Vinorelbine Inj. IP 50mg 1 Description 188. NRD-402 <td></td> <td></td> <td></td> <td>5</td> <td></td>				5	
8 Bacterial endorxins 9 Assay: (by IPLC) 10 Sterility 11 Description 12 Identification (by HPLC) 3 pH 4 Average net Content 5 Uniformity Of veright 6 Clarity of solution test a and b 7 Particulate matter 8 Bacterial endotoxins 9 Assay: (by IPLC) 10 Sterility 1184. NRD-396 Triptorelin Inj. 11.25 mg 1 12 Identification (by IPLC) 3 pH 4 Average net Content 5 Uniformity Of veright 6 Clarity of solution test and b 7 Particulate matter 8 Bacterial endotoxins 9 Assay: (by IPLC) 185 NRD-400 Vinorelbine Inj. IP 10mg 186 Releftication B (by UV) 19 Light absorption (by UV) 10 Releftication abcoxins					
9 Assay: (by HPLC) 10 Sterility 1183. NRD-395 Triptorelin Inj.3.75 mg 1183. NRD-395 Triptorelin Inj.3.75 mg 1184. NRD-396 Triptorelin Inj. 11.25 mg 1184. NRD-396 Triptorelin Inj. 11.25 mg 1185. NRD-400 Triptorelin Inj. 11.25 mg 1185. NRD-400 Vinorelbine Inj. IP 10mg 1185. NRD-400 Vinorelbine Inj. IP 10mg 1186. NRD-401 Vinorelbine Inj. IP 50mg 1186. NRD-401 Vinorelbine Inj. IP 50mg 1187. NRD-402 Vitamin D Inj. (600000 IU) 1187. NRD-402 Vitamin D Inj. (600000 IU)					
Image: Instance of the second secon					
183. NRD-395 Triptorelin Inj.3.75 mg 1 Description 2 Identification (by HPLC) 3 pH 4 Average net Content 4 Average net Content 5 Unformity Of weight 6 Clarity of Solution test a and b 7 Particulate matter 8 Bacterial endotoxins 9 Assay: (by HPLC) 10 Sterility 11 Description 12 Identification (by HPLC) 13 NRD-396 14 Average net Content 15 Uniformity Of weight 16 Clarity of Solution test a and b 17 Particulate matter 185 NRD-400 Vinorelbine Inj. IP 10mg 1 185 NRD-400 Vinorelbine Inj. IP 10mg 1 186 NRD-401 Vinorelbine Inj. IP 50mg 1 187 NRD-401 Vinorelbine Inj. IP 50mg 1 188 Bertify 19 Extractable volume					
184. NRD-396 Triptorelin Inj. 11.25 mg 2 Identification (by HPLC) 184. NRD-396 Triptorelin Inj. 11.25 mg 1 Description 184. NRD-396 Triptorelin Inj. 11.25 mg 1 Description 185. NRD-400 Vinorelbine Inj. IP 10mg 1 Description 185. NRD-400 Vinorelbine Inj. IP 10mg 1 Description A (by HPLC) 186. NRD-401 Vinorelbine Inj. IP 50mg 1 Description 186. NRD-401 Vinorelbine Inj. IP 50mg 1 Description 187. NRD-402 Vinorelbine Inj. IP 50mg 1 Description 188. NRD-401 Vinorelbine Inj. IP 50mg 1 Description 186. NRD-401 Vinorelbine Inj. IP 50mg 1 Description <td>102</td> <td>NDD 205</td> <td>Trintonolin Ini 2.75 mg</td> <td></td> <td></td>	102	NDD 205	Trintonolin Ini 2.75 mg		
184. NRD-396 Triptorelin Inj. 11.25 mg	103.	INKD-393	mptorenn mj.s./s mg		Identification (by HPLC)
4 Average are Content 5 Uniformity Of weight 6 Clarity of solution test a and b 7 Particulate matter 8 Bacterial endotoxins 9 Assay: (by HPLC) 10 Sterility 11 Description 12 Identification (by HPLC) 3 pH 4 Average net Content 5 Uniformity Of weight 6 Clarity oslution test and b 7 Particulate matter 8 Bacterial endotoxins 4 Average net Content 5 Uniformity Of weight 6 Clarity oslution test and b 7 Particulate matter 8 Bacterial endotoxins 9 Assay: (by HPLC) 10 Sterility 1185. NRD-400 Vinorelbine Inj. IP 10mg 1 11 Bacterial endotoxins 12 Identification A (by HPLC) 13 Identification A (by HPLC)					
6 Clarity of solution test a and b 7 Particulate matter 8 Bacterial endotoxins 9 Assay: (by IPIC) 10 Sterility 1184. NRD-396 Triptorelin Inj. 11.25 mg 11 Description 12 Identification (by IPIC) 13 pH 14 Average net Content 15 Uniformity Of weight 16 Clarity of solution test a and b 17 Particulate matter 185. NRD-400 Vinorelbine Inj. IP 10mg 1 185. NRD-400 Vinorelbine Inj. IP 10mg 1 185. NRD-400 Vinorelbine Inj. IP 10mg 1 186. NRD-401 Vinorelbine Inj. IP 50mg 1 186. NRD-401 Vinorelbine Inj. IP 50mg 1 186. NRD-401 Vinorelbine Inj. IP 50mg 1 187. NRD-401 Vinorelbine Inj. IP 50mg 1				4	Average net Content
184. NRD-396 Triptorelin Inj. 11.25 mg 10 Steriari endotxins 184. NRD-396 Triptorelin Inj. 11.25 mg 10 Sterini control (by HPLC) 184. NRD-396 Triptorelin Inj. 11.25 mg 1 Description 184. NRD-396 Triptorelin Inj. 11.25 mg 1 Description 184. NRD-396 Triptorelin Inj. 11.25 mg 1 Description 185. NRD-400 Vinorelbine Inj. IP 10mg 1 Steriit (contotx) 185. NRD-400 Vinorelbine Inj. IP 10mg 1 Description 186. NRD-400 Vinorelbine Inj. IP 10mg 1 Description 186. NRD-401 Vinorelbine Inj. IP 10mg 1 Description 187. NRD-401 Vinorelbine Inj. IP 50mg 1 Bacterial endotoxins 19 Average net Content 1 Bacterial endotoxins 19 Sterility 1 Bacterial endotoxins 19 Sterility 1 Bacterial endotoxins 10 Parterial endotoxins<				5	Uniformity Of weight
184. NRD-396 Triptorelin Inj. 11.25 mg 1 Description 184. NRD-396 Triptorelin Inj. 11.25 mg 1 Description 184. NRD-396 Triptorelin Inj. 11.25 mg 1 Description 185. NRD-400 Vinorelbine Inj. IP 10mg 1 Identification (by HPLC) 185. NRD-400 Vinorelbine Inj. IP 10mg 1 Description 185. NRD-400 Vinorelbine Inj. IP 10mg 1 Description 186. NRD-400 Vinorelbine Inj. IP 10mg 1 Description 187. NRD-401 Vinorelbine Inj. IP 10mg 1 Description 188. NRD-401 Vinorelbine Inj. IP 10mg 1 Description 188. NRD-401 Vinorelbine Inj. IP 50mg 1 Identification A (by HPLC) 188. NRD-401 Vinorelbine Inj. IP 50mg 1 Description 188. NRD-401 Vinorelbine Inj. IP 50mg 1 Description 188. Related substances (by HPLC) 3 Identification A (by HPLC)					
184. NRD-396 Triptorelin Inj. 11.25 mg 10 Sterijity 184. NRD-396 Triptorelin Inj. 11.25 mg 1 Description 2 Identification (by HPLC) 2 Identification (by HPLC) 4 Average net Content 3 DH 4 Average net Content 5 Uniformity Of weight 6 Clarity of solution test a and b 7 7 Particulate matter 8 8 Bacterial endoxins 9 9 Assay: (by HPLC) 10 185. NRD-400 Vinorelbine Inj. IP 10mg 1 185. NRD-400 Vinorelbine Inj. IP 10mg 1 186. NRD-401 Vinorelbine Inj. IP 50mg 1 18 Identification A (by HPLC) <td></td> <td></td> <td></td> <td></td> <td></td>					
184. NRD-396 Triptorelin Inj. 11.25 mg 1 Description 184. NRD-396 Triptorelin Inj. 11.25 mg 1 Description 1 Average net Content 3 pH 2 Identification (by HPLC) 3 3 pH 6 Clarity of solution test a and b 7 Particulate matter 8 Basterial endotoxins 8 Basterial endotoxins 9 Assay: (by HPLC) 10 Steriity 1 Description 11 Description 1 1 12 Identification A (by HPLC) 4 13 Identification B (by UV) 6 14 Description 1 15 Light absorption (by UV) 6 16 Rutrification A (by HPLC) 1 17 Average net Content 1 18 Informity Of weight 1 19 Extractable volume 10 10 Particulate matter 11 11					
184. NRD-396 Triptorelin Inj. 11.25 mg 1 Description 2 Identification (by HPLC) 3 pH 4 Average net Content 6 Clarity of solution test a and b 7 Particulate matter 8 Baterial endotoxins 9 Assay: (by HPLC) 10 Sterility 11 Description 12 Identification A (by HPLC) 13 Identification A (by HPLC) 14 Description 15 NRD-400 Vinorelbine Inj. IP 10mg 1 185 NRD-400 Vinorelbine Inj. IP 10mg 1 185 NRD-400 Vinorelbine Inj. IP 10mg 1 186 NRD-401 Vinorelbine Inj. IP 50mg 1 186 NRD-401 Vinorelbine Inj. IP 50mg 1 1 Basterial endotoxins 12 Assay: (by HPLC) 13 Sterility 14 Description 15 Identification A (by HPLC)					
185. NRD-400 Ninorelbine Inj. IP 10mg 2 Identification (by HPLC) 3 pH 1 Average net Content 5 Uniformity Of weight 6 Clarity of solution test and b 7 Particular matter 8 Batterial endotoxins 8 Batterial endotoxins 9 Assay: (by HPLC) 10 Sterility 10 Sterility 185. NRD-400 Vinorelbine Inj. IP 10mg 1 Description 10 Sterility 1 Description 11 Batterial endotoxins 9 Extractable volume 10 Sterility 10 9 11 Batterial endotoxins 10 9 12 Assay: (by HPLC) 11 13 13 Sterility 11 13 146. NRD-401 Vinorelbine Inj. IP 50mg 1 1 186. NRD-401 Vinorelbine Inj. IP 50mg 1 Description 18 Uniformity Of weight 1 1 10 18 Identification A (by HPLC) 1 <td< td=""><td>18/</td><td>NPD 306</td><td>Trintorolin Ini 11.25 mg</td><td></td><td></td></td<>	18/	NPD 306	Trintorolin Ini 11.25 mg		
185. NRD-400 Vinorelbine Inj. IP 10mg 1 Description 186. NRD-401 Vinorelbine Inj. IP 50mg 1 Bescription 186. NRD-401 Vinorelbine Inj. IP 50mg 1 Description 186. NRD-401 Vinorelbine Inj. IP 50mg 1 Description 187. NRD-401 Vinorelbine Inj. IP 50mg 1 Description 188. NRD-401 Vinorelbine Inj. IP 50mg 1 Description 188. NRD-401 Vinorelbine Inj. IP 50mg 1 Description 188. NRD-401 Vinorelbine Inj. IP 50mg 1 Description	104.	NKD-390	Inproteini inj. 11.23 liig		
185. NRD-400 Vinorelbine Inj. IP 10mg Identification A (by HPLC) Identification B (by UV) Identification B (by UV) Identification B (by UV) Related substances (by HPLC) Related substances (by HPLC) Related substances (by HPLC) Itight absorption (by UV) Identification B (by UV) Related substances (by HPLC) Related substances (by HPLC) Itight absorption (by UV) Identification B (by UV) Identification B (by UV) Identification B (by UV) Related substances (by HPLC) Assay: (by HPLC) Ibercription Identification A (by HPLC) Ibercription (by UV) Related substances (by HPLC) Ibercription (by UV) Ibercription (by UV) Ibercription <l< td=""><td></td><td></td><td></td><td></td><td></td></l<>					
185. NRD-400 Vinorelbine Inj. IP 10mg					
185. NRD-400 Vinorelbine Inj. IP 10mg 1 Description 185. NRD-400 Vinorelbine Inj. IP 10mg 1 Description 185. NRD-400 Vinorelbine Inj. IP 10mg 1 Description 186. NRD-401 Vinorelbine Inj. IP 10mg 1 Description 186. NRD-401 Vinorelbine Inj. IP 50mg 1 Identification A (by HPLC) 187. NRD-402 Vitamin D Inj. (600000 IU) 1 Description					
8 Bacterial endotoxins 9 Assay: (by HPLC) 10 Sterility 185. NRD-400 Vinorelbine Inj. IP 10mg 1 2 Identification A (by HPLC) 3 Identification B (by UV) 4 pH 5 Light absorption (by UV) 6 Related substances (by HPLC) 7 Average net Content 8 Uniformity Of weight 9 Extractable volume 10 Particulate matter 11 Bacterial endotoxins 12 Assay: (by HPLC) 13 Sterility 146. NRD-401 Vinorelbine Inj. IP 50mg 1 10 Particulate matter 11 Bacterial endotoxins 12 Assay: (by HPLC) 13 Identification A (by HPLC) 14 pH 15 Light absorption (by UV) 16 Related substance (by HPLC) 13 Identification A (by HPLC) 14 pH 15 Light absorption (by UV)					
9 Assay: (by HPLC) 10 Sterility 1185. NRD-400 Vinorelbine Inj. IP 10mg 1 Description 1185. NRD-400 Vinorelbine Inj. IP 10mg 1 Description 1185. NRD-400 Vinorelbine Inj. IP 10mg 1 Identification A (by HPLC) 186. Vinorelbine Inj. IP 50mg 1 Ight absorption (by UV) 186. NRD-401 Vinorelbine Inj. IP 50mg 1 Description 187. NRD-402 Vitamin D Inj. (600000 IU) 1 Description					
10 Sterility 185. NRD-400 Vinorelbine Inj. IP 10mg 1 Description 2 Identification A (by HPLC) 3 Identification B (by UV) 4 pH 5 Light absorption (by UV) 6 Related substances (by HPLC) 7 7 Average net Content 8 Uniformity Of weight 9 Extractable volume 10 Particulate matter 11 Bacterial endotoxins 12 Assay: (by HPLC) 13 Sterility 13 Sterility 186. NRD-401 Vinorelbine Inj. IP 50mg 1 Description 187. NRD-402 Vitamin D Inj. (600000 IU) 6 Related substances (by HPLC) 19 Extractable volume 0 Particulate matter 1					
 185. NRD-400 Vinorelbine Inj. IP 10mg 1 Description 2 Identification A (by HPLC) 3 Identification B (by UV) 4 pH 5 Light absorption (by UV) 6 Related substances (by HPLC) 7 Average net Content 8 Uniformity Of weight 9 Extractable volume 10 Particulate matter 11 Description 12 Assay: (by HPLC) 13 Sterility 14 Description 15 Light absorption (by UV) 16 Related substances (by HPLC) 17 Average net Content 186. NRD-401 Vinorelbine Inj. IP 50mg 11 Description 12 Identification A (by HPLC) 13 Sterility 14 Description 15 Light absorption (by UV) 16 Related substances (by HPLC) 17 Average net Content 187. NRD-402 Vitamin D Inj. (600000 IU) 10 Description 					
 2 Identification A (by HPLC) 3 Identification B (by UV) 4 pH 5 Light absorption (by UV) 6 Related substances (by HPLC) 7 Average net Content 8 Uniformity Of weight 9 Extractable volume 10 Particulate matter 11 Bacterial endotoxins 12 Assay: (by HPLC) 13 Sterility 14 Description 15 Light absorption (by UV) 6 Related substances (by HPLC) 16 Identification A (by HPLC) 17 Average net Content 18 Assay: (by HPLC) 18 Identification B (by UV) 10 Particulate matter 11 Bacterial endotoxins 12 Identification B (by UV) 14 pH 15 Light absorption (by UV) 16 Related substances (by HPLC) 17 Average net Content 18 Uniformity Of weight 10 Particulate matter 11 Bacterial endotoxins 12 Assay: (by HPLC) 13 Sterility 14 Description 14 Description 15 Light absorption (by UV) 16 Related substances (by HPLC) 17 Average net Content 18 Uniformity Of weight 10 Particulate matter 11 Bacterial endotoxins 12 Assay: (by HPLC) 13 Sterility 14 Description 15 Light absorption (by UV) 16 Related substances (by HPLC) 17 Assay: (by HPLC) 18 Assay: (by HPLC) 18 Assay: (by HPLC) 19 Escription 	185.	NRD-400	Vinorelbine Ini, IP 10mg	1	
 4 pH 5 Light absorption (by UV) 6 Related substances (by HPLC) 7 Average net Content 8 Uniformity Of weight 9 Extractable volume 10 Particulate matter 11 Bacterial endotoxins 12 Assay: (by HPLC) 13 Sterility 14 Identification A (by HPLC) 13 Identification A (by HPLC) 3 Identification B (by UV) 6 Related substances (by HPLC) 14 Description 15 Light absorption (by UV) 16 Related substances (by HPLC) 17 Average net Content 18 Uniformity Of weight 10 Description 11 Bacterial endotoxins 12 Assay: (by HPLC) 13 Identification B (by UV) 14 Related substances (by HPLC) 15 Light absorption (by UV) 16 Related substances (by HPLC) 7 Average net Content 10 Particulate matter 11 Bacterial endotoxins 12 Assay: (by HPLC) 13 Sterility 147. NRD-402 Vitamin D Inj. (600000 IU) 1 Description 			·g	2	
 Ish absorption (by UV) Related substances (by HPLC) Average net Content Uniformity Of weight Extractable volume NRD-401 Vinorelbine Inj. IP 50mg Description Identification B (by UV) Related substances (by HPLC) Average net Content Uniformity Of weight Extractable volume Particulate matter Bacterial endotoxins Related substances Sterility Sterility Sterility 					
6 Related substances (by HPLC) 7 Average net Content 8 Uniformity Of weight 9 Extractable volume 10 Particulate matter 11 Bacterial endotoxins 12 Assay: (by HPLC) 13 Sterility 186. NRD-401 Vinorelbine Inj. IP 50mg 1 1 Bescription 2 Identification A (by HPLC) 3 Identification B (by UV) 4 pH 5 Light absorption (by UV) 6 Related substances (by HPLC) 7 Average net Content 8 Uniformity Of weight 9 Extractable volume 10 Particulate matter 11 Bacterial endotoxins 12 Assay: (by HPLC) 13 Sterility					
 Relation of the second state of t					
8 Uniformity Of weight 9 Extractable volume 10 Particulate matter 11 Bacterial endotoxins 12 Assay: (by HPLC) 13 Sterility 186. NRD-401 Vinorelbine Inj. IP 50mg 1 1 Description 2 Identification A (by HPLC) 3 Identification B (by UV) 4 pH 5 Light absorption (by UV) 6 Related substances (by HPLC) 7 Average net Content 8 Uniformity Of weight 9 Extractable volume 10 Particulate matter 11 Bacterial endotoxins 12 Assay: (by HPLC) 13 Sterility					
 9 Extractable volume 10 Particulate matter 11 Bacterial endotoxins 12 Assay: (by HPLC) 13 Sterility 14 Description 2 Identification A (by HPLC) 3 Identification B (by UV) 4 pH 5 Light absorption (by UV) 6 Related substances (by HPLC) 7 Average net Content 8 Uniformity Of weight 9 Extractable volume 10 Particulate matter 11 Description 12 Identification A (by HPLC) 3 Identification B (by UV) 6 Related substances (by HPLC) 7 Average net Content 8 Uniformity Of weight 9 Extractable volume 10 Particulate matter 11 Bacterial endotoxins 12 Assay: (by HPLC) 13 Sterility 187. NRD-402 Vitamin D Inj. (600000 IU) 					
10Particulate matter11Bacterial endotoxins12Assay: (by HPLC)13Sterility186.NRD-401Vinorelbine Inj. IP 50mg11Description2Identification A (by HPLC)3Identification B (by UV)4pH5Light absorption (by UV)6Related substances (by HPLC)7Average net Content8Uniformity Of weight9Extractable volume10Particulate matter11Bacterial endotoxins21Assay: (by HPLC)33Sterility187.NRD-402Vitamin D Inj. (600000 IU)10Pacciption					
186.NRD-401Vinorelbine Inj. IP 50mg1Description186.NRD-401Vinorelbine Inj. IP 50mg1Description2Identification A (by HPLC)3Identification B (by UV)4pH5Light absorption (by UV)6Related substances (by HPLC)7Average net Content8Uniformity Of weight9Extractable volume10Particulate matter11Bacterial endotoxins12Assay: (by HPLC)13Sterility187.NRD-402Vitamin D Inj. (600000 IU)					
186.NRD-401Vinorelbine Inj. IP 50mg1Description2Identification A (by HPLC)3Identification B (by UV)4pH5Light absorption (by UV)6Related substances (by HPLC)7Average net Content8Uniformity Of weight9Extractable volume10Particulate matter11Bacterial endotoxins12Assay: (by HPLC)13Sterility187.NRD-402Vitamin D Inj. (600000 IU)					
186. NRD-401 Vinorelbine Inj. IP 50mg 1 Description 2 Identification A (by HPLC) 3 Identification B (by UV) 4 pH 5 Light absorption (by UV) 6 Related substances (by HPLC) 7 Average net Content 8 Uniformity Of weight 9 Extractable volume 10 Particulate matter 11 Bacterial endotoxins 12 Assay: (by HPLC) 13 Sterility 187. NRD-402 Vitamin D Inj. (600000 IU)					
2 Identification A (by HPLC) 3 Identification B (by UV) 4 pH 5 Light absorption (by UV) 6 Related substances (by HPLC) 7 Average net Content 8 Uniformity Of weight 9 Extractable volume 10 Particulate matter 11 Bacterial endotoxins 12 Assay: (by HPLC) 13 Sterility 187. NRD-402	10.5	NDD 101			
3 Identification B (by UV) 4 pH 5 Light absorption (by UV) 6 Related substances (by HPLC) 7 Average net Content 8 Uniformity Of weight 9 Extractable volume 10 Particulate matter 11 Bacterial endotoxins 12 Assay: (by HPLC) 13 Sterility 187. NRD-402 Vitamin D Inj. (600000 IU)	186.	NKD-401	vinorelbine Inj. IP 50mg		
4 pH 5 Light absorption (by UV) 6 Related substances (by HPLC) 7 Average net Content 8 Uniformity Of weight 9 Extractable volume 10 Particulate matter 11 Bacterial endotoxins 12 Assay: (by HPLC) 13 Sterility 187. NRD-402					
5 Light absorption (by UV) 6 Related substances (by HPLC) 7 Average net Content 8 Uniformity Of weight 9 Extractable volume 10 Particulate matter 11 Bacterial endotoxins 12 Assay: (by HPLC) 13 Sterility 187. NRD-402 Vitamin D Inj. (600000 IU)					
6 Related substances (by HPLC) 7 Average net Content 8 Uniformity Of weight 9 Extractable volume 10 Particulate matter 11 Bacterial endotoxins 12 Assay: (by HPLC) 13 Sterility 187. NRD-402 Vitamin D Inj. (600000 IU)					
187. NRD-402 Vitamin D Inj. (600000 IU) 8 Uniformity Of weight 9 Extractable volume 10 Particulate matter 11 Bacterial endotoxins 12 Assay: (by HPLC) 13 Sterility				6	Related substances (by HPLC)
9 Extractable volume 10 Particulate matter 11 Bacterial endotoxins 12 Assay: (by HPLC) 13 Sterility 187. NRD-402 Vitamin D Inj. (600000 IU)					
10 Particulate matter 11 Bacterial endotoxins 12 Assay: (by HPLC) 13 Sterility 187. NRD-402 Vitamin D Inj. (600000 IU)					
11 Bacterial endotoxins 12 Assay: (by HPLC) 13 Sterility 187. NRD-402 Vitamin D Inj. (600000 IU) 1 Description					
12 Assay: (by HPLC) 13 Sterility 187. NRD-402 Vitamin D Inj. (600000 IU) 1 Description					
13 Sterility 187. NRD-402 Vitamin D Inj. (600000 IU) 1 Description					
187. NRD-402 Vitamin D Inj. (600000 IU) 1 Description					
	187.	NRD-402	Vitamin D Ini. (600000 IU)		
		_		2	Identification (by HPLC)



			3	pH
			4	Average net Content
			5	Uniformity Of weight Clarity of solution test a and b
			7	Particulate matter
			8	Bacterial endotoxins
			9	Assay: (by HPLC)
			10	Sterility
188.	NRD-410	lotion Asceptic (chlorhexadine gluconate 7.5% +15% cetrimide solution in 500ml bottle with dispenser)		As per STP of Firm
189.	NRD-411	Clotrimazole 1%+Beclomethasone Lotion	1	Description
107.		0.025%	2	Identification (by HPLC)
		0.02370	2	Clotrimazole
				Beclomethasone
			3	Contents of Packaged Dosage Forms
			4	Assay: (by HPLC)
				Clotrimazole
				Beclomethasone
190.	NRD-412	Ketaconazole Lotion 2%	1	Description
190.	INIXD-412	Retaconazore Lotion 270	2	Identification (by HPLC)
				Contents of Packaged Dosage Forms
			3	
			4	Assay: (by HPLC)
191.	NRD-413	Minoxidil Lotion 2%	1	Description
			2	Identification (by HPLC)
			3	Contents of Packaged Dosage Forms
			4	Assay: (by HPLC)
192.	NRD-414	Minoxidil Lotion 5%	1	Description
172.			2	Identification (by HPLC)
			3	Contents of Packaged Dosage Forms
			-	
			4	Assay: (by HPLC)
193.	NRD-415	Minoxidil Lotion 10 %	1	Description
			2	Identification (by HPLC)
			3	Contents of Packaged Dosage Forms
			4	Assay: (by HPLC)
194.	NRD-418	sunscreen Lotion SPF 30 (Octinoxate 7.5%,Avobenzone 2%, Oxybenzone 3%, Octocrylene 3% and Zinc Oxide 2%) 50ml		As per STP of Firm
195.	NRD-419	Clotrimazole Lozenges USP 10Mg	1	Description
175.			2	Identification A (by HPLC)
			3	Identification B (by UV)
			4	Average Weight
			5	Dissolution (by HPLC)
			6	Organic Impurity (by HPLC)
			7	Uniformity of Dosage unit
			8	Contents of Packaged Dosage Forms Assay (by HPLC)
196.	NRD-421	Budesonide Inhalation IP 200 mcg.	1	Description
· 70.	11110-421	Badesoniae initiatation in 200 lifeg.	2	Identification A (by UV)
				Identification B (by HPLC)
			3	· · · ·
			4	Average weight
			5	Epimer-A (by HPLC)
			6	Related Substances (by HPLC)
			7	Content of Active Ingredient delivered per actuation
			8	Uniformity of delivered dose
			9	Particle Size
			10	Number of deliveries per container
			10	leak test
				deposition of the emitted dose
			12	Contents of Packaged Dosage Forms
			13	
	1		14	Assay: (by HPLC)
197.	NRD-422	Formeterol 6mcg.+ Fluticasone 250 mcg.		Description



		Inhalation MDI	2	Identification (by HPLC)
				Formetrol
				Budesonide
			3	Average weight
			4	Content of Active Ingredient delivered per actuation
			5	Uniformity of delivered dose
			6	Particle Size
			7	Number of deliveries per container
			8	leak test
			9	deposition of the emitted dose
			10	Contents of Packaged Dosage Forms
			10	Assay: (by HPLC)
			11	Formetrol
				Budesonide
100				
198.	NRD-423	Formoterol 6 mcg. + Budesonide 200 mcg.	1	Description
		MDI IP	2	Identification (by HPLC)
				Formetrol
				Budesonide
			3	Average weight
			4	Content of Active Ingredient delivered per actuation
			5	Uniformity of delivered dose
			6	Particle Size
			7	Number of deliveries per container
			8	leak test
			9	deposition of the emitted dose
			10	Contents of Packaged Dosage Forms
			11	Assay: (by HPLC)
			11	Formetrol
				Budesonide
199.	NRD-424	Formatoral 6 mag. Dudaganida 400 mag	1	Description
199.	NKD-424	Formoterol 6 mcg. + Budesonide 400 mcg.	1	Identification (by HPLC)
		MDI IP	2	
				Formetrol
				Budesonide
			3	Average weight
			4	Content of Active Ingredient delivered per actuation
			5	Uniformity of delivered dose
			6	Particle Size
			7	Number of deliveries per container
			8	leak test
			9	deposition of the emitted dose
			10	Contents of Packaged Dosage Forms
			10	Assay: (by HPLC)
			11	Formetrol
				Budesonide
200		I 11 / 170 I I I		
200.	NRD-425	Leosalbutamol 50mcg.+ Ipratopium	1	Description
				I Idoptition (by HULL')
		40mcg. MDI	2	Identification (by HPLC)
			2	Leosalbutamol
			2	Leosalbutamol Ipratopium
			2	Leosalbutamol Ipratopium Average weight
				Leosalbutamol Ipratopium Average weight Content of Active Ingredient delivered per
			3 4 5	Leosalbutamol Ipratopium Average weight Content of Active Ingredient delivered per actuation Uniformity of delivered dose
			34	Leosalbutamol Ipratopium Average weight Content of Active Ingredient delivered per actuation Uniformity of delivered dose Particle Size
			3 4 5	Leosalbutamol Ipratopium Average weight Content of Active Ingredient delivered per actuation Uniformity of delivered dose
			3 4 5 6	Leosalbutamol Ipratopium Average weight Content of Active Ingredient delivered per actuation Uniformity of delivered dose Particle Size
			3 4 5 6 7	Leosalbutamol Ipratopium Average weight Content of Active Ingredient delivered per actuation Uniformity of delivered dose Particle Size Number of deliveries per container
			3 4 5 6 7 8	Leosalbutamol Ipratopium Average weight Content of Active Ingredient delivered per actuation Uniformity of delivered dose Particle Size Number of deliveries per container leak test



				Leosalbutamol
				Ipratopium
201.	NDD 426	Laurallantamal inholation Calution	1	Description
201.	NRD-426	Levosalbutamol inhalation Solution	1	Identification (by HPLC)
		50mcg	2	Average weight
			3	Content of Active Ingredient delivered per
			4	actuation
			5	Uniformity of delivered dose
			6	Particle Size
			7	Number of deliveries per container
			8	leak test
			9	deposition of the emitted dose
			10	Contents of Packaged Dosage Forms
			11	Assay: (by HPLC)
202.	NRD-429	Fluticasone propionate Nasal Spray IP	1	Description
202.	NRD-42)	50mcg	2	Identification A (by TLC)
		Someg	2	Identification B(by HPLC)
				Related Substances (by HPLC)
			2	Contents of Packaged Dosage Forms
			3	Assay: (by HPLC)
0.2	NDD 421	N	4	
.03.	NRD-431	Neomycin sulphate and Bacitracin Zinc	1	Description
		ointment USP 5 mg + 500 IU/gm USP	2	Identification (by TLC)
				Neomycin sulphate
				Bacitracin
			3	Minimum Fill
			4	Water determination
			5	Uniformity of dosage unit
			6	Assay:
				Neomycin sulphate (microbial)
				Bacitracin (Chemical)
204.	NRD-432	Sodium Chloride Inj. IP 0.9%	1	Description
		3000ML(N.S)	2	Identification (Chemical)
			3	Heavy metals
			4	рН
			5	Particulate contamination (by particle counter)
			6	Extractable volume
			7	Bacterial endotoxins
			8	Assay: Sodium chloride (Chemical)
			9	Sterility
05.	NRD-433	Sodium Chloride Inj. 0.9% Biodegradable	1	Description
05.	100 155	bag non DEHP 500ML	2	Identification (Chemical)
			3	Heavy metals
			4	pH
			5	Particulate contamination (by particle counter)
			6	Extractable volume
			7	Bacterial endotoxins
				Assay: Sodium chloride (Chemical)
			8	Sterility
06	NDD 425	Clobatagol Saliguito agid Ointerent	-	Description
06.	NRD-435	Clobetasol+Salicylic acid Ointment $0.5\% + 6\%$	1	Identification (by HPLC)
		0.5%+6%	2	-
				Clobetasol Solicylia coid
				Salicylic acid
			3	Contents of Packaged Dosage Forms
			4	Assay: (by HPLC)
				Clobetasol
				Salicylic acid
207.	NRD-437	Fluticasone Ointment IP 0.005%	1	Description
			2	Identification A (by TLC)
	1		3	Identification B (by HPLC)



	1	1		
			4	Contents of Packaged Dosage Forms
			5	Assay: (by HPLC)
208.	NRD-439	Tacrolimus Ointment 0 .03%	1	Description
			2	Identification (by HPLC)
			3	Contents of Packaged Dosage Forms
			4	Assay: (by HPLC)
209.	NRD-440	Tacrolimus Ointment 0.1%	1	Description
			2	Identification (by HPLC)
			3	Contents of Packaged Dosage Forms
			4	Assay: (by HPLC)
210.	NRD-452	Bacillus Clausii Spores Suspension 2billion	1	Description
210.	11112 102	/ 5ml	2	Identification (by HPLC)
			3	Water
			4	pH
			5	Stability of Suspension (by HPLC)(if formulation is in suspension form)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
			8	Identification of colour
			9	Microbial Examination
				Total aerobic count
				Total fungal count
211.	NRD-453	Formeterol 20mcg +Budesonide 0.5mg	1	E. coli Description
211.	NKD-435			Identification (by HPLC)
		Respiratory Solution/Suspension	2	Formeterol
				Budesonide
			3	Average net Volume
			4	Uniformity of volume
			5	Assay: (by HPLC)
				Formeterol
				Budesonide
			6	Microbial Examination
				Total aerobic count
				Total fungal count
				E. coli
212.	NRD-454	Levosalbutamol 1.25 mg + Ipratropium	1	Description
	1010	500 mcg Respiratory Solution 2.5 ml	2	Identification (by HPLC)
				Levosalbutamol
				Internation
			2	Ipratropium Average net Volume
			3	Average net Volume
			4	Average net Volume Uniformity of volume
				Average net Volume Uniformity of volume Assay: (by HPLC)
			4	Average net Volume Uniformity of volume Assay: (by HPLC) Levosalbutamol
			4	Average net Volume Uniformity of volume Assay: (by HPLC) Levosalbutamol Ipratropium
			4	Average net Volume Uniformity of volume Assay: (by HPLC) Levosalbutamol Ipratropium Microbial Examination
			45	Average net Volume Uniformity of volume Assay: (by HPLC) Levosalbutamol Ipratropium Microbial Examination Total aerobic count
			45	Average net Volume Uniformity of volume Assay: (by HPLC) Levosalbutamol Ipratropium Microbial Examination
			45	Average net Volume Uniformity of volume Assay: (by HPLC) Levosalbutamol Ipratropium Microbial Examination Total aerobic count
213.	NRD-456	Budesonide 0.5mg/ml Respiratory Solution BP	45	Average net Volume Uniformity of volume Assay: (by HPLC) Levosalbutamol Ipratropium Microbial Examination Total aerobic count Total fungal count
213.	NRD-456	Budesonide 0.5mg/ml Respiratory Solution BP	4 5 6	Average net Volume Uniformity of volume Assay: (by HPLC) Levosalbutamol Ipratropium Microbial Examination Total aerobic count Total fungal count E. coli
213.	NRD-456	Budesonide 0.5mg/ml Respiratory Solution BP	4 5 6 1 2	Average net Volume Uniformity of volume Assay: (by HPLC) Levosalbutamol Ipratropium Microbial Examination Total aerobic count Total fungal count E. coli Description
213.	NRD-456	Budesonide 0.5mg/ml Respiratory Solution BP	4 5 6 1 2 3	Average net Volume Uniformity of volume Assay: (by HPLC) Levosalbutamol Ipratropium Microbial Examination Total aerobic count Total fungal count E. coli Description Identification A (by UV) Identification B (by HPLC)
213.	NRD-456	Budesonide 0.5mg/ml Respiratory Solution BP	$\begin{array}{c} 4\\5\\6\\1\\2\\3\\4\\\end{array}$	Average net VolumeUniformity of volumeAssay: (by HPLC)LevosalbutamolIpratropiumMicrobial ExaminationTotal aerobic countTotal fungal countE. coliDescriptionIdentification A (by UV)Identification B (by HPLC)pH
213.	NRD-456	Budesonide 0.5mg/ml Respiratory Solution BP	$\begin{array}{c} 4\\5\\6\\1\\2\\3\\4\\5\end{array}$	Average net VolumeUniformity of volumeAssay: (by HPLC)LevosalbutamolIpratropiumMicrobial ExaminationTotal aerobic countTotal fungal countE. coliDescriptionIdentification A (by UV)Identification B (by HPLC)pHRelated substances (by HPLC)
213.	NRD-456	Budesonide 0.5mg/ml Respiratory Solution BP		Average net VolumeUniformity of volumeAssay: (by HPLC)LevosalbutamolIpratropiumMicrobial ExaminationTotal aerobic countTotal fungal countE. coliDescriptionIdentification A (by UV)Identification B (by HPLC)pHRelated substances (by HPLC)Epimer A (by HPLC)
213.	NRD-456	Budesonide 0.5mg/ml Respiratory Solution BP	$ \begin{array}{r} 4 \\ 5 \\ \hline 6 \\ \hline 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ \hline 6 \\ 7 \\ \end{array} $	Average net VolumeUniformity of volumeAssay: (by HPLC)LevosalbutamolIpratropiumMicrobial ExaminationTotal aerobic countTotal fungal countE. coliDescriptionIdentification A (by UV)Identification B (by HPLC)pHRelated substances (by HPLC)Epimer A (by HPLC)Nominal Volume
213.	NRD-456	Budesonide 0.5mg/ml Respiratory Solution BP	$ \begin{array}{r} 4 \\ 5 \\ \hline 6 \\ \hline 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ \end{array} $	Average net VolumeUniformity of volumeAssay: (by HPLC)LevosalbutamolIpratropiumMicrobial ExaminationTotal aerobic countTotal fungal countE. coliDescriptionIdentification A (by UV)Identification B (by HPLC)pHRelated substances (by HPLC)Epimer A (by HPLC)Nominal VolumeUniformity of mass
213.	NRD-456	Budesonide 0.5mg/ml Respiratory Solution BP	$ \begin{array}{r} 4 \\ 5 \\ \hline 6 \\ \hline 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ \hline 6 \\ 7 \\ 8 \\ 9 \\ 9 \end{array} $	Average net VolumeUniformity of volumeAssay: (by HPLC)LevosalbutamolIpratropiumMicrobial ExaminationTotal aerobic countTotal fungal countE. coliDescriptionIdentification A (by UV)Identification B (by HPLC)pHRelated substances (by HPLC)Epimer A (by HPLC)Nominal VolumeUniformity of massUniformity of Dosage units
213.	NRD-456	Budesonide 0.5mg/ml Respiratory Solution BP	$ \begin{array}{r} 4 \\ 5 \\ \hline 6 \\ \hline 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ \end{array} $	Average net VolumeUniformity of volumeAssay: (by HPLC)LevosalbutamolIpratropiumMicrobial ExaminationTotal aerobic countTotal fungal countE. coliDescriptionIdentification A (by UV)Identification B (by HPLC)pHRelated substances (by HPLC)Epimer A (by HPLC)Nominal VolumeUniformity of massUniformity of Dosage unitsAssay: (by HPLC)
213.	NRD-456	Budesonide 0.5mg/ml Respiratory Solution BP	$ \begin{array}{r} 4 \\ 5 \\ \hline 6 \\ \hline 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ \hline 6 \\ 7 \\ 8 \\ 9 \\ 9 \end{array} $	Average net VolumeUniformity of volumeAssay: (by HPLC)LevosalbutamolIpratropiumMicrobial ExaminationTotal aerobic countTotal fungal countE. coliDescriptionIdentification A (by UV)Identification B (by HPLC)pHRelated substances (by HPLC)Epimer A (by HPLC)Nominal VolumeUniformity of massUniformity of Dosage units
213.	NRD-456	Budesonide 0.5mg/ml Respiratory Solution BP	$ \begin{array}{r} 4 \\ 5 \\ \hline 6 \\ \hline 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ \end{array} $	Average net VolumeUniformity of volumeAssay: (by HPLC)LevosalbutamolIpratropiumMicrobial ExaminationTotal aerobic countTotal fungal countE. coliDescriptionIdentification A (by UV)Identification B (by HPLC)pHRelated substances (by HPLC)Epimer A (by HPLC)Epimer A (by HPLC)Nominal VolumeUniformity of massUniformity of Dosage unitsAssay: (by HPLC)



			14	Staphylococcus aureus
			15	Pseudomonas curuginesa
			16	Bile-tolerant gram-negative bacteria
214.	NRD-458	Glycopyrronium 25mcg. Inhalation	1	Description
		Solution 2ml.	2	Identification (by HPLC)
			3	Average net Volume
			4	Uniformity of volume
			5	Assay: (by HPLC)
			6	Microbial Examination
			0	Total aerobic count
				Total fungal count
				E. coli
215.	NRD-459	Sadium Chlarida USD 2 0/ Dagningtony	1	Description
215.	NKD-459	Sodium Chloride USP 3 %Respiratory	1	Identification A
		solution	2	Sodium
				Chloride
			3	Identification B (by HPLC)
			4	Net Fill Weight
			5	pH
			6	Content Uniformity for premetered dosage form
			7	Foreign particulate matter
			8	Assay: (by HPLC)
			9	Sterility
216.	NRD-460	Tiotropium Bromide powder for	1	Description
_10.	1112 100	Inhalation IP 18mcg	2	Identification (by HPLC)
		initial in Tomog	3	Acceptance Criteria
			4	Average Fill
			5	Number of deliveries per container
				Uniformity of delivered dose
			6	Contents of Packaged Dosage Forms
			7	
			8	Assay: (by HPLC)
			9	Microbial Contamination
				Total aerobic count
				E. coli
				S. Aureus
				P. Aeruginosa
217.	NRD-463	Fosfomycin Trometamol powder 3gm	1	Description
217.	NRD-403	rosioniyeni rionetanioi powder 5gm	2	Identification (by HPLC)
			3	Average net Content
			4	Uniformity Of weight
210	NDD 465		5	
218.	NRD-465	L-Arginine 3gm and proanthocynadine	1	Description Identification (by HPLC)
		75mg granules	2	L-Arginine
				Proanthocynadine
				Disintegration Time
			3	Average net Content
			4 5	Uniformity Of weight Assay (by HPLC)
			5	L-Arginine
				Proanthocynadine
219.	NRD-467	Racecadotril Sachet IP 10 mg	1	Description
			2	Identification (by HPLC)
			3	
			4	Related substances (by HPLC)
			6	Average net Content Uniformity Of weight
			7	Assay (by HPLC)
220.	NRD-472	Mesalazine Suppository 500mg BP	1	Description
			2	Identification (by TLC)
			3	Related substances (by HPLC)
			4	Impurities A & C (by HPLC)
				Impurities K (by HPLC)
			5	I



			6	Uniformity of dosage Units
			7	Disintegration Time
			8	Assay: (by HPLC)
221.	NRD-475	Cefaclor Oral Suspension IP Each 5 ml	1	Description
221.	1000 175	contain Cefaclor 125 Mg	2	Identification A (by UV)
		contain certación 125 lvig	3	Identification B (by HPLC)
			4	Related substances (by HPLC)
			5	Contents of Packaged Dosage Forms
				Stability of Suspension (by HPLC)
			6	Assay (by HPLC)
			7	Identification of colour
			8	Microbial Examination
				Total aerobic count
				Total fungal count E. coli
222	NDD 476	Cadiena Dhaanhata and Trinalidina Sama	1	Description
222.	NRD-476	Codiene Phosphate and Tripolidine Syrup	2	Identification (by HPLC)
		(each 5ml contains Codiene Phosphate	2	Codiene Phosphate
		10mg and Tripolidine 1.25mg)		Tripolidine
				pH
				Water
			5	Contents of Packaged Dosage Forms
			6	Assay
				Codiene Phosphate
				Tripolidine
			7	Identification of colour
			8	
				Total aerobic count
				Total fungal count
222	NDD 477	Amindining and solution DD 1 MC/MI	- 1	E. coli
223.	NRD-477	Amlodipine oral solution BP 1 MG/ ML	1	Description
			2	Identification A (by TLC)
			3	Identification B (by HPLC)
			4	Related substances (by HPLC)
			5	Contents of Packaged Dosage Forms
			0	Identification of colour
			(Assay: (by HPLC)
			6	
			7	Microbial Examination
				Total aerobic count
				Total fungal count
				E. coli
224.	NRD-480	Baclofen Oral Solution IP 5 MG /ML	1	Description
	11112 100		2	Identification A (by TLC)
				Identification B (by HPLC)
			3	Lactam (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
			8	
			9	Microbial Examination
				Total aerobic count
				Total fungal count E. coli
225.	NRD-481	Coloium Dhoonhota, 200 ml Sumun (aach	1	
223.	NKD-481	Calcium Phosphate 200 ml Syrup (each	1	As per STP of Firm
		10ml contains elemental Calcium 300mg		
		Elemental Phosphorus 150mg, Elemental		
		Magnesium 75mg, Elemental Zinc 4mg,		
		Vitamin D3 200-300IU)		
226.	NRD-486	Cefuroxime Axetil oral suspension BP 125mg/5ml	1	Description
-			2	Identification A (by UV)
			3	Identification B (by HPLC)
			-	-
			4	Acidity and Alkanility
			5	Dissolution (by UV)
				Stability of Suspension (by HPLC)
			6	Related substances (by HPLC)
			7	Contents of Packaged Dosage Forms
			1	Identification of colour



		1		
			8	Assay: (by HPLC)
			9	Microbial Examination
				Total aerobic count
				Total fungal count
				E. coli
227.	NRD-487	Clarithromycin for oral suspension USP	1	Description
227.	11112 407	125mg/5ml	2	Identification (by HPLC)
		125111g/5111	3	pH
			4	Loss on drying
			5	Uniformity of dosage unit
			6	Deliverable Volume
			7	Contents of Packaged Dosage Forms
				Stability of Suspension (by HPLC)
			8	Assay (by HPLC)
			9	Identification of colour
			10	Microbial Examination
				Total aerobic count Total fungal count
				E. coli
228.	NDD 400	Cafanana Ini ID 1 an	1	Description
228.	NRD-488	Cefoperazone Inj. IP 1gm	1	
			2	Identification A (by HPLC)
			3	Identification B
			4	pH
			5	Average net Content
			6	Uniformity Of weight
			7	Bacterial endotoxins
			8	Water
			9	Clarity of solution test a and b
			10	Particulate matter
			11	Assay: (by HPLC)
			12	Sterility
229.	NRD-489	Cyclesnering Oral solution ID 100mg/ml	12	Description
229.	NKD-489	Cyclosporine Oral solution IP 100mg/ml	2	Identification A (by TLC)
			3	
			4	Alcohol (by GLC)
			5	
			6	
			7	Identification of colour
			8	Microbial Examination
				Total aerobic count
				Total fungal count
				E. coli
230.	NRD-491	Cyproheptadine HCL 2mg/5ml Syrup IP	1	Description
			2	Identification (by UV)
			3	pH
			4	Contents of Packaged Dosage Forms Assay (by HPLC)
			6	Identification of colour
			7	Microbial Examination
			/	Total aerobic count
				Total fungal count
				E. coli
231.	NRD-492	Dextromethorphan Hcl +	1	Description
2011	1110 172	Chlorpheniramine Syrup (each 5ml	2	Identification (by HPLC)
				Dextromethorphan
		contains Dextromethorphane HBr 10mg		Chlorpheniramine
		and Chlorpheniramine 2mg)	3	Water
			4	рН
			5	Stability of Suspension (by HPLC) (if
			<u> </u>	formulation is in suspension form)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Dextromethorphan
				Chlorpheniramine
			8	Identification of colour
			9	Microbial Examination
				Total aprobia court
				Total aerobic count
				Total aerobic count Total fungal count E. coli



232.	NRD-494	Drotavarine HCL 20mg/5ml	1	Description
		Syrup/Suspension	2	Identification (by HPLC) Water
			3	pH
			5	Stability of Suspension (by HPLC)(if formulation is in suspension form)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
			8	Identification of colour
			9	Microbial Examination
				Total aerobic count
				Total fungal count
222	NDD 405		1	E. coli
233.	NRD-495	Milk of Magnesia 11.25 ml+ Liquid	1	Description Identification (by HPLC)
		Paraffin 3.75 ml 170 ml Suspension Each	2	Milk of Magnesia
		15 ml contains: Milk of Magnesia 11.25		Liquid Paraffin
		ml+ Liquid Paraffin 3.75 ml 170 ml	3	Water
			4	pH
			5	Stability of Suspension (by HPLC)(if formulation is in suspension form)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Milk of Magnesia
			8	Liquid Paraffin Identification of colour
			9	Microbial Examination
				Total aerobic count
				Total fungal count
				E. coli
234.	NRD-496	Paracetamol 125 mg + Ibuprofen 100 mg	1	Description
		60 ml Suspension each 5 ml Containing :	2	Identification (by HPLC)
		Paracetamol 125 mg + Ibuprofen 100 mg		Ibuprofen Paracetamol
		60 ml	3	Water
			4	pH
			5	Stability of Suspension (by HPLC)(if formulation is in suspension form)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Ibuprofen
				Paracetamol
			8	Identification of colour
			9	Microbial Examination
				Total aerobic count Total fungal count
				E. coli
235.	NRD-497	Enzyme 100 ML Syrup (each contains	1	Description
255.		Diastase & Pepsin 10mg) 100ml	2	Identification (by HPLC)
		Diastase & repsin Tonig) Toolin		Diastase
				Pepsin
			3	Water
			4	pH Stability of Sugaranian (by UDLC)/if formulation
			5	Stability of Suspension (by HPLC)(if formulation is in suspension form)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Diastase
				Pepsin
			8	Identification of colour
			9	Microbial Examination
				Total aerobic count
				Total fungal count E. coli
236.	NRD-501	L-Carnitine 500mg/5ml in 30 ml USP	1	Description
250.	MIXD-301	L-Carmune 500mg/5mm m 50 mm OSF	2	Identification (by HPLC)
			3	pH
			4	Uniformity of dosage unit
			5	Contents of Packaged Dosage Forms
			6	Assay (by HPLC)
			7	Identification of colour
			8	Microbial Examination Total aerobic count

rr		1		
				Total fungal count
227	NDD 502	Levelleneric Octor Data / Data / C	1	E. coli
237.	NRD-503	Levofloxacin Oral Solution IP 125mg/5ml	2	Description Identification (by HPLC)
			4	pH
			5	Related substances (by HPLC)
			6	
			7	Assay (by HPLC)
			8	Identification of colour
			9	Microbial Examination
				Total aerobic count
				Total fungal count
			1	E. coli
238.	NRD-504	Linezolid Oral Suspension/Syrup	1 2	Description Identification (by HPLC)
		100mg/5ml in 30ml	3	
			4	pH
			5	Stability of Suspension (by HPLC) (if
				formulation is in suspension form)
			6	
			7	
			8	Identification of colour
			9	Microbial Examination
				Total aerobic count
				Total fungal count
220	NDD 505	Mafanamiaa Arit Granaria (C. a. a.	1	E. coli Description
239.	NRD-505	Mefenamice Acid Suspension/Syrup	2	Identification (by HPLC)
		100mg/5ml	3	Water
			4	pH
			5	Stability of Suspension (by HPLC) (if
				formulation is in suspension form)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
			8	Identification of colour
			9	Microbial Examination Total aerobic count
				Total fungal count
				E. coli
240.	NRD-508	Montelucast+Levocetrizine Oral	1	Description
2.01	1112 000	Solution/Suspension Each ml contains	2	Identification (by HPLC)
		Montelukast 4mg+Levocetrizine 2.5mg	3	Water
		Wontelukust Hing Devocetrizine 2.5mg	4	рН
			5	Stability of Suspension (by HPLC) (if
			6	formulation is in suspension form) Contents of Packaged Dosage Forms
			6	Assay (by HPLC)
			8	
			9	Microbial Examination
				Total aerobic count
				Total fungal count
				E. coli
241.	NRD-509	Nitrofurantoin oral suspension BP 25mg/5ml in	1	Description
		100ml	2	Identification A (by UV)
			-	Identification B (by chemical)
			3	
			3	Stability of Suspension (by HPLC)
			3	Stability of Suspension (by HPLC)
			4	Stability of Suspension (by HPLC) Contents of Packaged Dosage Forms
				Stability of Suspension (by HPLC) Contents of Packaged Dosage Forms Assay: (by Chemical)
			4 5	Stability of Suspension (by HPLC) Contents of Packaged Dosage Forms Assay: (by Chemical) Identification of colour
			4	Stability of Suspension (by HPLC) Contents of Packaged Dosage Forms Assay: (by Chemical) Identification of colour Microbial Examination
			4 5	Stability of Suspension (by HPLC) Contents of Packaged Dosage Forms Assay: (by Chemical) Identification of colour Microbial Examination Total aerobic count
			4 5	Stability of Suspension (by HPLC) Contents of Packaged Dosage Forms Assay: (by Chemical) Identification of colour Microbial Examination
			4 5	Stability of Suspension (by HPLC) Contents of Packaged Dosage Forms Assay: (by Chemical) Identification of colour Microbial Examination Total aerobic count
242	NRD-510	Ondansetron oral Solution IP 2mg/5ml	4 5	Stability of Suspension (by HPLC) Contents of Packaged Dosage Forms Assay: (by Chemical) Identification of colour Microbial Examination Total aerobic count Total fungal count
242.	NRD-510	Ondansetron oral Solution IP 2mg/5ml	4 5 6	Stability of Suspension (by HPLC) Contents of Packaged Dosage Forms Assay: (by Chemical) Identification of colour Microbial Examination Total aerobic count Total fungal count E. coli
242.	NRD-510	Ondansetron oral Solution IP 2mg/5ml	4 5 6 1 2	Stability of Suspension (by HPLC)Contents of Packaged Dosage FormsAssay: (by Chemical)Identification of colourMicrobial ExaminationTotal aerobic countTotal fungal countE. coliDescriptionIdentification A (by TLC)Identification B (by HPLC)
242.	NRD-510	Ondansetron oral Solution IP 2mg/5ml	4 5 6 1	Stability of Suspension (by HPLC) Contents of Packaged Dosage Forms Assay: (by Chemical) Identification of colour Microbial Examination Total aerobic count Total fungal count E. coli Description Identification A (by TLC) Identification B (by HPLC) pH
242.	NRD-510	Ondansetron oral Solution IP 2mg/5ml	4 5 6 1 2 4	Stability of Suspension (by HPLC)Contents of Packaged Dosage FormsAssay: (by Chemical)Identification of colourMicrobial ExaminationTotal aerobic countTotal fungal countE. coliDescriptionIdentification A (by TLC)Identification B (by HPLC)pHOndansetron Impurity-D (by HPLC)
242.	NRD-510	Ondansetron oral Solution IP 2mg/5ml	4 5 6 1 2 4 5	Stability of Suspension (by HPLC)Contents of Packaged Dosage FormsAssay: (by Chemical)Identification of colourMicrobial ExaminationTotal aerobic countTotal fungal countE. coliDescriptionIdentification A (by TLC)Identification B (by HPLC)pHOndansetron Impurity-D (by HPLC)Related substances (by HPLC)
242.	NRD-510	Ondansetron oral Solution IP 2mg/5ml	4 5 6 1 2 4	Stability of Suspension (by HPLC)Contents of Packaged Dosage FormsAssay: (by Chemical)Identification of colourMicrobial ExaminationTotal aerobic countTotal fungal countE. coliDescriptionIdentification A (by TLC)Identification B (by HPLC)pHOndansetron Impurity-D (by HPLC)



		1		
			8	Identification of colour
			9	Microbial Examination Total aerobic count
				Total fungal count
				Total Enterobacteriaceae
				E. coli
243.	NRD-512	Phenobarbitone 20mg/5ml in 100ml Syrup	1	Description
245.	NRD-312	Thenobaronone zonig/Jill in Toolin Syrup	2	Identification (by HPLC)
			3	Water
			4	pH
			5	Stability of Suspension (by HPLC) (if formulation is in suspension form)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
			8	Identification of colour
			9	Microbial Examination
				Total aerobic count
				Total fungal count
				E. coli
244.	NRD-514	Piracetam Syrup/Suspension 500mg/5ml	1	Description
	1112 011	in 100ml	2	Identification (by HPLC)
		III IOOIIII	3	Water
			4	рН
			5	Stability of Suspension (by HPLC) (if formulation is in suspension form)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
			8	
			9	Microbial Examination
				Total aerobic count
				Total fungal count
				E. coli
245.	NRD-515	Potassium & Magnesium citrate Oral	1	Description
		Solution Each 5ml contains Potassium	2	Identification (by HPLC)
		citrate 1100mg+Magnesium citrate 375mg		Potassium citrate
		entate 1100mg+Magnesium entate 575mg		Magnesium citrate
			3	Water
			4	рН
			5	Contents of Packaged Dosage Forms
			6	Assay (by HPLC)
				Potassium citrate
			7	Magnesium citrate Identification of colour
			8	Microbial Examination
			0	Total aerobic count
				Total fungal count
				E. coli
246.	NRD-516	Ranitidine oral Solution 75mg/5ml IP	1	Description
<i>2</i> 10.	111D J10		2	Identification (by HPLC)
				pH
			4	pm
			4 5	Related substances (by HPLC)
			5	Related substances (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC)
			5 6 7 8	Related substances (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Identification of colour
			5 6 7	Related substances (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Identification of colour Microbial Examination
			5 6 7 8	Related substances (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Identification of colour Microbial Examination Total aerobic count
			5 6 7 8	Related substances (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Identification of colour Microbial Examination Total aerobic count Total fungal count
			5 6 7 8 9	Related substances (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Identification of colour Microbial Examination Total aerobic count Total fungal count E. coli
247.	NRD-517	Rifaximin oral suspension 100mg/5ml	5 6 7 8 9	Related substances (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Identification of colour Microbial Examination Total aerobic count Total fungal count E. coli Description
247.	NRD-517	Rifaximin oral suspension 100mg/5ml	5 6 7 8 9	Related substances (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Identification of colour Microbial Examination Total aerobic count Total fungal count E. coli Description Identification (by HPLC)
247.	NRD-517	Rifaximin oral suspension 100mg/5ml	5 6 7 8 9 9	Related substances (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Identification of colour Microbial Examination Total aerobic count Total fungal count E. coli Description Identification (by HPLC)
247.	NRD-517	Rifaximin oral suspension 100mg/5ml	5 6 7 8 9 9	Related substances (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Identification of colour Microbial Examination Total aerobic count Total fungal count E. coli Description Identification (by HPLC) Water pH
247.	NRD-517	Rifaximin oral suspension 100mg/5ml	5 6 7 8 9 9	Related substances (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Identification of colour Microbial Examination Total aerobic count Total fungal count E. coli Description Identification (by HPLC) Water pH Stability of Suspension (by HPLC) (if
247.	NRD-517	Rifaximin oral suspension 100mg/5ml	5 6 7 8 9 9	Related substances (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Identification of colour Microbial Examination Total aerobic count Total fungal count E. coli Description Identification (by HPLC) Water pH Stability of Suspension (by HPLC) (if formulation is in suspension form)
247.	NRD-517	Rifaximin oral suspension 100mg/5ml	$ \begin{array}{r} 5\\ 6\\ 7\\ 8\\ 9\\ \hline 1\\ 2\\ 3\\ 4\\ 5\\ \end{array} $	Related substances (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Identification of colour Microbial Examination Total aerobic count Total aerobic count Total fungal count E. coli Description Identification (by HPLC) Water pH Stability of Suspension (by HPLC) (if formulation is in suspension form) Contents of Packaged Dosage Forms
247.	NRD-517	Rifaximin oral suspension 100mg/5ml	$ \frac{5}{6} \frac{7}{7} \frac{8}{9} 9 \frac{1}{2} \frac{1}{3} \frac{4}{5} 6 $	Related substances (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Identification of colour Microbial Examination Total aerobic count Total aerobic count Total fungal count E. coli Description Identification (by HPLC) Water pH Stability of Suspension (by HPLC) (if formulation is in suspension form) Contents of Packaged Dosage Forms Assay (by HPLC)
247.	NRD-517	Rifaximin oral suspension 100mg/5ml	$ \begin{array}{r} 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 9 \\ 9 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ \hline 6 \\ 7 \\ 7 \end{array} $	Related substances (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Identification of colour Microbial Examination Total aerobic count Total aerobic count Total fungal count E. coli Description Identification (by HPLC) Water pH Stability of Suspension (by HPLC) (if formulation is in suspension form) Contents of Packaged Dosage Forms
247.	NRD-517	Rifaximin oral suspension 100mg/5ml	5 6 7 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	Related substances (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Identification of colour Microbial Examination Total aerobic count Total fungal count E. coli Description Identification (by HPLC) Water pH Stability of Suspension (by HPLC) (if formulation is in suspension form) Contents of Packaged Dosage Forms Assay (by HPLC) Identification of colour
247.	NRD-517	Rifaximin oral suspension 100mg/5ml	5 6 7 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	Related substances (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Identification of colour Microbial Examination Total aerobic count Total aerobic count Total fungal count E. coli Description Identification (by HPLC) Water pH Stability of Suspension (by HPLC) (if formulation is in suspension form) Contents of Packaged Dosage Forms Assay (by HPLC) Identification of colour Microbial Examination
247.	NRD-517		5 6 7 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	Related substances (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Identification of colour Microbial Examination Total aerobic count Total fungal count E. coli Description Identification (by HPLC) Water pH Stability of Suspension (by HPLC) (if formulation is in suspension form) Contents of Packaged Dosage Forms Assay (by HPLC) Identification of colour Microbial Examination Total aerobic count Total aerobic count
247.	NRD-517 NRD-519	Rifaximin oral suspension 100mg/5ml Sodium Picosulphate Oral Solution 5mg/5ml BP	5 6 7 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	Related substances (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Identification of colour Microbial Examination Total aerobic count Total fungal count E. coli Description Identification (by HPLC) Water pH Stability of Suspension (by HPLC) (if formulation is in suspension form) Contents of Packaged Dosage Forms Assay (by HPLC) Identification of colour Microbial Examination Total aerobic count Total aerobic count



			3	Identification (by HPLC)
			4	Impurity A (by HPLC)
			7	Contents of Packaged Dosage Forms
				Identification of colour
			8	Assay: (by HPLC)
			9	Microbial Examination
				Total aerobic count
				Total fungal count
				E. coli
249.	NRD-520	Sorbitol + Tricholine Citrate	1	Description
,,	1112 020	Syrup/Solution Each 10ml contains	2	Identification (by HPLC)
		Sorbitol(70%) 7.15gm & Tricholine Citrate	3	Water
		(66%) 0.55gm	4	pH Stability of Suspension (by HPLC) (if
			5	formulation is in suspension form)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
			8	
			9	Microbial Examination Total aerobic count
				Total fungal count
				E. coli
250.	NRD-521	Sucralphate Oral Suspension/Syrup Each	1	Description
		5ml contains sucralphate 500mg	2	Identification (by HPLC)
			3	Water pH
			4	Stability of Suspension (by HPLC) (if
			5	formulation is in suspension form)
			6	Contents of Packaged Dosage Forms
			7	
			8	Identification of colour
			9	Microbial Examination Total aerobic count
				Total fungal count
				E. coli
251.	NRD-522	Triclofos oral Solution 500 mg/ 5ml in	1	Description
		30ml	2	Identification A (by Chemical)
			3	Identification B (by Chemical)
			4	Weight per ml
			5	Contents of Packaged Dosage Forms
			6	Assay: (by Chemical)
				Identification of colour
			7	Microbial Examination
				Total Aerobic Count
				Total fungal Count
				E. coli
252.	NRD-523	Ursodeoxycholic oral suspension BP 125mg/5ml	1	Description
252.		100ml Bottle	2	Identification A (by Chemical)
			3	Identification B (by HPLC)
				pH
			4	Related substances (by HPLC)
			5	Contents of Packaged Dosage Forms
			6	
			7	Assay: (by HPLC)
, I			-	Identification of colour
				Microbial Examination
			8	T + 1 11
			0	Total aerobic count
			0	Total fungal count
			0	Total fungal count E. coli
			8	Total fungal count
253.	NRD-524	Zinc Sulpate oral Solution IP 20 mg/5ml		Total fungal count E. coli Assay: (by UV) Description
253.	NRD-524	Zinc Sulpate oral Solution IP 20 mg/5ml	8	Total fungal count E. coli Assay: (by UV)
253.	NRD-524	Zinc Sulpate oral Solution IP 20 mg/5ml	8	Total fungal count E. coli Assay: (by UV) Description
253.	NRD-524	Zinc Sulpate oral Solution IP 20 mg/5ml	8	Total fungal count E. coli Assay: (by UV) Description Identification (by Chemical)



	1			
			4	Weight per ml
			5	Contents of Packaged Dosage Forms
			6	Assay: (by Chemical)
				Identification of colour
			7	Microbial Examination
				Total Aerobic Count
				Total fungal Count
				E. coli
254.	NRD-525	Azithromycin oral suspension IP	1	Description
		100mg/5ml	2	Identification (by HPLC)
		1 ° ° 11 g ° 11 1	3	pH
			4	Related substances (by HPLC)
				Contents of Packaged Dosage Forms
			5	
				Stability of Suspension (by HPLC)
			6	Assay: (by HPLC)
				Identification of colour
			7	Microbial Examination
				Total Aerobic Count
				Total fungal Count
				E. coli
255.	NRD-526	Azithromycin oral suspension IP	1	Description
255.	NKD-520	200mg/5ml		Identification (by HPLC)
		20011g/3111	2	
			3	pH
			4	Related substances (by HPLC)
				Stability of Suspension (by HPLC)
			5	Contents of Packaged Dosage Forms
			6	Assay: (by HPLC)
				Identification of colour
			7	Microbial Examination
				Total Aerobic Count
				Total fungal Count
				E. coli
256	NDD 537		1	Description
256.	NRD-527	Midodrine Tab. 5mg	1	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
257.	NRD-528	Hydroxyurea Cap. 500mg	1	Description
			2	Identification (by IR)
			3	Average weight
			4	Uniformity of weight
			5	Dissolution (by HPLC)
			6	Contents of Packaged Dosage Forms
				Assay: (by HPLC)
250	NIDD 520		7	
258.	NRD-530	Everolimus Tab./Cap. 5mg	1	Description Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
250	NRD-531	Everolimus Tab./Cap. 10mg	1	Description
259.			2	Identification (by HPLC)
259.			3	Average Weight
259.			A	Disintegration or Dissolution (by IIDI C)
259.			4	Disintegration or Dissolution (by HPLC)
259.			5	Uniformity of Content (by HPLC)
259.				Uniformity of Content (by HPLC) Contents of Packaged Dosage Forms
	NRD-532	Tacrolimus Cap. IP 0.25mg	5	Uniformity of Content (by HPLC)
259. 260.	NRD-532	Tacrolimus Cap. IP 0.25mg	5 6 7	Uniformity of Content (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC)



			5	Uniformity of content (by HPLC)
			7	Dissolution (by HPLC)
				Related substances (by HPLC)
			8	Contents of Packaged Dosage Forms
			9	Assay: (by HPLC)
261.	NRD-533	Nintedanib 150MG Tab./Cap.	1	Description
		I I I I I I I I I I I I I I I I I I I	2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	
			7	Assay (by HPLC)
262.	NRD-535	Acebrophylline SR Tab. 200 Mg	1	Description
202.	100 555	Accorophymne Six rub. 200 Mg	2	Identification (by HPLC)
			3	Average Weight
			4	Dissolution (by HPLC)
				1 st time point
				2 nd time point 3 rd time point
			5	Uniformity of Weight
			6	
			7	Assay (by HPLC)
263.	NRD-536	Aceclofenac 100mg + Thiocolchicoside	1	Description
		4mg Tab.	2	Identification (by HPLC)
				Aceclofenac
			3	Thiocolchicoside Average Weight
			4	Disintegration or Dissolution (by HPLC)
			-	Aceclofenac/Thiocolchicoside
			5	Uniformity of Weight
				Uniformity of Content (by HPLC)
				Thiocolchicoside 4mg
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC) Aceclofenac
				Thiocolchicoside
264.	NRD-537	Aceclofenac SR Tab. 200 mg	1	Description
			2	Identification (by HPLC) Average Weight
			4	Dissolution (by HPLC)
			· · ·	1 st time point
				2 nd time point
				3 rd time point
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms Assay (by HPLC)
265.	NRD-538	Aceclofenac+Paracetamol+	1	Description
203.	NKD-338		2	Identification (by HPLC)
		Serratiopeptidase Tab. (100+325+15 mg)		Aceclofenac
				Paracetamol
				Serratiopeptidase
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC) Aceclofenac/Paracetamol/Serratiopeptidase
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Aceclofenac
				Paracetamol
				Serratiopeptidase
266	NDD 520	Africit Tab. 20 and	1	
266.	NRD-539	Afatinib Tab. 20 mg	1	Description Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
267.	NRD-540	Afatinib Tab. 30 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight



			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	
			7	Assay (by HPLC)
268.	NRD-541	Afatinib Tab. 40 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	
			7	Assay (by HPLC)
269.	NRD-542	Alendronate Sodium Tab. IP 70 mg	1	Description
207.	111D 542	Mendronate Bodrum Tub. II 70 mg		Identification A (by HPLC)
			2	-
			3	Average weight
			4	Uniformity of weight
			5	Dissolution (by HPLC)
				Phosphate and Phosphite (by HPLC)
				4-Aminobutanoic Acid (by HPLC)
			7	Contents of Packaged Dosage Forms
				Assay: (by HPLC)
			8	
270.	NRD-543	Alfuzosin Tab. IP 10 mg	1	Description
			2	Identification A (by IR)
			3	Average weight
			4	Uniformity of Content (by HPLC)
			5	Dissolution (by HPLC)
			6	Related substances (by HPLC)
				Contents of Packaged Dosage Forms
			7	
			8	Assay: (by HPLC)
271.	NRD-544	Alpelisib Tab. 150 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4 5	Disintegration or Dissolution (by HPLC)
			6	Uniformity of Weight Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
272.	NRD-545	Alpelisib Tab. 200 mg	1	Description
212.	111D 545	Tupensio Tuo. 200 mg	2	Identification (by HPLC)
			3	
			4	Disintegration or Dissolution (by HPLC)
			5	
			6	
			7	Assay (by HPLC)
273.	NRD-546	Alpelisib Tab. 250 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	
			7	Assay (by HPLC)
274.	NRD-547	Amantidine Tab./Cap. 100mg	1	Description
	1.120 017		2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
075			7	Assay (by HPLC)
275.	NRD-548	Amisulpride Tab. IP 50 mg	1	Description
			2	Identification (by HPLC)
			3	Average weight
			4	Uniformity of weight
			5	Dissolution (by UV)
				Related substances (by HPLC)
			6	
			7	Contents of Packaged Dosage Forms
			8	Assay: (by HPLC)
			0	
276.	NRD-549	Apixaban Tab. 2.5 mg	1	Description
276.	NRD-549	Apixaban Tab. 2.5 mg		



			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
277.	NRD-550	Aniyahan Tah. 5mg	7	Assay (by HPLC) Description
211.	NKD-330	Apixaban Tab. 5mg	2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	
			7	Assay (by HPLC)
278.	NRD-551	Aripiprazole Tab. IP 10 mg	1	Description
			2	Identification(by HPLC)
			3	Average weight
			4	Uniformity of content (by HPLC)
			5	Related Substances (by HPLC)
			6	Dissolution (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	Assay: (by HPLC)
270	NDD 552	A initial Table ID 5 and		Description
279.	NRD-552	Aripiprazole Tab. IP 5 mg	1	
			2	Identification(by HPLC)
			3	Average weight
			4	Uniformity of content (by HPLC)
			5	Related Substances (by HPLC)
			6	Dissolution (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	Assay: (by HPLC)
280.	NRD-553	Aspirin Tab. IP 300 mg	1	Description
280.	NKD-555	Aspirin rao. Ir 500 mg	2	Identification (by Chemical)
			3	Average weight
			4	Uniformity of weight
			5	Salicylic Acid
			6	Dissolution (by UV)
			7	Contents of Packaged Dosage Forms
			8	Assay: (by Chemical)
281.	NRD-555	Atomoxetin Tab. 10 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC) Contents of Packaged Dosage Forms
			6	Assay (by HPLC)
282.	NRD-556	Atomoxetin Tab. 18 mg	1	Description
202.	11110-330	Atomoreun Tau. To mg	2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
202	NDD 555		7	Assay (by HPLC)
283.	NRD-557	Atomoxetin Tab. 25 mg	1	Description Identification (by HPLC)
			2	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
284.	NRD-559	Axitinib Tab. 5mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC) Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
285.	NRD-560	Bilastin Tab. 20mg	1	Description
_000	1.120 000		2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC) Uniformity of Weight



			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
286.	NRD-561	Biotin 5 MG Tab. USP	1	Description
			2	Identification A (by HPLC)
			3	Average weight
			4	Uniformity of dosage unit
			5	Dissolution (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	Assay: (by HPLC)
287.	NRD-562	Bosentan Tab. IP 62.5 mg	1	Description
			2	Identification A (by HPLC)
			3	Average weight
			4	Uniformity of weight
			5	Dissolution (by HPLC)
			6	Related substances (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	Assay: (by HPLC)
200	NRD-564	Deinenseten Tel 50m e	0	Description
288.	NKD-504	Brivaracetam Tab. 50mg	2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	
			6	8 8
289.	NRD-565	Buprenorphine Sublingual	7	Assay (by HPLC) Description
289.	NKD-303		2	Identification A (by TLC)
		Tablet/Buprenorphine HCL Tablet 0.2mg		Identification B (by UV)
			3	Average Weight
				Related substances (by HPLC)
			4	Disintegration Time
			6	Uniformity of Weight Contents of Packaged Dosage Forms
			8	Assay (by UV)
290.	NRD-566	Calcium Acetate Tab. USP 667mg	1	Description
_> 0.	1112 000		2	Identification
				Calcium
			2	Acetate
			3	Limit of Aluminium (by Fluroscence Spectroscopy)
			4	Average Weight
			5	Dissolution (by AAS)
			6	Uniformity of dosage unit
			7	Contents of Packaged Dosage Forms
201	NDD 579	Convertinit Tot. 200	8	Assay (by chemical) Description
291.	NRD-568	Capmatinib Tab. 200 mg	2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
202	NDD 500	Carbimagala Tab. ID 10	7	Assay (by HPLC) Description
292.	NRD-569	Carbimazole Tab. IP 10 mg	1	-
			2	Identification A (by IR)
			3	Identification B (Chemical)
			4	Average weight
			5	Uniformity of content (by UV)
			6	Thiamazole and other related substances (by
			7	HPLC) Disintegration time
			7	_
			8	Contents of Packaged Dosage Forms
			9	Assay: (by HPLC)
293.	NRD-570	Cefixime + Potassium Clavulanate Tab.	1	Description
		200+125mg	2	Identification (by HPLC) Cefixime
				Clavulanic Acid
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC) Cefixime/Clavulanic Acid
				I Chathaning a / Changelania A aid



6			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Cefixime
				Clavulanic Acid
294.	NRD-571	Cefpodoxime proxetil Tab. IP 100mg/	1	Description
		Cefpodoxime proxetil Dispersible Tab.	2	Identification A (by HPLC)
		100mg	3	Average weight
		Tooms	4	Uniformity of weight
				Dissolution (by UV)
			5	
			6	Contents of Packaged Dosage Forms
			7	Assay: (by HPLC)
295.	NRD-572	Cefpodoxime Tab. IP 200mg	1	Description
			2	Identification A (by HPLC)
			3	Average weight
			4	Uniformity of weight
			5	Dissolution (by UV)
			6	Contents of Packaged Dosage Forms
			-	Assay: (by HPLC)
			7	
296.	NRD-573	Cefpodoxime CV 375 Tab.	1	Description Identification (by HPLC)
			2	Identification (by HPLC) Cefpodoxime
				Clavulanic Acid
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
				Cefpodoxime/Clavulanic Acid
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Cefpodoxime
				Clavulanic Acid
297.	NRD-574	Chlordiazepoxide Tab. IP 25 mg	1	Description
297.	INKD-374	Chlordiazepoxide 1 ab. IP 25 llig		-
			2	Identification A (by UV)
			3	Identification B (by Chemical)
			4	Average weight
			5	Uniformity of weight
			6	Dissolution (by UV)
			7	Contents of Packaged Dosage Forms
ŀ				Related substances (by TLC)
1			0	Related substances (by TLC)
200			8	Assay: (by UV)
298.	NRD-575	Chlordiazepoxide 5 Mg + Clidinium 2.5	1	Assay: (by UV) Description
298.	NRD-575	Chlordiazepoxide 5 Mg + Clidinium 2.5 mg Tab.	-	Assay: (by UV) Description Identification (by HPLC)
298.	NRD-575		1	Assay: (by UV) Description Identification (by HPLC) Chlordiazepoxide
298.	NRD-575		1 2	Assay: (by UV) Description Identification (by HPLC) Chlordiazepoxide Clidinium
298.	NRD-575			Assay: (by UV) Description Identification (by HPLC) Chlordiazepoxide Clidinium Average Weight
298.	NRD-575		1 2	Assay: (by UV) Description Identification (by HPLC) Chlordiazepoxide Clidinium
298.	NRD-575			Assay: (by UV) Description Identification (by HPLC) Chlordiazepoxide Clidinium Average Weight Disintegration or Dissolution (by HPLC) Chlordiazepoxide/Clidinium Uniformity of Weight
298.	NRD-575		1 2 3 4	Assay: (by UV) Description Identification (by HPLC) Chlordiazepoxide Clidinium Average Weight Disintegration or Dissolution (by HPLC) Chlordiazepoxide/Clidinium Uniformity of Weight Unifromity of Content (by HPLC)
298.	NRD-575		1 2 3 4	Assay: (by UV) Description Identification (by HPLC) Chlordiazepoxide Clidinium Average Weight Disintegration or Dissolution (by HPLC) Chlordiazepoxide/Clidinium Uniformity of Weight Unifromity of Content (by HPLC) Chlordiazepoxide 5 Mg
298.	NRD-575		1 2 3 4 5	Assay: (by UV) Description Identification (by HPLC) Chlordiazepoxide Clidinium Average Weight Disintegration or Dissolution (by HPLC) Chlordiazepoxide/Clidinium Uniformity of Weight Unifromity of Content (by HPLC) Chlordiazepoxide 5 Mg Clidinium 2.5 mg
298.	NRD-575	· ·	1 2 3 4 5 6	Assay: (by UV) Description Identification (by HPLC) Chlordiazepoxide Clidinium Average Weight Disintegration or Dissolution (by HPLC) Chlordiazepoxide/Clidinium Uniformity of Weight Unifromity of Content (by HPLC) Chlordiazepoxide 5 Mg Clidinium 2.5 mg Contents of Packaged Dosage Forms
298.	NRD-575	· ·	1 2 3 4 5	Assay: (by UV) Description Identification (by HPLC) Chlordiazepoxide Clidinium Average Weight Disintegration or Dissolution (by HPLC) Chlordiazepoxide/Clidinium Uniformity of Weight Uniformity of Content (by HPLC) Chlordiazepoxide 5 Mg Clidinium 2.5 mg Contents of Packaged Dosage Forms Assay (by HPLC)
298.	NRD-575	· ·	1 2 3 4 5 6	Assay: (by UV)DescriptionIdentification (by HPLC)ChlordiazepoxideClidiniumAverage WeightDisintegration or Dissolution (by HPLC)Chlordiazepoxide/ClidiniumUniformity of WeightUnifromity of Content (by HPLC)Chlordiazepoxide 5 MgClidinium 2.5 mgContents of Packaged Dosage FormsAssay (by HPLC)Chlordiazepoxide
298.	NRD-575	· ·	1 2 3 4 5 6	Assay: (by UV) Description Identification (by HPLC) Chlordiazepoxide Clidinium Average Weight Disintegration or Dissolution (by HPLC) Chlordiazepoxide/Clidinium Uniformity of Weight Uniformity of Content (by HPLC) Chlordiazepoxide 5 Mg Clidinium 2.5 mg Contents of Packaged Dosage Forms Assay (by HPLC)
		mg Tab.	1 2 3 4 5 6	Assay: (by UV)DescriptionIdentification (by HPLC)ChlordiazepoxideClidiniumAverage WeightDisintegration or Dissolution (by HPLC)Chlordiazepoxide/ClidiniumUniformity of WeightUnifromity of Content (by HPLC)Chlordiazepoxide 5 MgClidinium 2.5 mgContents of Packaged Dosage FormsAssay (by HPLC)Chlordiazepoxide
	NRD-575 NRD-576	· ·	1 2 3 4 5 6 7	Assay: (by UV) Description Identification (by HPLC) Chlordiazepoxide Clidinium Average Weight Disintegration or Dissolution (by HPLC) Chlordiazepoxide/Clidinium Uniformity of Weight Uniformity of Content (by HPLC) Chlordiazepoxide 5 Mg Clidinium 2.5 mg Contents of Packaged Dosage Forms Assay (by HPLC) Chlordiazepoxide Clidinium Description
		mg Tab.	$ \begin{array}{c} 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 1 \\ 2 \\ \end{array} $	Assay: (by UV) Description Identification (by HPLC) Chlordiazepoxide Clidinium Average Weight Disintegration or Dissolution (by HPLC) Chlordiazepoxide/Clidinium Uniformity of Weight Uniformity of Content (by HPLC) Chlordiazepoxide 5 Mg Clidinium 2.5 mg Contents of Packaged Dosage Forms Assay (by HPLC) Chlordiazepoxide Clidinium Description Identification A (by IR)
		mg Tab.	1 2 3 4 5 6 7	Assay: (by UV)DescriptionIdentification (by HPLC)ChlordiazepoxideClidiniumAverage WeightDisintegration or Dissolution (by HPLC)Chlordiazepoxide/ClidiniumUniformity of WeightUniformity of Content (by HPLC)Chlordiazepoxide 5 MgClidinium 2.5 mgContents of Packaged Dosage FormsAssay (by HPLC)ChlordiazepoxideClidiniumDescriptionIdentification A (by IR)Identification B (by UV)
		mg Tab.	$ \begin{array}{c} 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ \end{array} $	Assay: (by UV) Description Identification (by HPLC) Chlordiazepoxide Clidinium Average Weight Disintegration or Dissolution (by HPLC) Chlordiazepoxide/Clidinium Uniformity of Weight Uniformity of Content (by HPLC) Chlordiazepoxide 5 Mg Clidinium 2.5 mg Contents of Packaged Dosage Forms Assay (by HPLC) Chlordiazepoxide Clidinium Description Identification A (by IR) Identification B (by UV) Identification C (by Chemical)
		mg Tab.	$ \begin{array}{c} 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 4 \end{array} $	Assay: (by UV)DescriptionIdentification (by HPLC)ChlordiazepoxideClidiniumAverage WeightDisintegration or Dissolution (by HPLC)Chlordiazepoxide/ClidiniumUniformity of WeightUniformity of Content (by HPLC)Chlordiazepoxide 5 MgClidinium 2.5 mgContents of Packaged Dosage FormsAssay (by HPLC)ChlordiazepoxideClidiniumDescriptionIdentification A (by IR)Identification B (by UV)Identification C (by Chemical)Average weight
		mg Tab.	$ \begin{array}{c} 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ \end{array} $	Assay: (by UV)DescriptionIdentification (by HPLC)ChlordiazepoxideClidiniumAverage WeightDisintegration or Dissolution (by HPLC)Chlordiazepoxide/ClidiniumUniformity of WeightUniformity of Content (by HPLC)Chlordiazepoxide 5 MgClidinium 2.5 mgContents of Packaged Dosage FormsAssay (by HPLC)ChlordiazepoxideClidiniumDescriptionIdentification A (by IR)Identification B (by UV)Identification C (by Chemical)Average weightUniformity of Content (by HPLC)
298.		mg Tab.	$ \begin{array}{c} 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 4 \end{array} $	Assay: (by UV)DescriptionIdentification (by HPLC)ChlordiazepoxideClidiniumAverage WeightDisintegration or Dissolution (by HPLC)Chlordiazepoxide/ClidiniumUniformity of WeightUniformity of Content (by HPLC)Chlordiazepoxide 5 MgClidinium 2.5 mgContents of Packaged Dosage FormsAssay (by HPLC)ChlordiazepoxideClidiniumDescriptionIdentification A (by IR)Identification B (by UV)Identification C (by Chemical)Average weight
		mg Tab.	$ \begin{array}{c} 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 4 \\ 5 \\ \end{array} $	Assay: (by UV)DescriptionIdentification (by HPLC)ChlordiazepoxideClidiniumAverage WeightDisintegration or Dissolution (by HPLC)Chlordiazepoxide/ClidiniumUniformity of WeightUniformity of Content (by HPLC)Chlordiazepoxide 5 MgClidinium 2.5 mgContents of Packaged Dosage FormsAssay (by HPLC)ChlordiazepoxideClidiniumDescriptionIdentification A (by IR)Identification B (by UV)Identification C (by Chemical)Average weightUniformity of Content (by HPLC)



r		1		
• • • •			9	Assay: (by UV)
300.	NRD-577	Colchicine Tab. IP 0.5mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by Chemical)
			4	Average weight
			5	Uniformity of Content (by HPLC)
			6	Disintegration Time
			7	Related substances (by TLC)
			8	Contents of Packaged Dosage Forms
			9	Assay: (by HPLC)
301.	NRD-578	Cilostazol Tab. IP 50mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by HPLC)
			4	Average weight
			5	Uniformity of weight
			6	Dissolution (by UV)
			7	Contents of Packaged Dosage Forms
			8	Assay: (by HPLC)
202	NRD-579	Cilesterel Teh. ID 100mg		Description
302.	INKD-3/9	Cilostazol Tab. IP 100mg	1	Identification A (by IR)
			2	Identification A (by IK) Identification B (by HPLC)
			4	Average weight
			5	Uniformity of weight
			6	Dissolution (by UV)
			7	Contents of Packaged Dosage Forms
			8	Assay: (by HPLC)
303.	NRD-580	Clarithromycin Tab. IP 250 MG	1	Description
			2	Identification A (by HPLC)
			3	Average weight
			4	Uniformity of weight
			5	Dissolution (by HPLC)
			6	Related substances (by HPLC)
			7	Loss on drying
			8	Contents of Packaged Dosage Forms
			9	Assay: (by HPLC)
304.	NRD-581	Clarithromycin Tab. IP 500mg	1	Description
501.	1000 501		2	Identification A (by HPLC)
			3	Average weight
			4	Uniformity of weight
			5	Dissolution (by HPLC)
				Related substances (by HPLC)
			6	
			7	Loss on drying
			8	Contents of Packaged Dosage Forms
			9	Assay: (by HPLC)
305.	NRD-582	Cilnidipine Tab. IP 5 mg	1	Description
			2	Identification A (by HPLC)
			3	Average weight
			4	Uniformity of Content (by HPLC)
			5	Dissolution (by UV)
			6	Related substances (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	Assay: (by HPLC)
306.	NRD-583	Cilnidipine Tab. IP 10 mg	1	Description
			2	Identification A (by HPLC)
			3	Average weight
			4	Uniformity of Content (by HPLC)
			4	Dissolution (by UV)
			_	Related substances (by HPLC)
			6	Contents of Packaged Dosage Forms
			/	Contents of 1 ackaged Dosage POIIIIS



			1	
			8	Assay: (by HPLC)
307.	NRD-584	Cilnidipine Tab. IP 20 mg	1	Description
			2	Identification A (by HPLC)
			3	Average weight
			4	Uniformity of weight
			5	Dissolution (by UV)
			6	Related substances (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	Assay: (by HPLC)
308.	NRD-585	Clonazepam Tab. IP 0.25	1	Description
500.	1000 505		2	Identification A (by IR)
			3	Identification B (by HPLC)
			4	Average weight
			5	Uniformity of Content (by HPLC)
				Dissolution (by HPLC)
			6	
			7	Related substances (by HPLC)
			8	Contents of Packaged Dosage Forms
			9	Assay: (by HPLC)
309.	NRD-586	Clonazepam Tab. IP 1Mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by HPLC)
			4	Average weight
			5	Uniformity of Content (by HPLC)
			6	Dissolution (by HPLC)
			7	Related substances (by HPLC)
			8	Contents of Packaged Dosage Forms
			9	Assay: (by HPLC)
310.	NRD-587	Clozapine Tab. IP 25 mg	1	Description
510.	11112 507		2	Identification A (by TLC)
			3	Identification B (by HPLC)
			4	Average weight
			5	Uniformity of weight
			6	Dissolution (by UV)
			-	Related substances (by TLC)
			7	Contents of Packaged Dosage Forms
			8	
			9	Assay: (by HPLC)
311.	NRD-588	Clozapine Tab. IP 50 mg	1	Description
			2	Identification A (by TLC)
			3	Identification B (by HPLC)
			4	Average weight
			5	Uniformity of weight
			6	Dissolution (by UV)
			7	Related substances (by TLC)
			8	Contents of Packaged Dosage Forms
			9	Assay: (by HPLC)
312.	NRD-589	Clozapine Tab. IP 100 mg	1	Description
-			2	Identification A (by TLC)
			3	Identification B (by HPLC)
			4	Average weight
			5	Uniformity of weight
			6	Dissolution (by UV)
			7	Related substances (by TLC)
				Contents of Packaged Dosage Forms
			8	
212			9	Assay: (by HPLC)
313.	NRD-590	Co-trimoxazole Tablet IP 480mg	1	Description
		(Trimethoprim 80mg+Sulphamethoxazole	2	Identification A (by IR)
		400mg)		Identification B (by IR)
			3	Identification C (by TLC) Average weight



	1	1	-	
			5	Uniformity of weight
			6	Disintegration Time
			8	Contents of Packaged Dosage Forms
			9	Assay: (by HPLC)
				Trimethoprim (by HPLC)
				Sulphamethoxazole (by HPLC)
314.	NRD-591	Cefuroxime Axetil Tab. IP 500 mg.	1	Description
514.	NRD-391	Ceruroxinie Axetii 1 ab. ii 500 ilig.		Identification A (by IR)
			2	
			3	Identification B (by HPLC)
			4	Average weight
			5	Uniformity of weight
			6	Dissolution (by UV)
			7	Related substances (by HPLC)
			8	Contents of Packaged Dosage Forms
			9	Assay: (by HPLC)
			10	Identification of colour
15	NRD-592	Commelantadina Tal. ID 4Ma	10	Description
315.	NKD-592	Cyproheptadine Tab. IP 4Mg	2	Identification A (by IR)
			3	Identification B (by TLC)
			4	Identification C (by Chemical)
			5	Average Weight
			6	Disintegration Time
			7	Related substances (by TLC)
			8	
			9	Contents of Packaged Dosage Forms
316.	NRD-593	Commentante en Alectado 2 mais (Ethomit	10	Assay (by HPLC) Description
10.	NKD-595	Cyproterone Acetate 2 mg +Ethynil	2	Identification (by HPLC)
		Estradiol 0.035mg Tab.		Cyproterone Acetate
				Ethynil Estradiol
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
				Cyproterone Acetate HCL/Ethynil Estradiol
			5	Uniformity of Content (by HPLC)
				Cyproterone Acetate
			(Ethynil Estradiol
			6	Contents of Packaged Dosage Forms Assay (by HPLC)
			/	Cyproterone Acetate
				Ethynil Estradiol
317.	NRD-594	Dabigatran Tab. 150 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC) Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
18.	NRD-595	Dabigatran Tab. 110 mg	1	Description
- 01			2	Identification (by HPLC)
			3	Average Weight
	1		4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
10	NDD 507	Dahasfanih Tak (Car 50 mg	6 7	Contents of Packaged Dosage Forms Assay (by HPLC)
19.	NRD-596	Dabrafenib Tab./Cap. 50 mg	6 7 1	Contents of Packaged Dosage Forms Assay (by HPLC) Description
19.	NRD-596	Dabrafenib Tab./Cap. 50 mg	6 7	Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC)
19.	NRD-596	Dabrafenib Tab./Cap. 50 mg	6 7 1 2	Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Average Weight
19.	NRD-596	Dabrafenib Tab./Cap. 50 mg	6 7 1 2 3	Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Average Weight Disintegration or Dissolution (by HPLC) Uniformity of Weight
19.	NRD-596	Dabrafenib Tab./Cap. 50 mg	$ \begin{array}{r} 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \end{array} $	Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Average Weight Disintegration or Dissolution (by HPLC)
			$ \begin{array}{r} 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \end{array} $	Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Average Weight Disintegration or Dissolution (by HPLC) Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC)
	NRD-596 NRD-597	Dabrafenib Tab./Cap. 50 mg Dacomitinib Tab. 15 mg	$ \begin{array}{r} 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 1 \end{array} $	Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Average Weight Disintegration or Dissolution (by HPLC) Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC) Description
			$ \begin{array}{r} 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 1 \\ 2 \end{array} $	Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Average Weight Disintegration or Dissolution (by HPLC) Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC)
			$ \begin{array}{r} 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 3 3 $	Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Average Weight Disintegration or Dissolution (by HPLC) Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Average Weight
			$ \begin{array}{r} 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 4 \\ 5 \\ 4 \\ 4 \\ 3 \\ 4 \\ 4 \\ 4 \\ 5 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 4 \\ 5 \\ 7 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 4 \\ 5 \\ 7 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 4 \\ 5 \\ 7 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 4 \\ 4 \\ 4 \\ 4 \\ 5 \\ 7 \\ 7 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 4 \\ 4 \\ 4 \\ 4 \\ 4 \\ 4 \\ 4 \\ 4 \\ 5 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ $	Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Average Weight Disintegration or Dissolution (by HPLC) Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Average Weight Disintegration or Dissolution (by HPLC)
			$ \begin{array}{r} 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ \end{array} $	Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Average Weight Disintegration or Dissolution (by HPLC) Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Average Weight Disintegration or Dissolution (by HPLC) Uniformity of Weight
319. 320.			$ \begin{array}{r} 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 4 \\ 5 \\ 4 \\ 4 \\ 3 \\ 4 \\ 4 \\ 4 \\ 5 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 4 \\ 5 \\ 7 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 4 \\ 5 \\ 7 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 4 \\ 5 \\ 7 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 4 \\ 4 \\ 4 \\ 4 \\ 5 \\ 7 \\ 7 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 4 \\ 4 \\ 4 \\ 4 \\ 4 \\ 4 \\ 4 \\ 4 \\ 5 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ $	Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Average Weight Disintegration or Dissolution (by HPLC) Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Average Weight Disintegration or Dissolution (by HPLC)



			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
322.	NRD-599	Dapagliflozin Tab. 10 MG	1	Description
322.	INKD-399	Dapaginiozini Tao. 10 MG	2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
323.	NRD-600	Dapoxetine Tab. IP 30 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Dissolution (by HPLC)
			6	Uniformity of weight Related substances (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	Assay (by HPLC)
324.	NRD-601	Dapsone Tab. IP 100 mg	1	Description
524.	NKD-001	Dapsone rab. If 100 llig	2	Identification A (by IR)
			3	Identification B (by TLC)
			4	Average Weight
			5	Dissolution (by UV)
			6	Uniformity of weight
			7	Related substances (by TLC)
			8	Contents of Packaged Dosage Forms
			9	Assay (by Chemical)
325.	NRD-602	Deflazacort Tab. 6mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
326.	NRD-603	Deflazacort Tab. 12 MG	1	Description
520.	NRD-005	Denazacon rab. 12 WG	2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
327.	NRD-604	Desvenlafaxine Tab. 50mg CR/PR/SR/ER	1	Description
			2	Identification (by HPLC)
			3	Average Weight Dissolution (by HPLC)
			4	1 st time point
				2 nd time point
			-	3 rd time point
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
328.	NRD-605	Diclofenac Sodium 50mg+ Paracetamol	1	Description
		325mg+ Serratiopeptidase 10mg Tab.	2	Identification (by HPLC)
		6		Diclofenac
				Serratiopeptidase
			^	Paracetamol
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC) Diclofenac/Serratiopeptidase/Paracetamol
			5	Uniformity of Weight
				Uniformity of Content (by HPLC)
				Serratiopeptidase 10mg
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Diclofenac
			-	Serratiopeptidase
				* *
			1	Paracetamol
329.	NRD-606	Diclofenac 50 mg and Thiocolchicoside 8	1	Description Identification (by HPLC)



		mg Tab.		Diclofenac
			3	Thiocolchicoside Average Weight
			4	
			-	Diclofenac/Thiocolchicoside
			5	Uniformity of Weight
			6	
				Thiocolchicoside 8 mg
			7	Contents of Packaged Dosage Forms
			8	Assay (by HPLC) Diclofenac
				Thiocolchicoside
330.	NRD-608	Diltiazem CR/prolonged released Tab. BP	1	Description
		90mg	2	Identification A (by TCL)
		Ū.		dentification B (by HPLC)
			3	Related substances (by HPLC)
			4	Average weight
				Uniformity of weight
			5	
			6	Disintegration Time
			7	Contents of Packaged Dosage Forms
			8	Assay: (by HPLC)
331.	NRD-609	Dimethyl Fumarate Tab. 120 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			7	Contents of Packaged Dosage Forms Assay (by HPLC)
332.	NRD-610	Dimethyl Fumarate Tab. 240mg	1	Description
552.	NKD-010	Dimetry Fundrate 1 ab. 240mg	2	Identification (by HPLC)
			3	
			4	
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
333.	NRD-611	Disulfiram Tab. 500mg	1	Description
			2	Identification A (by IR) Identification B (by TLC)
			4	Identification C (by Chemical)
			5	
			6	
			7	Disintegration Time
			8	Uniformity of weight
			9	Related substances (by TLC)
			10	8 8
a a i			11	Assay (by UV)
334.	NRD-612	Disulfiram Tab. IP 250mg	1	Description
			2	Identification A (by IR) Identification B (by TLC)
			5	Average Weight
			6	Diethyldithiocarbamate
			7	Disintegration Time
			8	Uniformity of weight
			9	Related substances (by TLC)
			10	Contents of Packaged Dosage Forms
			11	Assay (by UV)
335.	NRD-613	Donepezil Tab. IP 5 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			5	Dissolution (by HPLC) Related substances (by HPLC)
			6	Uniformity of Content (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	Assay (by HPLC)
336.	NRD-614	Duloxetine gastro resistant Tab. IP 20 mg	1	Description
			2	Identification (by HPLC)
			3	Average weight
			4	Uniformity of weight
			5	Dissolution (by HPLC)



	1		1	0.1M HCL
				Phosphate Buffer
			6	Contents of Packaged Dosage Forms
			7	Assay: (by HPLC)
337.	NRD-615	Duloxitine gastro resistant Tab. IP 30 mg	1	Description
			2	Identification (by HPLC)
			3	Average weight
			4	Uniformity of weight
			5	Dissolution (by HPLC)
			5	0.1M HCL
				Phosphate Buffer
			6	Contents of Packaged Dosage Forms
			7	Assay: (by HPLC)
338.	NRD-616	Dydrogesterone Tab. IP 10mg	1	Description
			2	Identification A (by IR)
				Identification B (by HPLC)
			3	Average Weight Disintegration Time
			4	Related substances (by HPLC)
			5	Uniformity of Content (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	Assay (by HPLC)
339.	NRD-617	Eltrombopag Tab./Cap. 25MG	1	Description
		F.8 f	2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
240	NDD (10		7	Assay (by HPLC)
340.	NRD-618	Eltrombopag Tab./Cap. 50MG	1 2	Description Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
341.	NRD-619	Empagliflazone Tab. 10mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms Assay (by HPLC)
342.	NRD-620	Empediflezone Teh. 25mg	1	Description
342.	NKD-020	Empagliflazone Tab. 25mg	2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
343.				
545.	NRD-621	Entacapone Tab. IP 200 mg	1	Description
545.	NRD-621	Entacapone Tab. IP 200 mg	2	Identification A (by IR)
545.	NRD-621	Entacapone Tab. IP 200 mg	2 3	Identification A (by IR) Identification B (by HPLC)
545.	NRD-621	Entacapone Tab. IP 200 mg	2 3 4	Identification A (by IR) Identification B (by HPLC) Average Weight
545.	NRD-621	Entacapone Tab. IP 200 mg	2 3 4 5	Identification A (by IR) Identification B (by HPLC) Average Weight Dissolution (by UV)
545.	NRD-621	Entacapone Tab. IP 200 mg	2 3 4 5 6	Identification A (by IR) Identification B (by HPLC) Average Weight Dissolution (by UV) Uniformity of weight
545.	NRD-621	Entacapone Tab. IP 200 mg	2 3 4 5	Identification A (by IR) Identification B (by HPLC) Average Weight Dissolution (by UV) Uniformity of weight Related substances (by HPLC)
545.	NRD-621	Entacapone Tab. IP 200 mg	$ \begin{array}{r} 2\\ 3\\ 4\\ 5\\ 6\\ 7 \end{array} $	Identification A (by IR) Identification B (by HPLC) Average Weight Dissolution (by UV) Uniformity of weight
			$ \begin{array}{r} 2\\ 3\\ 4\\ 5\\ 6\\ 7\\ 8\\ \end{array} $	Identification A (by IR) Identification B (by HPLC) Average Weight Dissolution (by UV) Uniformity of weight Related substances (by HPLC) Contents of Packaged Dosage Forms
	NRD-621 NRD-622	Entacapone Tab. IP 200 mg Erlotinib Tab. IP 150 mg	$ \begin{array}{r} 2\\ 3\\ 4\\ 5\\ 6\\ 7\\ 8\\ 9 \end{array} $	Identification A (by IR) Identification B (by HPLC) Average Weight Dissolution (by UV) Uniformity of weight Related substances (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC)
			$ \begin{array}{r} 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 1 \end{array} $	Identification A (by IR) Identification B (by HPLC) Average Weight Dissolution (by UV) Uniformity of weight Related substances (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Average Weight
			$ \begin{array}{r} 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 1 \\ 2 \\ 3 \\ 4 \\ 4 \end{array} $	Identification A (by IR) Identification B (by HPLC) Average Weight Dissolution (by UV) Uniformity of weight Related substances (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Average Weight Dissolution (by HPLC)
			$ \begin{array}{r} 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ \end{array} $	Identification A (by IR) Identification B (by HPLC) Average Weight Dissolution (by UV) Uniformity of weight Related substances (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Average Weight Dissolution (by HPLC) Uniformity of weight
			$ \begin{array}{r} 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ \end{array} $	Identification A (by IR) Identification B (by HPLC) Average Weight Dissolution (by UV) Uniformity of weight Related substances (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Average Weight Dissolution (by HPLC) Uniformity of weight Related substances (by HPLC)
			$ \begin{array}{r} 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7$	Identification A (by IR) Identification B (by HPLC) Average Weight Dissolution (by UV) Uniformity of weight Related substances (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Average Weight Dissolution (by HPLC) Uniformity of weight Related substances (by HPLC) Contents of Packaged Dosage Forms
344.	NRD-622	Erlotinib Tab. IP 150 mg	$ \begin{array}{r} 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 8 \\ 8 \\ 8 \\ 8 \\ 8 \\ 8 \\ 8 \\ 8 \\ 8$	Identification A (by IR) Identification B (by HPLC) Average Weight Dissolution (by UV) Uniformity of weight Related substances (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Average Weight Dissolution (by HPLC) Uniformity of weight Related substances (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC)
			$ \begin{array}{r} 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7 \\ 7$	Identification A (by IR) Identification B (by HPLC) Average Weight Dissolution (by UV) Uniformity of weight Related substances (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Average Weight Dissolution (by HPLC) Uniformity of weight Related substances (by HPLC) Contents of Packaged Dosage Forms



I I				
1			4	Dissolution (by HPLC)
			5	Uniformity of weight
			6	
			7 8	Contents of Packaged Dosage Forms Assay (by HPLC)
346.	NRD-624	Esomeprazole Gastro resistant Tab. IP 40	1	Description
540.	NKD-024	-	_	Identification (by HPLC)
		Mg	2	
			3	Average weight
			4	Uniformity of weight
			5	Dissolution (by HPLC)
				0.1M HCL
				Phosphate Buffer
			7	Contents of Packaged Dosage Forms
			8	Assay: (by HPLC)
347.	NRD-625	Estradiol Valerate Tab. 2 mg	1	Description
517.	10020	Estimator vincinie rub. 2 mg	2	Identification (by HPLC)
			3	
			4	8
			5	
			6	8 8
348.	NRD-627	Enzalupamide Tab./Cap. 40mg	1	Assay (by HPLC) Description
540.	MKD-027	Enzalupannue Tau./Cap. 40mg	2	*
			3	
			4	Disintegration or Dissolution (by HPLC)
			5	
				Contents of Packaged Dosage Forms
2.40			7	
349.	NRD-628	Ethynil Estradiol 0.02mg+ Desogestral	1	Description Identification (by HPLC)
		0.15mg Tab.	2	Ethynil Estradiol
				Desogestral
			3	0
			4	
				Ethynil Estradiol/Desogestral
				Unifromity of Content (by HPLC)
				Ethynil Estradiol
			6	Desogestral Contents of Packaged Dosage Forms
			7	
				Ethynil Estradiol
				Desogestral
250	NDD (20		1	Description
350.	NRD-629			Description
		Etizolam Tab. IP 0.5 mg	1	Identification A (by UV)
		Etizolam Tab. IP 0.5 mg	2	Identification A (by UV) Identification B (by HPLC)
		Etizolam 1 ab. IP 0.5 mg		Identification B (by HPLC) Average Weight
		Etizolam 1 ab. IP 0.5 mg	2 3 4	Identification B (by HPLC) Average Weight Dissolution (by HPLC)
		Etizolam 1 ab. IP 0.5 mg	2 3 4 5	Identification B (by HPLC) Average Weight Dissolution (by HPLC) Uniformity of Content (by HPLC)
		Etizolam 1 ab. IP 0.5 mg	2 3 4 5 7	Identification B (by HPLC) Average Weight Dissolution (by HPLC) Uniformity of Content (by HPLC) Contents of Packaged Dosage Forms
251			2 3 4 5 7 8	Identification B (by HPLC) Average Weight Dissolution (by HPLC) Uniformity of Content (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC)
351.	NRD-630	Etoricoxib+Thiocolchicoside(60+8 mg)	2 3 4 5 7 8 1	Identification B (by HPLC) Average Weight Dissolution (by HPLC) Uniformity of Content (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Description
351.	NRD-630		2 3 4 5 7 8	Identification B (by HPLC) Average Weight Dissolution (by HPLC) Uniformity of Content (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC)
351.	NRD-630	Etoricoxib+Thiocolchicoside(60+8 mg)	2 3 4 5 7 8 1	Identification B (by HPLC) Average Weight Dissolution (by HPLC) Uniformity of Content (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Etoricoxib Thiocolchicoside
351.	NRD-630	Etoricoxib+Thiocolchicoside(60+8 mg)	2 3 4 5 7 8 1	Identification B (by HPLC) Average Weight Dissolution (by HPLC) Uniformity of Content (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Etoricoxib Thiocolchicoside Average Weight
351.	NRD-630	Etoricoxib+Thiocolchicoside(60+8 mg)	2 3 4 5 7 8 1 2	Identification B (by HPLC) Average Weight Dissolution (by HPLC) Uniformity of Content (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Etoricoxib Thiocolchicoside Average Weight Disintegration or Dissolution (by HPLC)
351.	NRD-630	Etoricoxib+Thiocolchicoside(60+8 mg)	$\begin{array}{c} 2\\ \hline \\ 3\\ \hline \\ 4\\ \hline \\ 5\\ \hline \\ 7\\ \hline \\ 8\\ 1\\ \hline \\ 2\\ \hline \\ \\ \\ \\ 3\\ 4\\ \end{array}$	Identification B (by HPLC) Average Weight Dissolution (by HPLC) Uniformity of Content (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Etoricoxib Thiocolchicoside Average Weight Disintegration or Dissolution (by HPLC) Etoricoxib/Thiocolchicoside
351.	NRD-630	Etoricoxib+Thiocolchicoside(60+8 mg)	$ \begin{array}{r} 2\\ 3\\ 4\\ 5\\ 7\\ 8\\ 1\\ 2\\ 3\\ 3 \end{array} $	Identification B (by HPLC) Average Weight Dissolution (by HPLC) Uniformity of Content (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Etoricoxib Thiocolchicoside Average Weight Disintegration or Dissolution (by HPLC) Etoricoxib/Thiocolchicoside Uniformity of Weight
351.	NRD-630	Etoricoxib+Thiocolchicoside(60+8 mg)	$\begin{array}{c} 2\\ \hline \\ 3\\ \hline \\ 4\\ \hline \\ 5\\ \hline \\ 7\\ \hline \\ 8\\ 1\\ \hline \\ 2\\ \hline \\ \\ \\ \\ 3\\ 4\\ \end{array}$	Identification B (by HPLC) Average Weight Dissolution (by HPLC) Uniformity of Content (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Etoricoxib Thiocolchicoside Average Weight Disintegration or Dissolution (by HPLC) Etoricoxib/Thiocolchicoside Uniformity of Weight Unifromity of Content (by HPLC)
351.	NRD-630	Etoricoxib+Thiocolchicoside(60+8 mg)	$ \begin{array}{r} 2 \\ 3 \\ 4 \\ 5 \\ 7 \\ 8 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ $	Identification B (by HPLC) Average Weight Dissolution (by HPLC) Uniformity of Content (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Etoricoxib Thiocolchicoside Average Weight Disintegration or Dissolution (by HPLC) Etoricoxib/Thiocolchicoside Uniformity of Weight Unifromity of Content (by HPLC) Thiocolchicoside 8 mg
351.	NRD-630	Etoricoxib+Thiocolchicoside(60+8 mg)	$\begin{array}{c} 2\\ \hline \\ 3\\ \hline \\ 4\\ \hline \\ 5\\ \hline \\ 7\\ \hline \\ 8\\ 1\\ \hline \\ 2\\ \hline \\ \\ \\ \\ 3\\ 4\\ \end{array}$	Identification B (by HPLC) Average Weight Dissolution (by HPLC) Uniformity of Content (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Etoricoxib Thiocolchicoside Average Weight Disintegration or Dissolution (by HPLC) Etoricoxib/Thiocolchicoside Uniformity of Weight Unifromity of Content (by HPLC)
351.	NRD-630	Etoricoxib+Thiocolchicoside(60+8 mg)	$ \begin{array}{r} 2 \\ 3 \\ 4 \\ 5 \\ 7 \\ 8 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 5 \\ 6 \\ \end{array} $	Identification B (by HPLC) Average Weight Dissolution (by HPLC) Uniformity of Content (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Etoricoxib Thiocolchicoside Average Weight Disintegration or Dissolution (by HPLC) Etoricoxib/Thiocolchicoside Uniformity of Weight Uniformity of Content (by HPLC) Thiocolchicoside 8 mg Contents of Packaged Dosage Forms
351.	NRD-630	Etoricoxib+Thiocolchicoside(60+8 mg)	$ \begin{array}{r} 2 \\ 3 \\ 4 \\ 5 \\ 7 \\ 8 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 5 \\ 6 \\ \end{array} $	Identification B (by HPLC) Average Weight Dissolution (by HPLC) Uniformity of Content (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Etoricoxib Thiocolchicoside Average Weight Disintegration or Dissolution (by HPLC) Etoricoxib/Thiocolchicoside Uniformity of Weight Unifromity of Content (by HPLC) Thiocolchicoside 8 mg Contents of Packaged Dosage Forms Assay (by HPLC) Etoricoxib
		Etoricoxib+Thiocolchicoside(60+8 mg) Tab.	$ \begin{array}{c} 2 \\ 3 \\ 4 \\ 5 \\ 7 \\ 8 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 6 \\ 7 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1$	Identification B (by HPLC) Average Weight Dissolution (by HPLC) Uniformity of Content (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Etoricoxib Thiocolchicoside Average Weight Disintegration or Dissolution (by HPLC) Etoricoxib/Thiocolchicoside Uniformity of Weight Uniformity of Content (by HPLC) Thiocolchicoside 8 mg Contents of Packaged Dosage Forms Assay (by HPLC) Etoricoxib Thiocolchicoside
351.	NRD-630 NRD-632	Etoricoxib+Thiocolchicoside(60+8 mg)	$ \begin{array}{r} 2 \\ 3 \\ 4 \\ 5 \\ 7 \\ 8 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ \hline 6 \\ 7 \\ 1 \\ 1 \end{array} $	Identification B (by HPLC) Average Weight Dissolution (by HPLC) Uniformity of Content (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Etoricoxib Thiocolchicoside Average Weight Disintegration or Dissolution (by HPLC) Etoricoxib/Thiocolchicoside Uniformity of Content (by HPLC) Thiocolchicoside 8 mg Contents of Packaged Dosage Forms Assay (by HPLC) Etoricoxib Thiocolchicoside Description
		Etoricoxib+Thiocolchicoside(60+8 mg) Tab.	$ \begin{array}{c} 2 \\ 3 \\ 4 \\ 5 \\ 7 \\ 8 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 2 \\ 1 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2$	Identification B (by HPLC) Average Weight Dissolution (by HPLC) Uniformity of Content (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Etoricoxib Thiocolchicoside Average Weight Disintegration or Dissolution (by HPLC) Etoricoxib/Thiocolchicoside Uniformity of Content (by HPLC) Thiocolchicoside 8 mg Contents of Packaged Dosage Forms Assay (by HPLC) Etoricoxib Thiocolchicoside Description Identification (by HPLC)
		Etoricoxib+Thiocolchicoside(60+8 mg) Tab.	$ \begin{array}{c} 2 \\ 3 \\ 4 \\ 5 \\ 7 \\ 8 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 3 \\ 1 \\ 2 \\ 3 \\ 3 \\ 4 \\ 5 \\ 5 \\ 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 3 \\ 4 \\ 5 \\ 5 \\ 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 3 \\ 5 \\ 5 \\ 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 3 \\ 5 \\ 5 \\ 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 3 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5 \\ 5$	Identification B (by HPLC) Average Weight Dissolution (by HPLC) Uniformity of Content (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Etoricoxib Thiocolchicoside Average Weight Disintegration or Dissolution (by HPLC) Etoricoxib/Thiocolchicoside Uniformity of Weight Unifromity of Content (by HPLC) Thiocolchicoside 8 mg Contents of Packaged Dosage Forms Assay (by HPLC) Etoricoxib Thiocolchicoside Description Identification (by HPLC) Average Weight
		Etoricoxib+Thiocolchicoside(60+8 mg) Tab.	$ \begin{array}{c} 2 \\ 3 \\ 4 \\ 5 \\ 7 \\ 8 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 1 \\ 2 \\ 2 \\ 1 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2$	Identification B (by HPLC) Average Weight Dissolution (by HPLC) Uniformity of Content (by HPLC) Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Etoricoxib Thiocolchicoside Average Weight Disintegration or Dissolution (by HPLC) Etoricoxib/Thiocolchicoside Uniformity of Content (by HPLC) Etoricoxib/Thiocolchicoside Uniformity of Content (by HPLC) Etoricoxib/Thiocolchicoside 8 mg Contents of Packaged Dosage Forms Assay (by HPLC) Etoricoxib Thiocolchicoside 8 mg Contents of Packaged Dosage Forms Assay (by HPLC) Etoricoxib Thiocolchicoside Description Identification (by HPLC) Average Weight Disintegration or Dissolution (by HPLC) Average Weight



			7	Assay (by HPLC)
353.	NRD-633	Febuxostat Tab. 80 mg	1	Description
555.	1000 000	resulting	2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	
			6	
251	NDD (24	Fexofenadine Tab. IP 120 MG	7	Assay (by HPLC) Description
354.	NRD-634	Fexorenadine 1 ab. IP 120 MG	1	-
			2	Identification (by HPLC)
			3	Average weight
			4	Uniformity of weight
			5	Dissolution (by HPLC)
			6	Related substances (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	Assay: (by HPLC)
755	NRD-635	Fexofenadine Tab. IP 180 MG		Description
355.	NKD-635	Fexorenadine 1 ab. IP 180 MG	1	_
			2	Identification (by HPLC)
			3	Average weight
			4	Uniformity of weight
			5	Dissolution (by HPLC)
			6	Related substances (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	Assay: (by HPLC)
356.	NRD-637	Eludrosortisono Teh. DD 100Mag	1	Description
550.	NKD-037	Fludrocortisone Tab. BP 100Mcg		Identification A (by TCL)
			2	
			3	Identification B (by HPLC)
			4	Average weight
			5	Uniformity of Content (by HPLC)
			6	Disintegration Time
			7	Contents of Packaged Dosage Forms
			8	Assay: (by HPLC)
357.	NRD-638	Flunarizine Tab. 10mg	1	Description
557.	NKD-036	Fluitalizine 1ab. Tollig	2	
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
358.	NRD-639	Fluvoxamine Tab. IP 100 mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by TLC)
			4	Average weight
			5	Uniformity of weight
			6	Dissolution (by UV)
				Related substances (by HPLC)
			7	
			8	Contents of Packaged Dosage Forms
			9	Assay: (by HPLC)
359.	NRD-640	Fluvoxamine Tab. IP 50 mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by TLC)
			4	Average weight
			5	Uniformity of weight
				Dissolution (by UV)
			6	-
			7	Related substances (by HPLC)
			8	Contents of Packaged Dosage Forms
			9	Assay: (by HPLC)
360.	NRD-643	Furosemide 20mg + Spironolactone 50mg	1	Description
		Tab.	2	Identification (by HPLC)
				Furosemide
				Spironolactone
			-	
			3	Average Weight Disintegration or Dissolution (by HPLC)



				Furosemide/Spironolactone
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms Assay (by HPLC)
			/	Furosemide
				Spironolactone
261			1	Description
361.	NRD-644	Glucosamine hydrocloride 750mg +	2	Identification (by HPLC)
		Diacerin 50 mg Tab.	2	Glucosamine hydrocloride
				Diacerin
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Glucosamine hydrocloride/Diacerin Uniformity of Weight
			5	
			7	Assay (by HPLC)
				Glucosamine hydrocloride
				Diacerin
260	NDD 645	Ibrutinih Tab. 140mg/Can	1	Description
362.	NRD-645	Ibrutinib Tab. 140mg/Cap.	2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	
			6	Contents of Packaged Dosage Forms
262		Indomethodin Tab /Con 75 and CD	7	Assay (by HPLC) Description
363.	NRD-646	Indomethacin Tab./Cap. 75 mg SR	2	Identification A (by HPLC)
			3	Average Weight
			4	Dissolution (by HPLC)
				1 st time point
				2 nd time point
			5	3 rd time point
			5	Uniformity of Weight Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
364.	NRD-648	Ivabradine Tab. 5mg	1	Description
501.		Truoradine Tuo. ong	2	Identification (by HPLC)
			3	Average Weight
			4	
			5	Uniformity of Content (by HPLC) Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
365.	NRD-649	Ivermectin 6 mg + Albendazole 400 mg	1	Description
505.		Trefficetin o hig + Thoenduzole 100 hig		Identification (by HPLC)
				Ivermectin
				Albendazole
			3	Average Weight Disintegration or Dissolution (by HPLC)
			4	Ivermectin/Albendazole
			5	Uniformity of Weight
			3	
			3	Unifromity of Content (by HPLC) Ivermectin 6
				Unifromity of Content (by HPLC) Ivermectin 6 mg
			6	Unifromity of Content (by HPLC) Ivermectin 6 mg Contents of Packaged Dosage Forms
				Unifromity of Content (by HPLC) Ivermectin 6 mg Contents of Packaged Dosage Forms Assay (by HPLC)
			6	Unifromity of Content (by HPLC) Ivermectin 6 mg Contents of Packaged Dosage Forms Assay (by HPLC) Ivermectin
			6 7	Unifromity of Content (by HPLC) Ivermectin 6 mg Contents of Packaged Dosage Forms Assay (by HPLC) Ivermectin Albendazole
366.	NRD-650	Ivermectin Tab. IP 6mg	6 7 	Unifromity of Content (by HPLC) Ivermectin 6 mg Contents of Packaged Dosage Forms Assay (by HPLC) Ivermectin Albendazole Description
366.	NRD-650	Ivermectin Tab. IP 6mg	6 7 1 2	Unifromity of Content (by HPLC) Ivermectin 6 mg Contents of Packaged Dosage Forms Assay (by HPLC) Ivermectin Albendazole Description Identification (by HPLC)
366.	NRD-650	Ivermectin Tab. IP 6mg	6 7 1 2 3	Unifromity of Content (by HPLC) Ivermectin 6 mg Contents of Packaged Dosage Forms Assay (by HPLC) Ivermectin Albendazole Description Identification (by HPLC) Average Weight
366.	NRD-650	Ivermectin Tab. IP 6mg	6 7 1 2	Unifromity of Content (by HPLC) Ivermectin 6 mg Contents of Packaged Dosage Forms Assay (by HPLC) Ivermectin Albendazole Description Identification (by HPLC) Average Weight Dissolution (by HPLC)
366.	NRD-650	Ivermectin Tab. IP 6mg	$ \begin{array}{c} 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \end{array} $	Unifromity of Content (by HPLC) Ivermectin 6 mg Contents of Packaged Dosage Forms Assay (by HPLC) Ivermectin Albendazole Description Identification (by HPLC) Average Weight Dissolution (by HPLC)
366.	NRD-650	Ivermectin Tab. IP 6mg		Unifromity of Content (by HPLC) Ivermectin 6 mg Contents of Packaged Dosage Forms Assay (by HPLC) Ivermectin Albendazole Description Identification (by HPLC) Average Weight Dissolution (by HPLC) Uniformity of Content (by HPLC) Limit of 8a-oxo-H2B1a Contents of Packaged Dosage Forms
			$ \begin{array}{c} $	Unifromity of Content (by HPLC) Ivermectin 6 mg Contents of Packaged Dosage Forms Assay (by HPLC) Ivermectin Albendazole Description Identification (by HPLC) Average Weight Dissolution (by HPLC) Uniformity of Content (by HPLC) Limit of 8a-oxo-H2B1a Contents of Packaged Dosage Forms Assay (by HPLC)
366. 367.	NRD-650 NRD-651	Ivermectin Tab. IP 6mg Ivermectin Tab. IP 12mg	6 7 1 2 3 4 5 6 7 8 8	Unifromity of Content (by HPLC) Ivermectin 6 mg Contents of Packaged Dosage Forms Assay (by HPLC) Ivermectin Albendazole Description Identification (by HPLC) Average Weight Dissolution (by HPLC) Uniformity of Content (by HPLC) Limit of 8a-oxo-H2B1a Contents of Packaged Dosage Forms Assay (by HPLC) Description
			$ \begin{array}{c} 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 1 \\ 2 \\ \end{array} $	Unifromity of Content (by HPLC) Ivermectin 6 mg Contents of Packaged Dosage Forms Assay (by HPLC) Ivermectin Albendazole Description Identification (by HPLC) Average Weight Dissolution (by HPLC) Uniformity of Content (by HPLC) Limit of 8a-oxo-H2B1a Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC)
			$ \begin{array}{c} 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 1 \\ 2 \\ 3 \\ \end{array} $	Unifromity of Content (by HPLC) Ivermectin 6 mg Contents of Packaged Dosage Forms Assay (by HPLC) Ivermectin Albendazole Description Identification (by HPLC) Average Weight Dissolution (by HPLC) Uniformity of Content (by HPLC) Limit of 8a-oxo-H2B1a Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Average Weight
			$ \begin{array}{c} 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 1 \\ 2 \\ \end{array} $	Unifromity of Content (by HPLC) Ivermectin 6 mg Contents of Packaged Dosage Forms Assay (by HPLC) Ivermectin Albendazole Description Identification (by HPLC) Average Weight Dissolution (by HPLC) Uniformity of Content (by HPLC) Limit of 8a-oxo-H2B1a Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Average Weight Dissolution (by HPLC)
			$ \begin{array}{c} 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 1 \\ 2 \\ 3 \\ 4 \\ \end{array} $	Unifromity of Content (by HPLC) Ivermectin 6 mg Contents of Packaged Dosage Forms Assay (by HPLC) Ivermectin Albendazole Description Identification (by HPLC) Average Weight Dissolution (by HPLC) Uniformity of Content (by HPLC) Limit of 8a-oxo-H2B1a Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Average Weight



			8	Assay (by HPLC)
368.	NRD-652	Ketoconazole Tab. IP 200 mg	1	Description
			2	Identification A (by TLC)
			3	Average weight
			4	Uniformity of weight
			5	Dissolution (by UV)
			6	Contents of Packaged Dosage Forms
			7	Assay: (by HPLC)
369.	NRD-653	Lacosamide Tab. BP 50 mg	1	Description
507.	1111D 055	Lacosannae 1 ab. Di 50 mg	2	Identification A (by UV)
			3	Identification B (by HPLC)
			5	Related substances (by HPLC)
			4	Average weight
			5	Uniformity of weight
			6	Dissolution (by HPLC)
			7	Contents of Packaged Dosage Forms
			-	
270			8	Assay: (by HPLC)
370.	NRD-654	Lamotrigine Dispersible 100MG Tab. IP	1	Description
			2	Identification (by HPLC)
			3	Average weight
			4	Uniformity Of Weight
			5	Dissolution (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	Assay: (by HPLC)
371.	NRD-655	Lapatinib Tab. IP 250mg	1	Description
			2	Identification (by HPLC)
			3	Average weight
			4	Uniformity Of Weight
			5	Dissolution (by HPLC)
			6	Related substances (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	Assay: (by HPLC)
372.	NRD-656	Lenalidomide Tab. 25mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4 5	Disintegration or Dissolution (by HPLC) Uniformity of Weight
			6	
			7	Assay (by HPLC)
373.	NRD-657	Lenalidomide Tab. 10 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
374.	NRD-658	Lenvatinib Tab. 4 mg	1	Description
			2	Identification (by HPLC) Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
375.	NRD-659	Lenvatinib Tab. 10 mg	1	Description Identification (by HPLC)
			3	
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	8 8
276			7	Assay (by HPLC)
376.	NRD-660	Levetiracetam Tab. IP 250 mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by HPLC)
			4	Average weight
			5	Uniformity Of Weight



			-	
			6	Dissolution (by HPLC)
			7	Related substances (by HPLC)
			8	Contents of Packaged Dosage Forms
			9	Assay: (by HPLC)
377.	NRD-662	Levodopa+Carbidopa+Entacapone	1	Description
		100mg/25mg/200mg Tab.	2	Identification (by HPLC)
				Levodopa
				Carbidopa Entacapone
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
				Levodopa/Carbidopa/Entacapone
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC) Tramadol
				Paracetamol
				Entacapone
378.	NRD-663	Levofloxacin Tab. IP 750 mg	1	Description
			2	Identification (by HPLC)
			3	Average weight
			4	Uniformity of weight
			5	Related substances (by HPLC)
			6	Dissolution (by UV)
			7	Contents of Packaged Dosage Forms
			8	Assay: (by HPLC)
			9	Identification of colours
379.	NRD-665	Levothyroxine Sodium Tab. IP 25 mcg	1	Description
517.	11112 005	Levotnyroxine Sourdin 140. If 25 meg	2	Identification A
			3	Identification B (by HPLC)
			4	Average weight
			-	Uniformity of content (by HPLC)
			5	
			6	Contents of Packaged Dosage Forms
			7	Disintegration time
			8	Assay: (by HPLC)
380.	NRD-666	Levothyroxine Sodium Tab. IP 75 mcg	1	Description
			2	Identification A
			3	Identification B (by HPLC)
			4	Average weight
			5	Uniformity of content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Disintegration time
			8	Assay: (by HPLC)
381.	NRD-668	Linaglipitin Tab. 5mg	1	Description
		0 F · ····0	2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC) Uniformity of Content (by HPLC)
			5	
			7	Assay (by HPLC)
382.	NRD-669	Lopinavir 200Mg+Ritonavir Tab. IP 50	1	Description
		mg	2	Identification (by HPLC)
				Lopinavir
			2	Ritonavir Average Weight
			3	Average Weight Dissolution (by HPLC)
				Lopinavir
				Ritonavir
			5	Uniformity of Weight
				Related substances (by HPLC)
			-	Water
			6	Contents of Packaged Dosage Forms Assay (by HPLC)
			/	Lopinavir
				Ritonavir
				Kitollavli



383.	NRD-670	Loratadine Tab. IP 10 mg	1	Description
			2	Identification (by IR)
			3	Average weight
			4	Impurity- H (by GLC)
			5	Uniformity of Content (by HPLC)
			6	Related substances (by HPLC)
			7	Disintegration Time
			8	Contents of Packaged Dosage Forms
			9	Assay: (by HPLC)
384.	NRD-671	Lorlatinib Tab. 25 mg	1	Description
		C C	2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC) Uniformity of Weight
			6	
			7	Assay (by HPLC)
385.	NRD-672	Lorlatinib Tab. 100 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	
			7	Assay (by HPLC)
386.	NRD-673	Megestrol Acetate Tab. IP 160 mg	1	Description
			2	Identification (by IR)
			3	Average weight
			4	Uniformity of Weight
			6	Disintegration Time
			7	Contents of Packaged Dosage Forms
			8	Assay: (by UV)
387.	NRD-674	Melatonin Tab. 3 mg	1	Description
00/1	11120 071		2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC) Uniformity of Content (by HPLC)
			5	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
388.	NRD-675	Melphalan Tab. IP 2mg	1	Description
			2	Identification A (by UV)
			3	Identification B (by Chemical)
			4	Average weight
			5	Uniformity of Content (by HPLC)
			6	Disintegration Time
			7	Contents of Packaged Dosage Forms
			8	Assay: (by HPLC)
389.	NRD-678	Methimazole Tab. USP 10mg	1	Description
507.	11110-070	Meaninazoic Fao. OSF Tonig	2	Identification (by IR)
			3	Average weight
				Uniformity of Content (by UV)
			4	Dissolution (by UV)
			5	Contents of Packaged Dosage Forms
			6	u u
		1	7	Assay: (by Chemical)
266				
390.	NRD-681	Methylphenidate Tab. 10 mg	1	Description Identification (by HPLC)
390.	NRD-681	Methylphenidate Tab. 10 mg CR/PR/SR/ER	$\frac{1}{2}$	Identification (by HPLC)
390.	NRD-681		$ \begin{array}{r} 1\\ 2\\ 3\\ 4 \end{array} $	
390.	NRD-681		3	Identification (by HPLC) Average Weight Dissolution (by HPLC) 1 st time point
390.	NRD-681		3	Identification (by HPLC) Average Weight Dissolution (by HPLC) 1 st time point 2 nd time point
390.	NRD-681		3 4	Identification (by HPLC) Average Weight Dissolution (by HPLC) 1 st time point 2 nd time point 3 rd time point
390.	NRD-681		3 4 5	Identification (by HPLC) Average Weight Dissolution (by HPLC) 1 st time point 2 nd time point 3 rd time point Uniformity of Weight
390.	NRD-681		3 4 5 6	Identification (by HPLC) Average Weight Dissolution (by HPLC) 1 st time point 2 nd time point 3 rd time point Uniformity of Weight Contents of Packaged Dosage Forms
		CR/PR/SR/ER	3 4 5 6 7	Identification (by HPLC) Average Weight Dissolution (by HPLC) 1 st time point 2 nd time point 3 rd time point Uniformity of Weight
390. 391.	NRD-681 NRD-682		3 4 5 6	Identification (by HPLC) Average Weight Dissolution (by HPLC) 1 st time point 2 nd time point 3 rd time point Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC)



	r	1		
			4	Average weight
			5	Uniformity of Content (by HPLC)
			6	Related substances (by HPLC)
			7	Dissolution (by UV)
			8	Contents of Packaged Dosage Forms
			9	Assay: (by HPLC)
392.	NRD-683	Methylprednisolone Tab. IP 16mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by TLC)
			4	Average weight
			5	Uniformity of Weight
			6	Related substances (by HPLC)
			7	Dissolution (by UV)
			8	Contents of Packaged Dosage Forms
			9	Assay: (by HPLC)
393.	NRD-684	Methylprednisolone Tab. IP 8mg	1	Description
393.	NKD-064	Methylprednisolone 1ab. IF sling	2	Identification A (by IR)
				Identification B (by TLC)
			3	-
			4	Average weight
			5	Uniformity of Content (by HPLC)
			6	Related substances (by HPLC)
			7	Dissolution (by UV)
			8	Contents of Packaged Dosage Forms
			9	Assay: (by HPLC)
394.	NRD-686	Midostaurin Tab. 25 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
395.	NRD-687	Mirabegeron Tab. 25 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
396.	NRD-688	Mirabegeron Tab. 50 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
397.	NRD-689	Mirtazapine Tab. IP 7.5mg	1	Description
			2	Identification (by IR)
			3	Average weight
			4	Uniformity of Content (by HPLC)
			5	Related substances (by HPLC)
			6	Dissolution (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	Assay: (by HPLC)
398.	NRD-690	Mirtazapine Tab. IP 15mg	1	Description
590.	11110-070	Mintazapine rab. ir ronig	2	Identification (by IR)
				Average weight
			3	
			4	Uniformity of weight
			5	Related substances (by HPLC)
			6	Dissolution (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	Assay: (by HPLC)
	NIDD (02	Montelukast Tab. IP 4 mg	1	Description
399.	NRD-692	Montelukast 1 ab. 1r 4 mg	1	Identification (by HPLC)



			3	Average weight
			4	Uniformity of content (by HPLC)
			5	Related substances (by HPLC)
			6	Dissolution (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	Assay: (by HPLC)
400.	NRD-693	Montelukast Tab. IP 5 mg	1	Description
	1112 070		2	Identification (by HPLC)
			3	Average weight
			4	Uniformity of content (by HPLC)
				Related substances (by HPLC)
			5	
			6	Dissolution (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	Assay: (by HPLC)
401.	NRD-694	Montelukast Tab. IP 10 mg	1	Description
			2	Identification (by HPLC)
			3	Average weight
			4	Uniformity of content (by HPLC)
			5	Related substances (by HPLC)
			6	Dissolution (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	Assay: (by HPLC)
402.	NRD-695	Morphine Tab. IP 10mg	1	Description
402.	NKD-095	Morphine 1ab. IF Tollig	2	Identification A (by Chemical)
				Identification B (by Chemical)
			3	-
			4	Identification C (by Chemical)
			5	Average weight
			6	Uniformity of content (by HPLC)
			7	Related substances (by HPLC)
			8	Dissolution (by HPLC)
			9	Contents of Packaged Dosage Forms
			10	Assay: (by Chemical)
403.	NRD-696	Morphine Tab. IP 30mg	1	Description
			2	Identification A (by Chemical)
			3	Identification B (by Chemical)
			4	Identification C (by Chemical)
			5	Average weight
			6	Uniformity of weight
			7	Related substances (by HPLC)
				Dissolution (by HPLC)
			8	Contents of Packaged Dosage Forms
			9	
			10	Assay: (by Chemical)
404.	NRD-697	Moxifloxacin Tab. BP 400 Mg	1	Description
			2	Identification A (by TLC)
			3	Identification B (by HPLC)
			4	Related substances (by HPLC)
			5	Average weight
			6	Uniformity of weight
			7	Dissolution (by UV)
			8	Contents of Packaged Dosage Forms
			9	Impurity
			10	Assay: (by HPLC)
405	NRD-698	Moyoniding Tab. PD 0.2 mg		Description
////	INKD-098	Moxonidine Tab. BP 0.2 mg	1	Identification A (by TCL)
405.			2	-
405.				
405.			3	Identification B (by HPLC)
405.			4	Average weight
405.				Average weight Uniformity of Content (by HPLC)
405.			4	Average weight



		1		
			8	Assay: (by HPLC)
406.	NRD-699	Moxonidine Tab. BP 0.3 mg	1	Description
			2	Identification A (by TCL)
			3	Identification B (by HPLC)
			4	Average weight
			5	Uniformity of Content (by HPLC)
			6	Dissolution (by HPLC)
			7	Contents of Packaged Dosage Forms
			8	Assay: (by HPLC)
407.	NRD-700	N-Acetylecystine effervescent form,	1	Description
		orange flavour, 600 mg Tab.	2	Identification (by HPLC)
			3	
			4	Disintegration Time Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
408.	NRD-701	Naltrexone Tab. IP 50 mg	1	Description
			2	Identification (by HPLC)
			3	Average weight
			4	Uniformity of Weight
			5	Dissolution (by HPLC)
			6	Contents of Packaged Dosage Forms
				Assay: (by HPLC)
400	NDD 702		7	
409.	NRD-702	Nebivolol Tab. IP 5mg	1	Description
			2	Identification (by HPLC)
			3	Average weight
			4	Uniformity of content (by HPLC)
			5	Dissolution (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay: (by HPLC)
410.	NRD-703	Nebivolol Tab. IP 10mg	1	Description
			2	Identification (by HPLC)
			3	Average weight
			4	Uniformity of content (by HPLC)
			5	Dissolution (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay: (by HPLC)
411.	NRD-704	Nicorandil Tab. IP 5mg	1	Description
711.	1111D-704	Nicolandii 1 ao. Il Shig	2	Identification A (by HPLC)
			3	Average weight
			-	Uniformity of content (by HPLC)
			4	Dissolution (by HPLC)
			5	
			6	Contents of Packaged Dosage Forms
			7	Assay: (by HPLC)
412.	NRD-705	Nicoumalone Tab. IP 1 Mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by UV)
			4	Identification C (Chemical)
			5	Average weight
			6	Related substances (by TLC)
			7	Uniformity of content (by UV)
			8	Disintegration Time
			9	Contents of Packaged Dosage Forms
			10	Assay: (by UV)
413.	NRD-706	Nicoumalone Tab. IP 3 Mg	10	Description
<i>ч</i> 1 <i>3</i> .	11110-700	Theorematione 1 ab. II 5 141g	2	Identification A (by IR)
			-	Identification B (by UV)
			3	Identification B (by UV)
			4	
			5	Average weight Related substances (by TLC)



				1
			7	Uniformity of content (by UV)
			8	Disintegration Time
			9	Contents of Packaged Dosage Forms
			10	Assay: (by UV)
414.	NRD-707	Nicoumalone Tab. IP 4 Mg	1	Description
		C	2	Identification A (by IR)
			3	Identification B (by UV)
			4	Identification C (Chemical)
				Average weight
			5	
			6	Related substances (by TLC)
			7	Uniformity of content (by UV)
			8	Disintegration Time
			9	Contents of Packaged Dosage Forms
			10	Assay: (by UV)
415.	NRD-708	Nifidipine Cap. IP 10mg	1	Description
			2	Identification (by TLC)
			3	Average Weight
			4	Dissolution (by UV)
			5	Related substances (by HPLC)
			6	Uniformity of content (by UV)
			7	Contents of Packaged Dosage Forms Assay (by UV)
416.	NRD-709	Nifidipine Tab. Prolonged Release IP	1	Description
H 10.	1110-707	20mg	2	Identification (by TLC)
		2011g	3	Average Weight
			4	Dissolution (by UV)
				0.1M HCL
				Phosphate buffer
			5	
			6	Uniformity of Weight Contents of Packaged Dosage Forms
			7	Assay (by UV)
417.	NRD-710	Nilotinib Tab./Cap. 150 mg	1	Description
417.	NRD-/10	Nilotino Tao./Cap. 150 liig	2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
418.	NRD-711	Nilotinib Tab./Cap. 200 mg	1	Description
			2	Identification (by HPLC) Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
419.	NRD-712	Nilotinib Tab. 300mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4 5	Disintegration or Dissolution (by HPLC) Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
420.	NRD-713	Nitazoxanide Tab. 500mg	1	Description
120.	1110 /13	Thuzonaniae Tub. Soonig	2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	
			6	Contents of Packaged Dosage Forms
401	NDD 714	Nitro-on Tal. ID Succession	7	Assay (by HPLC) Description
421.	NRD-714	Nitrazepam Tab. IP 5mg	2	Identification A (by UV)
			3	
			4	Average Weight
			5	Dissolution (by UV)
			6	Related substances (by TLC)
			7	Uniformity of Content (by UV)
			8	Contents of Packaged Dosage Forms
422.	NRD-715	Nitrazepam Tab. IP 10 mg		



			2	Identification A (by UV)
			3	Identification B (by TLC)
			4	Average Weight
			5	Dissolution (by UV) Related substances (by TLC)
			7	Uniformity of Content (by UV)
			8	Contents of Packaged Dosage Forms
			9	Assay (by HPLC)
423.	NRD-716	Olaparib Tab. 100 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	
			6	Contents of Packaged Dosage Forms Assay (by HPLC)
424.	NRD-717	Olaparib Tab. 150 mg	1	Description
424.	INKD-/1/	Olapario Tao. 150 llig	2	Identification (by HPLC)
			3	
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	
			7	Assay (by HPLC)
425.	NRD-718	Olmesartan medoxomil Tab. IP 20mg	1	Description
			2	Identification A (by HPLC)
			4 5	Average Weight Dissolution (by HPLC)
			6	
			7	Uniformity of Weight
			8	
			9	Assay (by HPLC)
426.	NRD-720	Osimertinib Tab. 80 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4 5	Disintegration or Dissolution (by HPLC) Uniformity of Weight
			6	
			7	Assay (by HPLC)
427.	NRD-721	Oxcarbazepine Tab. IP 300MG	1	Description
727.	100 721	Oxearbazephie 140. If 500MG	2	Identification A (by HPLC)
			3	Identification B (by UV)
			4	Average Weight
			5	Dissolution (by UV)
			6	Related substances (by HPLC)
			7	Uniformity of Weight Contents of Packaged Dosage Forms
			9	Assay (by HPLC)
428.	NRD-722	Oxcarbazepine Tab. IP 450MG	1	Description
720.	1111D-722	Oxearbazepine 1ab. ir 450MB	2	Identification A (by HPLC)
			3	Identification B (by UV)
			4	Average Weight
			5	Dissolution (by UV)
			6	
			7	Uniformity of Weight
			8	Contents of Packaged Dosage Forms
420	NDD 702	Overanem Teh. ID 15mg	9	Assay (by HPLC) Description
429.	NRD-723	Oxazepam Tab. IP 15mg	2	Identification A (by IR)
				Identification B (by UV)
			3	Average Weight
			4	
			5	Related substances (by HPLC)
			6	Uniformity of Weight
			7	Contents of Packaged Dosage Forms
100	100 222		8	Assay (by UV)
430.	NRD-725	Pantoprazole Gastro-resistant Tab. IP	1	Description Identification A (by HPLC)
		20mg	2	Identification A (by HPLC) Identification B (by UV)
			4	Average Weight
			5	Dissolution (by HPLC)
				· · · · · · · · · · · · · · · · · · ·
				in 0.1 M HCL
				in 0.1 M HCL in tri-acetate buffer solution
			6 7	



			8	Assay (by HPLC)
431.	NRD-726	Paracetomol Tab. IP 650 mg	1	Description
			2	
			3	Identification B (by Chemical) Average Weight
				Dissolution (by UV)
			6	
			7	Uniformity of Weight
			8	
			9	
32.	NRD-727	Paroxetine Control Release/Prolonged	1	Description
		Release Tab. IP 12.5mg	2	Identification A (by HPLC)
		Release Fust in 12.5mg	3	
			4	
				1 st time point
				2 nd time point
			5	3 rd time point
			5	Related substances (by HPLC) Uniformity of Weight
			7	
			8	
33.	NRD-728	Paroxetine Control Release/Prolonged	1	Description
55.	NKD-720		2	
		Release Tab. IP 25mg	3	
			4	
				1 st time point
				2 nd time point
				3 rd time point
			5	Related substances (by HPLC)
				Uniformity of Weight
			7	
			8	
34.	NRD-729	Pazopanib Tab./Cap. 200mg	1	Description
			2	
			4	5
			5	
			6	
			7	
35.	NRD-730	Pazopanib Tab./Cap. 400mg	1	Description
55.	11112 750	r azopanio rao., cap. roonig	2	
			3	
			4	
			5	
			6	
			7	Assay (by HPLC)
36.	NRD-732	Pentoxifylline Extended Release/SR Tab.	1	Description
		IP 400mg	2	Identification A (by IR)
			4	Identification B (by HPLC) Average Weight
			5	Dissolution (by HPLC)
			5	1 st time point
				2 nd time point
				3 rd time point
			6	Chromatographic Purity (by HPLC)
			7	Uniformity of Weight
			8	Contents of Packaged Dosage Forms
			9	Assay (by HPLC)
37.	NRD-733	Perampanel Tab. 2 mg	1	Description
			2	
			3	
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6 7	Contents of Packaged Dosage Forms Assay (by HPLC)
20	NRD-734	Derempenal Tab. Ama	1	Description
38.	INKD-/34	Perampanel Tab. 4mg	2	Identification (by HPLC)
			3	
			4	
			5	
			6	
	1		7	Assay (by HPLC)
			,	



			2	Identification A (by IR)
			3	Identification B (by UV)
			5	Identification C (by Chemical) Average Weight
				Disintegration Time
			7	Related substances (by TLC)
			8	Uniformity of Weight
			9	Contents of Packaged Dosage Forms
			10	Assay (by UV)
440.	NRD-737	Pirfenidone Tab. IP 200 mg	1	Description
		_	2	Identification A (by UV)
			3	Average Weight
				Disintegration Time
			6	Related substances (by HPLC) Uniformity of Weight
			7	Contents of Packaged Dosage Forms
			8	Assay (by UV)
441.	NRD-738	Pirfenidone Tab. IP 400 mg	1	Description
	11112 ,000		2	Identification A (by UV)
			3	Average Weight
			4	
			5	Related substances (by HPLC)
			6	
			7	Contents of Packaged Dosage Forms
442.	NRD-739	Direction DT 20mg Tab. ID	8	Assay (by UV) Description
442.	NKD-739	Piroxicam DT 20mg Tab. IP		-
			2	Identification A (by HPLC)
			4	Average weight
			6	Uniformity of weight
			7	Dissolution (by UV)
			8	Contents of Packaged Dosage Forms
			9	Assay: (by HPLC)
443.	NRD-740	Pomalidomide Tab. 2 mg	1	Description
тт.).	100^{-740}	Tomandonnide Tab. 2 mg	2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	
	NDD 741		7	Assay (by HPLC)
444.	NRD-741	Pomalidomide Tab. 4 mg	2	Description Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
445.	NRD-742	Posacozazole 100mg Tab.	1	Description
			2	Identification (by HPLC)
			3	Average Weight Disintegration or Dissolution (by HPLC)
			5	
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
446.	NRD-743	Posacozazole oral Syrup 40mg/ml	1	Description
			2	Identification (by HPLC)
			3	Water
			4	pH Stability of Suggestion (by UDLC) (if
			5	Stability of Suspension (by HPLC) (if formulation is in suspension form)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
			8	Identification of colour
			9	Microbial Examination
				Total aerobic count
				Total fungal count
				E. coli
447.	NRD-744	Prasugrel Tab. 10mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC) Contents of Packaged Dosage Forms
		1	6	L CONTENTS OF PACKAGED DOSAGE Forms



440	NDD 745 -	Drana sin Tah ID Saua	7	Assay (by HPLC) Description
448.	NRD-745 a	Prazosin Tab. IP 5mg		Identification A (by IR)
			2	-
			3	Average weight
			4	Uniformity of Content (by HPLC)
			5	Related substances (by TLC)
			6	Disintegration Time
			7	Contents of Packaged Dosage Forms
			8	Assay: (by HPLC)
449.	NRD-745 b	Prazosin Tab. 5mg ER/PR/CR	1	Description
			2	Identification (by HPLC) Average Weight
			4	Dissolution (by HPLC)
				1 st time point
				2 nd time point
				3 rd time point
			5	Uniformity of Weight Contents of Packaged Dosage Forms
			6	Assay (by HPLC)
450.	NRD-746	Prednisolone Tab. IP 40mg	1	Description
150.	11112 / 10	ricumbolone rub. n tonig	2	Identification A (by IR)
			3	Identification B (by TLC)
			4	Average weight
			5	Related substances (by HPLC)
			6	Uniformity of weight
				Dissolution (by UV)
			7	Contents of Packaged Dosage Forms
			8	
			9	Assay: (by HPLC)
451.	NRD-747	Primidone Tab. BP 50 mg	1	Description
			2	Identification A (by TLC)
			3	Identification B (by Chemical)
			4	2-Ethyl-2-phenylmalondiamide (by GLC)
			5	Average weight
			6	Uniformity of weight
			7	Disintegration Time
			8	Contents of Packaged Dosage Forms
			9	Assay: (by GLC)
452.	NRD-749	Prochlorperazine Tab. IP 5mg	1	Description
			2	Identification A (by IR)
			3	Identification B (by Chemical)
			4	Identification C (by Chemical)
			5	Average weight
			6	Uniformity of Content (by HPLC)
			7	Related substances (by HPLC)
			8	Dissolution (by UV)
			9	Contents of Packaged Dosage Forms
			10	Assay: (by UV)
453.	NRD-750	Desognatoral 0.075mg Tab	10	Description
433.	INKD-750	Desogesterol 0.075mg Tab.	2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms Assay (by HPLC)
454.	NRD-751	Propranolol Tab. IP 10mg	1	Description
434.	11110-731		2	Identification A (by IR)
				Identification B (by UV)
			3	
			4	Average weight
			5	Uniformity of Content (by HPLC)
			6	Related substances (by HPLC)
			7	Dissolution (by UV)
			8	Contents of Packaged Dosage Forms
			-	Assay: (by UV)



455.	NRD-752	Propranolol Cap. 40 mg SR IP	1	Description
455.	NKD-752	riopranoior Cap. 40 mg SK fr	2	Identification A (by UV)
			3	Identification B (by TLC)
			4	Average Weight
			5	Dissolution (by HPLC)
				1 st time point 2 nd time point
				3 rd time point
			6	Related substances (by HPLC)
			7	Uniformity of Weight
			8	Contents of Packaged Dosage Forms
			9	Assay (by UV)
456.	NRD-755	Ranolazine Tab. 500MG ER/PR/CR	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4 5	Disintegration or Dissolution (by HPLC) Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
457.	NRD-756	Rasagiline Tab. 1mg	1	Description
1071	111112 700	rusuginite rus. ring	2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
150	NDD 757	Description in Tab. DD 40 mag	7	Assay (by HPLC) Description
458.	NRD-757	Regorafenib Tab. BP 40 mg	1	*
			2	Identification A (by UV)
			3	Identification B (by HPLC)
			4	Impurity-A (by HPLC)
			5	Related substances (by HPLC)
			6	Average weight
			7	Uniformity of weight
			8	Dissolution (by UV)
			9	Contents of Packaged Dosage Forms
			10	Assay: (by HPLC)
459.	NRD-758	Repaglinamide Tab. 0.5mg	1	Description Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
460.	NRD-759	Repaglinamide Tab. 1mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC) Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
461.	NRD-760	Ribociclib Tab. 200 mg	1	Description
	1,112 /00		2	Identification (by HPLC)
	1		3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			4 5	Uniformity of Weight
			4 5 6	Uniformity of Weight Contents of Packaged Dosage Forms
462	NDD 7/1	Diferenciaio Tel ID 150	4 5 6 7	Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC)
462.	NRD-761	Rifampicin Tab. IP 150 mg	4 5 6 7 1	Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC) Description
462.	NRD-761	Rifampicin Tab. IP 150 mg	4 5 6 7 1 2	Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification A (by IR)
462.	NRD-761	Rifampicin Tab. IP 150 mg	4 5 6 7 1	Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification A (by IR) Identification B (by HPLC)
462.	NRD-761	Rifampicin Tab. IP 150 mg	$ \begin{array}{r} 4 \\ 5 \\ 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ \end{array} $	Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification A (by IR) Identification B (by HPLC) Average Weight Dissolution (by UV)
462.	NRD-761	Rifampicin Tab. IP 150 mg	$ \begin{array}{r} 4 \\ 5 \\ 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \end{array} $	Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification A (by IR) Identification B (by HPLC) Average Weight Dissolution (by UV) Related substances (by HPLC)
462.	NRD-761	Rifampicin Tab. IP 150 mg	$ \begin{array}{r} 4 \\ 5 \\ 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ \end{array} $	Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification A (by IR) Identification B (by HPLC) Average Weight Dissolution (by UV) Related substances (by HPLC) Uniformity of Weight
462.	NRD-761	Rifampicin Tab. IP 150 mg	$ \begin{array}{r} 4 \\ 5 \\ 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ \end{array} $	Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification A (by IR) Identification B (by HPLC) Average Weight Dissolution (by UV) Related substances (by HPLC) Uniformity of Weight Contents of Packaged Dosage Forms
			$ \begin{array}{r} 4 \\ 5 \\ 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ \end{array} $	Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification A (by IR) Identification B (by HPLC) Average Weight Dissolution (by UV) Related substances (by HPLC) Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC)
	NRD-761 NRD-762	Rifampicin Tab. IP 150 mg Rifampicin Tab. IP 450 mg	$ \begin{array}{r} 4 \\ 5 \\ 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 1 \\ \end{array} $	Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification A (by IR) Identification B (by HPLC) Average Weight Dissolution (by UV) Related substances (by HPLC) Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC) Description
			$ \begin{array}{r} 4 \\ 5 \\ 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 1 \\ 2 \end{array} $	Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification A (by IR) Identification B (by HPLC) Average Weight Dissolution (by UV) Related substances (by HPLC) Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification A (by IR)
462.			$ \begin{array}{r} 4 \\ 5 \\ 6 \\ 7 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 1 \\ \end{array} $	Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification A (by IR) Identification B (by HPLC) Average Weight Dissolution (by UV) Related substances (by HPLC) Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC) Description



				Deleted substance (4 UDLO)
			6	Related substances (by HPLC) Uniformity of Weight
			8	
			9	
464.	NRD-763	Rifampicin Tab. IP 600 mg	1	Description
			2	
			3	
			4	6 6
			5	
			7	Uniformity of Weight
			8	Contents of Packaged Dosage Forms
			9	
465.	NRD-764	Rifaximin Tab. BP 200mg	1	Description
			2	Identification (by UV)
			3	Related substances (by HPLC)
			4	Average weight
			5	Uniformity of weight
			6	Water
				Dissolution (by UV)
			7	
			8	Contents of Packaged Dosage Forms
			9	Impurity
			10	Assay: (by HPLC)
466.	NRD-765	Rifaximin Tab. BP 550mg	1	Description
			2	Identification (by UV)
			3	Related substances (by HPLC)
			4	Average weight
			5	Uniformity of weight
			6	Water
				Dissolution (by UV)
			7	
			8	Contents of Packaged Dosage Forms
			9	Impurity
			10	Assay: (by HPLC)
467.	NRD-766	Rivaroxaban Tab. BP 10mg	1	Description
			2	Identification A (by UV)
			3	Identification B (by HPLC)
			4	Related substances (by HPLC)
			5	Average weight
				Uniformity of weight
			7	Dissolution (by HPLC)
				Contents of Packaged Dosage Forms
			8	
			9	Impurity
			10	Assay: (by HPLC)
468.	NRD-767	Rivaroxaban Tab. BP 15mg	1	Description
			2	Identification A (by UV)
			3	Identification B (by HPLC)
			4	Related substances (by HPLC)
			5	Average weight
			6	Uniformity of weight
			7	Dissolution (by HPLC)
				Contents of Packaged Dosage Forms
			8	
			9	Impurity
			10	Assay: (by HPLC)
469.	NRD-768	Rivaroxaban Tab. BP 20mg	1	Description
		-	2	Identification A (by UV)
			3	Identification B (by HPLC)
			4	Related substances (by HPLC)
			5	Average weight
				Uniformity of weight
			6	Dissolution (by HPLC)
			7	
			8	Contents of Packaged Dosage Forms Impurity
			9	



		1	10	Assay: (by HPLC)
470.	NRD-769	Rizatriptan Tab. IP 10mg	10	Description
470.	INKD-/09	Kizaulptali 1 aŭ. Ir 10111g	3	Identification (by HPLC)
			4	Average Weight
			6	Dissolution (by UV)
			7	Related substances (by HPLC)
			8	Uniformity of Content (by HPLC)
			9	Contents of Packaged Dosage Forms
			10	Assay (by HPLC)
471.	NRD-770	Ropinirole Tab. IP 0.25mg	1	Description Identification (by HPLC)
			4	Average Weight
			6	
			7	Related substances (by HPLC)
			8	Uniformity of Content (by HPLC)
			9	Contents of Packaged Dosage Forms
			10	Assay (by HPLC)
472.	NRD-771	Rosuvastatin 10mg + Fenofibrate 160mg	1	Description
		Tab. IP	2	Identification (by HPLC)
				Rosuvastatin Fenofibrate
			3	Average Weight
			4	Dissolution (by HPLC)
				Rosuvastatin
				Fenofibrate
			5	
			6	
			7	Related substances (by HPLC)
			8	8 8
			9	Assay (by HPLC)
				Rosuvastatin
				Fenofibrate
473.	NRD-772	Ruxolitinib Tab./Cap. 5 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	
			6	8 8
477.4	NDD 774		7	Assay (by HPLC) Description
474.	NRD-774	Ruxolitinib Tab./Cap. 15 mg	2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
475.	NRD-775	Ruxolitinib Tab./Cap. 20 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4 5	Disintegration or Dissolution (by HPLC)
			6	Uniformity of Weight Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
476.	NRD-776	Selegiline Tab. IP 5mg	1	Description
ч/0.	$MD^{-1/0}$	Selegimie 1ao. II Jilig	2	Identification A (by IR)
			3	Identification B (by HPLC)
			4	Average Weight
			5	(S)-Selegiline (by HPLC)
			6	Disintegration Time
			7	Related substances (by HPLC)
			8	Uniformity of Content (by HPLC)
			9	Contents of Packaged Dosage Forms
477	NDD 777		10	Assay (by HPLC)
477.	NRD-777	Serratiopeptidase Tab. IP 10mg	1	Description Identification (by Chemical)
			3	Average Weight
			4	Disintegration Time
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by Chemical)
			-	
478.	NRD-778	Serratiopeptidase Tab. IP 20 mg	1	Description



			3	Average Weight
			4	Disintegration Time
			5	Uniformity of Weight
			6 7	Contents of Packaged Dosage Forms
479.	NRD-779	Saudaman Carbonata Tab. 800 ma	1	Assay (by Chemical) Description
479.	NKD-//9	Sevelamer Carbonate Tab. 800 mg	2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
480.	NRD-780	Sildosin 8mg + Dutasteride 0.5mg	1	Description
		Tab./Cap.	2	Identification (by HPLC)
		L		Sildosin
			2	Dutasteride
			3	Average Weight Disintegration or Dissolution (by HPLC)
			4	Sildosin /Dutasteride
			5	Uniformity of Content (by HPLC)
				Sildosin
				Dutasteride
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Sildosin
				Dutasteride
481.	NRD-782	Sitagliptine Tab. 50 mg + Metformin Tab.	1	Description
401.	11110-702		2	Identification (by HPLC)
		500mg		Sitagliptine
				Metformin
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
				Sitagliptine /Metformin
			5	Uniformity of Weight
			6	
			7	Assay (by HPLC)
				Sitagliptine
				Metformin
482.	NRD-783	Sildenafil Tab. IP 20 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Dissolution (by UV) Related substances (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
483.	NRD-784	Sofosbuvir 400 mg+ Velpatasvir 100 mg	1	Description
		Tab.	2	Identification (by HPLC)
		140.		Sofosbuvir
			-	Velpatasvir
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Sofosbuvir/Velpatasvir Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
			· ·	Sofosbuvir
				Velpatasvir
43.4				-
484.	NRD-785	Solifenacin succinate Tab. IP 10 mg	1	Description
			2	Identification (by HPLC) Average Weight
			4	Average weight Dissolution (by HPLC)
			4	Related substances (by HPLC)
			5	Uniformity of Content (by HPLC)
			5	
			6	Contents of Packaged Dosage Forms
			6 7	Contents of Packaged Dosage Forms Assay (by HPLC)
485	NRD-786	Sorafenib Tab. IP 200 mg		Contents of Packaged Dosage Forms Assay (by HPLC) Description
485.	NRD-786	Sorafenib Tab. IP 200 mg	7 1 2	Assay (by HPLC) Description Identification (by HPLC)
485.	NRD-786	Sorafenib Tab. IP 200 mg	$ \begin{array}{r} 7\\1\\2\\3\end{array} $	Assay (by HPLC) Description Identification (by HPLC) Average Weight
485.	NRD-786	Sorafenib Tab. IP 200 mg	7 1 2	Assay (by HPLC) Description Identification (by HPLC)



	1			
			5	Uniformity of Weight Contents of Packaged Dosage Forms
			6	Assay (by HPLC)
486.	NRD-788	Sunitinih Tah. 125 mg	1	Description
480.	INKD-788	Sunitinib Tab. 12.5 mg	2	Identification (by HPLC)
			3	
			4	
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
487.	NRD-789	Sunitinib Tab.25 mg	1	Description
		C	2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	
			6	5 5
100	NDD 700	G	7	Assay (by HPLC) Description
488.	NRD-790	Sunitinib Tab.50 mg	2	Identification (by HPLC)
			3	
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	
			7	Assay (by HPLC)
189.	NRD-791	Tacrolimus Tab./Cap. 1mg	1	Description
	10102 771	ruoronnus ruor cup: ning	2	Identification (by HPLC)
			3	Average Weight
			4	
			5	Uniformity of Content (by HPLC)
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
90.	NRD-792	Tamsulosin HCL 0.4mg + Dutasteride	1	Description
		0.5mg Tab./Cap.	2	Identification (by HPLC)
				Tamsulosin HCL
			3	Dutasteride Average Weight
			4	Disintegration or Dissolution (by HPLC)
			+	Tamsulosin HCL/Dutasteride
			5	Uniformity of Content (by HPLC)
			5	Tamsulosin HCL
				Dutasteride
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Tamsulosin HCL
				Dutasteride
101	NDD 702	Tananta dal Tab. 50ma	1	Description
491.	NRD-793	Tapentadol Tab. 50mg	2	Identification (by HPLC)
			3	Average Weight
			4	
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
192.	NRD-794	Tegafur 100mg + Uracil 224 mg Cap.	1	Description
			2	Identification (by HPLC)
				Tegafur
				Uracil
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			~	Tegafur/Uracil
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms Assay (by HPLC)
			/	Assay (by HPLC) Tegafur
				-
				Uracil
193.	NRD-795	Tenofovir Tab. 300mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	Contents of Packaged Dosage Forms
194.	NRD-796	Tetrabenazine Tab. 25mg	7	Assay (by HPLC) Description



Identification (by HPLC) Average Weight Disintegration or Dissoluti Uniformity of Weight Contents of Packaged Dos Assay (by HPLC) Description Identification A (by UV) Identification B (by HPLC) Related substances (by HF	
Disintegration or Dissoluti Uniformity of Weight Contents of Packaged Dos Assay (by HPLC) Description Identification A (by UV) Identification B (by HPLC) Related substances (by HPLC)	
Uniformity of Weight Contents of Packaged Dos Assay (by HPLC) Description Identification A (by UV) Identification B (by HPLC Related substances (by HP	
Contents of Packaged Dos Assay (by HPLC) Description Identification A (by UV) Identification B (by HPLC Related substances (by HP	age Forms
Assay (by HPLC) Description Identification A (by UV) Identification B (by HPLC) Related substances (by HPLC)	
Description Identification A (by UV) Identification B (by HPLC) Related substances (by HP	
Identification B (by HPLC Related substances (by HF	
Identification B (by HPLC Related substances (by HF	
Related substances (by HP)
	LC)
Average weight	
Uniformity of weight	
Dissolution (by UV)	
Contents of Packaged Dos	age Forms
Impurity	
Assay: (by HPLC)	
Description	
Identification (by HPLC)	
Average Weight	
Disintegration or Dissolution	
Uniformity of Content (by	
Contents of Packaged Dos	age Forms
Assay (by HPLC) Description	
Identification (by HPLC)	
Average Weight	
Disintegration or Dissoluti	on (by HPLC)
Uniformity of Weight	
Contents of Packaged Dos	age Forms
Assay (by HPLC)	
Description	
Identification A (by IR)	\ \
Identification B (by HPLC	.)
Average weight Related substances (by HF	DI C)
Uniformity of weight	LC)
Dissolution (by HPLC)	
Contents of Packaged Dos	age Forms
Assay: (by HPLC)	•
Description	
Identification (by HPLC)	
Average weight	
Related substances (by HF	LC)
-	20)
Contents of Packaged Dos	age Forms
Assay: (by HPLC)	
Description	
Identification (by HPLC)	
Tramadol	
	on (by HDLC)
	on (by th LC)
	age Forms
Assay (by HPLC)	
Tramadol	
Paracetamol	
1	
Average net content	
Disintegration or Dissoluti	on (by HPLC)
Trametinib	
Uniformity of Content (by	aga Earma
	age ronns
4 5 6 7	Tramadol Paracetamol 1 Description



			2	Identification A (by HPLC)
				Identification B (by Chemical)
			3	
			4	Dissolution (by HPLC) Uniformity of Weight
			7	
			8	
503.	NRD-805	Trimetazidine Modified release Tab.	1	Description
505.	NKD-803	CR/PR/SR 60mg		Identification (by HPLC)
		CR/PR/SR 60mg	3	
			4	
				1 st time point
				2 nd time point
				3 rd time point
			5	
			6	6 6
504		T	7	Assay (by HPLC) Description
504.	NRD-806	Trypsin 48mg + Rutoside 100mg	1	*
		+Bromelain 90mg tab.		Trypsin
				Rutoside
				Bromelain
			3	Average Weight
			4	0 0
				Trypsin/Rutoside/Bromelain
			5	
				Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
				Trypsin
				Rutoside
				Bromelain
505.	NRD-807	Truncin & Chymotringin Tab (Each	1	Description
505.	NKD-807	Trypsin & Chymotripsin Tab. (Each	2	Identification (by HPLC)
		enteric coated tab. Contains 1 lakhs unit of	2	Trypsin
		enzymetic activity)		Chymotripsin
			3	Average Weight
			4	
				Acidic medium
				Phosphate medium
			5	
			6	5 5
			7	Assay (by HPLC)
				Trypsin
				Chymotripsin
506.	NRD-808	Ulipristal Tab. 5mg	1	Description
			2	Identification (by HPLC)
			3	
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Content (by HPLC)
			6	5 5
507		Varianna la Tal. ID 200	7	Assay (by HPLC) Description
507.	NRD-809	Voriconazole Tab. IP 200 mg	2	Identification A (by HPLC)
			3	Average Weight
				in orașe morgine
			-	Dissolution (by HPLC)
			4	Dissolution (by HPLC) Related substances (by HPLC)
			4	Dissolution (by HPLC) Related substances (by HPLC) Uniformity of Weight
			4 5	Related substances (by HPLC)
			4 5 6	Related substances (by HPLC) Uniformity of Weight
508.	NRD-812	Vildagliptin Tab. IP 50mg	4 5 6 7 8 1	Related substances (by HPLC) Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC) Description
508.	NRD-812	Vildagliptin Tab. IP 50mg	$ \begin{array}{r} 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 1 \\ 2 \end{array} $	Related substances (by HPLC) Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC)
508.	NRD-812	Vildagliptin Tab. IP 50mg	$ \begin{array}{r} 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 1 \\ 2 \\ 3 \\ \end{array} $	Related substances (by HPLC) Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Average Weight
508.	NRD-812	Vildagliptin Tab. IP 50mg	$ \begin{array}{r} $	Related substances (by HPLC) Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Average Weight Dissolution (by HPLC)
508.	NRD-812	Vildagliptin Tab. IP 50mg	$ \begin{array}{r} 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ \end{array} $	Related substances (by HPLC) Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Average Weight Dissolution (by HPLC) Related substances (by HPLC)
508.	NRD-812	Vildagliptin Tab. IP 50mg	$ \begin{array}{r} 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ \end{array} $	Related substances (by HPLC) Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Average Weight Dissolution (by HPLC) Related substances (by HPLC) Uniformity of Weight
508.	NRD-812	Vildagliptin Tab. IP 50mg	$ \begin{array}{r} 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ \end{array} $	Related substances (by HPLC) Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Average Weight Dissolution (by HPLC) Related substances (by HPLC) Related substances (by HPLC) Uniformity of Weight Contents of Packaged Dosage Forms
			$ \begin{array}{r} 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ \end{array} $	Related substances (by HPLC) Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Average Weight Dissolution (by HPLC) Related substances (by HPLC) Related substances (by HPLC) Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC)
508.	NRD-812 NRD-813	Vildagliptin Tab. IP 50mg Voglibose Tab. IP 0.2 mg	$ \begin{array}{r} 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 $	Related substances (by HPLC) Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Average Weight Dissolution (by HPLC) Related substances (by HPLC) Related substances (by HPLC) Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC) Description
			$ \begin{array}{r} 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 1 \\ 2 \\ \end{array} $	Related substances (by HPLC) Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Average Weight Dissolution (by HPLC) Related substances (by HPLC) Related substances (by HPLC) Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC)
			$ \begin{array}{r} 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 $	Related substances (by HPLC) Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC) Description Identification (by HPLC) Average Weight Dissolution (by HPLC) Related substances (by HPLC) Related substances (by HPLC) Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC) Description



			6	Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
510.	NRD-814	Voglibose Tab. IP 0.3 mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4 5	Disintegration Time Uniformity of Content (by HPLC)
			6	
			7	Assay (by HPLC)
511.	NRD-815	Warfarin Tab. IP 1MG	1	Description
511.	1010 015		2	Identification A (by Chemical)
			3	Identification B (by Chemical)
			4	Average Weight
			5	
			6	
			7	Uniformity of Content (by HPLC)
			8	Contents of Packaged Dosage Forms Assay (by UV)
512.	NRD-816	Warfarin Tab. IP 2MG	9	Description
312.	NKD-810	wariarini Tab. IP 21MG	2	Identification A (by Chemical)
			3	Identification B (by Chemical)
			4	Average Weight
			5	Dissolution (by UV)
			6	Related substances (by TLC)
			7	Uniformity of Content (by HPLC)
			8	Contents of Packaged Dosage Forms
			9	Assay (by UV)
513.	NRD-817	Warfarin Tab. IP 3MG	1	Description
			2	Identification A (by Chemical)
			3	Identification B (by Chemical)
			4	Average Weight Dissolution (by UV)
			6	Related substances (by TLC)
			7	Uniformity of Content (by HPLC)
			8	Contents of Packaged Dosage Forms
			9	Assay (by UV)
514.	NRD-818	Zinc Tab. 50MG	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	8 8
515	NDD 010	7.1.1.1. T.1. ID 10	7	Assay (by HPLC) Description
515.	NRD-819	Zolpidem Tab. IP 10mg	2	Identification A (by IR)
			3	Identification B (by HPLC)
			4	Average Weight
			5	Dissolution (by HPLC)
			6	
			7	Uniformity of Content (by HPLC)
			8	Contents of Packaged Dosage Forms
			9	Assay (by HPLC)
516.	NRD-820	Zonisamide Tab. 50mg	1	Description
			2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			6	Uniformity of Weight Contents of Packaged Dosage Forms
			7	Assay (by HPLC)
517.	NRD-821	Zonisamide Tab. 100 mg	1	Description
517.	1110-021	Zomsannae rab. 100 mg	2	Identification (by HPLC)
			3	Average Weight
			4	Disintegration or Dissolution (by HPLC)
			5	Uniformity of Weight
			6	5 5
			7	Assay (by HPLC)
518.	NRD-822	Tiotropium 9mcg Inhalation	1	Description
			2	Identification (by HPLC)
			4	Average weight
			5	Content of Active Ingredient delivered per
				aen erea per
			5	actuation Uniformity of delivered dose



			8	Assay: (by HPLC)
			<u> </u>	Contents of Packaged Dosage Forms
			5	Related Substances (by HPLC) Dissolution (by UV)
524.				Uniformity)
			4	Uniformity of dosage Unit (Content
		Faropenem Sodium 200 mg)	2	Average weight
	713	Tab. Faropenem Sodium 200 mg (Each Film coated Tablet contains Faropenem Sodium equivalent to	1	Description Identification (by UV)
			8	Assay: (by HPLC)
			7	Contents of Packaged Dosage Forms
			5	
523.			4 5	Uniformity of weight Uniformity of Dispersion
			3	Average weight
			2	Identification (by TLC)
	709	Tab. Cefadroxil 250 mg	1	Description
			11	Sterility
				Tazobactum (by HPLC)
			10	Assay: Ceftriaxone (by HPLC)
			9	Bacterial endotoxins
			8	Particulate matter
			7	Clarity of solution test a and b
522.			6	Water
			4 5	pH
			3	Average net content Uniformity of weight
				Tazobactum (by HPLC)
				Ceftriaxone (by HPLC)
	,00		2	Identification of:
	708	Inj. Ceftriaxone 1 gm + Tazobactum 1.25 gm	1	Description
			6 7	Dissolution (by HPLC) Assay: (by HPLC)
			G	Contents of Packaged Dosage Forms
521.			5	
521.			4	Uniformity of dosage unit
			3	Average weight
	/04	contains Lacosamide 100 mg	2	
	704	Tab. Lacosamide 100 mg (Each Film Coated Tablet	7	Assay: (by HPLC) Description
			6	Contents of Packaged Dosage Forms
				Related Substances (by GC)
				4th stage
				3rd stage
520.				2nd stage
			5	1st stage
		200 mg/	4	Uniformity of weight Dissolution:
		Divalproex Sodium IP Equivalent to Valproic acid 250 mg)	3	
		Extended Release Film Coated Tablet contains	2	Identification (by HPLC)
	702	Tab Divalproex Extended Release IP 250 mg (Each	1	Description
			8	Assay: (by HPLC)
			7	Contents of Packaged Dosage Forms
			6	Uniformity of content (by UV)
			5	Uniformity of Dispersion
519.			4	Disintegration test
510			2	Identification (by HPLC) Average weight
	697	Tab. Ketorolac 10 mg, IP	1	Description
			12	Assay: (by HPLC)
			11	Contents of Packaged Dosage Forms
			10	deposition of the emitted dose
			9	leak test
			8	Number of deliveries per container
			7	Particle Size



	-			
			2	Identification A (by UV)
			3	Identification B (by HPLC)
			4	Uniformity of dosage Unit (Content
				Uniformity)
			5	Organic Impurities (By HPLC)
			6	
			7	Contents of Packaged Dosage Forms
			8	Assay: (by HPLC)
	738	Capsule Mycophenolate mofetil USP 250 mg (Each		Mycophenolate mofetil Capsules IP
		Capsule Contain Mycophenolate mofetil USP 250	1	Description
		mg)	2	Identification A (by HPLC)
			3	Identification B (by UV)
			4	Average net content
526.			6	Uniformity of weight
			7	Related substances (by HPLC)
			9	Dissolution (by HPLC)
			10	Water
			11	Contents of Packaged Dosage Forms
			12	Assay: (by HPLC)
	740	Tab. Mycophenolate Sodium 360 mg (Each Enteric	1	Description
		Coated tablet Contain Mycophenolate Sodium 360	2	Identification (by HPLC)
		mg)	3	Identification (by UV)
			4	Average weight
527.			5	Uniformity of content (by HPLC)
			6	Disintegration test /Dissolution (By UV
)
			9	Contents of Packaged Dosage Forms
			10	Assay: (by HPLC)
	NE25	Moxifloxacin Tablets 400mg	1	Description
			2	Identification A (by TLC)
				Identification B (by HPLC)
			3	Average weight
528.			4	Uniformity of weight
			5	
			6	Contents of Packaged Dosage Forms
			7	Related substances (by HPLC)
			8	Assay: (by UV)

Note:- Tablet /Capsules/Solution/Suspension/Syrup are different dosage forms and Testing Parameters may vary as per their Dosage form.



ANNEXURE –VIII Ref: Clause no. 3 (p)

To fill up the remark column of the enclosed Performa to access the existing facilities of your laboratories

A - General requirements and premises

S.N.	Details of the requirement	Remark
1	For Laboratory management a qualified individual known as quality manager	
	or technical manager is appointment.	
2	The Laboratory is designed, contracted and maintained to prevent entry of	
	insects and rodents besides cross contaminations;	
3	Interior surface (wall, floor, and ceilings) are smooth and free from cracks,	
	and permit easy cleaning and disinfection ;	
4	Adequate provision for space and equipment for carrying out necessary test is	
	provided & also unities like water, power and gas;	
5	Air ventilations system is provide to ensure dust free environments	
6	The laboratories provided with adequate lighting and ventilation, air	
	conditioning to maintain satisfactory temperature and relative humidity	
7	The faculties of drainage system and to prevent water logging in the	
	laboratory	
8	Tables tops is made of with acid, alkali and solvent resistant material	
9	Adequate space with proper storage conditions in the laboratory shall be	
	provided for keeping Reference and working standards	
10	The air circulation is maintained in the area where sterility test is carried out	
	as per Schedule M.	

B- Personal & Equipment

S.N.	Details of the requirement	Remark
1	Staff in the laboratory shall possess necessary qualification, proper training	
	and shall have Adequate, experience for the assigned duties.	
2	A training record of all the personal shall be maintained.	
3	Head of the laboratory must be high professional standing with experience in	
	drug analysis and laboratories management	
4	The analytical instrument shall be housed in the dust-free environment and	
	with controlled conditions of temperature and humidity	
5	A progress register for non functional equipments and action for procurement	
	of spares and accessories, monitoring there of, shall be maintained	
6	A standard operating procedure for preventive maintenance of machine or	
	equipment or apparatus shall be prepared by the laboratory	
7	Equipments such as burette, pipettes, volumetric flasks, weight boxes,	
	thermometers etc. shall be thoroughly checked for accuracy for calibration	
	before acceptance of use	
8	Equipments, instruments giving anomalous results or defective must be	
	labeled as out of order	
9	Autoclaves must meet the requirements described for operations, safety and	
	validation procedures	
10	Work involving the evolution of harmful and obnoxious vapors shall be	
	carried out in a fume cupboard	



Chemicals and Reagents, Good housekeeping and safety

S.N.	Details of the requirement	Remark
1	All reagents and solutions in the laboratory shall be property identified with a	
	label.	
2	A standardization register shall be maintained, with its raw date and SOP for	
	preparation and standardization on stock solutions, standard solutions and	
	volumetric solutions.	
3	Containers of stock solutions and of standard solutions shall bear the details.	
4	The storage and handling of chemicals and reagents shall be done in a manner	
	considering the physicochemical properties substances and the hazard	
	involved in their use.	
5	General and specific written down instructions for safety shall be circulated to	
	each staff member.	
6	SOP for safety, house-keeping and loss prevention.	
7	Drinking, eating and smoking shall not be permitted in the laboratories.	
8	Staff must wear laboratory coats or other protective clothing including gloves	
	and face masks and eye protection wherever required	
9	The laboratories shall have adequate firs aid kit and fire fighting equipments.	
10	Operators carrying out sterility tests shall wear sterilized garments including	
	headgear, face masks and shoes.	
11	The staff must be educated in the first aid techniques, emergency care and use	
	of antidotes.	
12	Safety rules in handling cylinders of compressed gases must be observed and	
	staff must be familiar with relevant colors identification codes ;	
13	Protective Precautions -	
	1- water showered	
	2- Rubber suction bulbs must be used on manual and siphons;	
	3- Warnings, precautions and written Instructions violent, uncontrollable or	
	reactions.	
	4- Appropriate facilities for the collection, storage and disposal of wasters.	
	5- Safe disposal of corrosive or dangerous products by neutralization or	
	deactivation.	
	6- Safety precautions to be adopted while handling potassium cyanide and	
	bromide ;	
	7- SOP for handing, collection, disposal of chemical and biological wastes.	

Maintenance, calibration, and validation of equipment & Reference materials : Microbiological Cultures :

	Details of the requirement	Remark
S.N.		
1	All equipments, instruments and other devices used in the laboratory shall use appropriate methods and procedures for all tests or calibrations and they shall be regularly Calibrated and validated.	
2	For most of the equipments and instruments, SOP for calibration and calibration schedule be the laboratory and a logbook shall also be prepared by each laboratory for proper documentation of calibrations results.	



-		
3	Reference material shall be traceable to agency authorized by Government of	
	India or any other International body.	
4	The laboratory shall prepare working standard by comparing with the	
	reference standards and shall be routinely checked for their purity.	
5	Whenever, any new reference material is received by the laboratory following	
	details are to be written -	
	a- Source of supply;	
	b- Code number of the reference material;	
	c- Date of receipt ;	
	d- Batch number or identification number of the supplying agency ;	
	e- Details like assay value, water content or information provided ;	
	f- Storage condition of the material;	
	g- Date of expiry, if any and date of manufacturing if possible.	
6	SOP for maintenance of microbial culture and sub-culture must be prepared	
	by the laboratories ;	

Quality system : & internal quality audits, management review :

S.N.	Details of the requirement	Remark
1	The measurements and calibrations shall fully conform to the compendia	
	requirements and the method demonstrably based on validation protocols are	
	followed.	
2	Remedial action o the observations by internal and external audits are taken	
	appropriately	
3	Documented quality policy for the organization.	
4	Internal audits are done to assure the integrity of the analysis ad such audits	
	shall be conducted periodically	
5	Each activity is audited at least once in a year.	
6	The quality manager shall maintain all the records of the analysis being	
	conducted which includes test system, the type of analysis , date on which	
	analysis is done	
7	Review yearly	
	1- Report or input	
	2- Matter arising from previous reviews ;	
	3- Report of external audits, if any ;	
	4- Surveillance report, if any ;	
	5- Result of proficiency testing ;	
	6- Complaints or feedback received from users	
	7- Details of in-house quality control checks ;	
	8- Need of amendment of the quality system and documentation ;	
	9- Introduction training of new staff.	

Standard operating Procedures

S.N.	Details of the requirement	Remark
1	Shall be written in a chronological order listing different steps leading to an	
	analysis of drugs or calibration of an instruments ;	
2	Shall have SOP manuals and have periodic Review.	
3	Standard Operation Procedures for the followings are required	
	(i) Sample handling and accountability;	
	(ii) Receipt identification, storage, mixing and method sampling of the test	



S.N.	Details of the requirement	Remark
	and control articles ;	
	(iii) Record keeping, reporting, storage and retrieval of data;	
	(iv) Coding of different studies, handling of data including use of	
	computerized data system :	
	(v) Operation of technical audit personnel in performing and reporting audits,	
	inspections and final report reviews;	
	(vi) Routing inspection of cleaning maintenance, testing, calibration and	
	standardization of instruments;	
	(vii) Action to be taken in respect of equipment failure ;	
	(viii) Analytical data methods	
	(ix) Health and safety protection ;	
	(x) Date handling and storage retrieval ;	
	(xi) Health and safety protection ;	
	(xii) Animal room preparations ;	
	(xiii) Animal care ;	
	(xiv) Storage and maintenance of microbial cultures ;	
	(xv) Maintenance of sterility room (i.e. constant maintenance and monitoring	
	of Aseptic condition room);	
	(xvi) Use and storage of reference standards;	
	(xvii) Procurement of stores and equipment ;	
	(xviii) Monitoring of testing of samples ;	
	(xix) Method of retention of unexpended samples, their location, maintenance	
	and disposal ;	
	(xx) Document control ;	
	(xxi) Redressal of technical complaints ;	
	(xxii) House- keeping	
	(xxiii) Corrective and preventive action ;	
	(xxv) Calibration manual.	
	(xxvi) Training manual.	
4	Protocols and specification archive :-	
	List of all the pharmacopeias a file on patent and proprietary medicines (non-	
	Pharmacopeia) test methods to specification prepared and validated by the	
	manufacturer. The test methods shall be submitted to the concerned Drug	
	Control Authority.	
5	Raw data -	
	Date integrity and security shall be maintained Original entry must be saved	
	and the system shall trail for all data.	
6	Storage and archival;	
	The residual sample shall be retained in proper storage condition for a period	
	of one year after the final report.	
7	The laboratory must establish and maintain procedures for the identification	
	collection, indexing, retrieval, storage, maintenance, and Disposal of all	
	quality documents.	
8	All the raw date, documentation, SOP, protocols and final reports are the be	
2	retained and there shall be archives of orderly storage and expeditious	
	retrieval of all raw data, documentation, protocols, interim and final report.	
9	The condition under which the original documents are stored must ensure	



S.N.	Details of the requirement	Remark
	their security and confidentiality.	
10	Raw data on thermal paper might fad away with time ; therefore, a photocopy	
	of the thermal paper shall be retained in the archive.	

Above mentioned information correct as per our record and if found incorrect, RMSC may take action against our firm and reject our bid.

Signature: Name of the Lab: Date: Official Seal:



ANNEXURE –IX Ref: Clause no. 9 (2)

AGREEMENT

This Deed of Agreement is made on thisday		
of 2022 by M/s represented by its		
Proprietor/ Managing partner /Managing Director having its laboratory Premises at		
(hereinafter referred to as "Service provider" which		
term shall include its successors, representatives, heirs, executors and administrators unless excluded		
by the Contract) on one part and Rajasthan Medical Services Corporation Ltd, represented by its		
Executive Director (P) having is office at Swasthya Bhawan, Tilak Marg, C-Scheme, Jaipur		
(hereinafter referred to as "The Purchaser" which term shall include its successors, representatives,		
executors assigns and administrator unless excluded by the Contract) on the other part.		

Whereas the Service provider has agreed to test the Drugs and Medicines for RMSC with specifications mentioned in the Schedule attached here to and mentioned at the prices noted there

in and in the manner and under the terms and conditions here in after mentioned and where as the Service provider with Purchaser sum has deposited the а of Rs (Rupees only) as Performance Security Deposit for the due and faithful performance of this Agreement, to be forfeited in the event of the Service provider failing duly and faithfully to perform it. Now these presents witness that for carrying duly and faithfully to perform it. Now these presents witness that for carrying out the said Agreement in this behalf into execution the Service provider and the Purchaser do hereby mutually covenant, declare, contract and agree each of them with the other of them in the manner following, that is to say.

The term "Agreement", wherever used in this connection, shall mean and include the terms and conditions including amendments contained in the invitation to tender floated for the Empanelment of Analytical Testing Laboratories for the test and Analysis of Drugs for Rajasthan Medical Services Corporation Ltd F.02(355)/RMSCL/ED (P) EMPANELMENT/DTL/NIB-12/2022/2277 Dated :- 27.07.2022, the instruction to Bidders, the conditions of Bid, acceptance of Bid, particulars hereinafter defined and those general and special conditions that may be added from time to time.

1. (a) The Agreement is for the test by the Service provider to the Purchaser of the testing of Drug and Medicines specified in the Schedule attached here to at process noted against each therein on the terms and conditions set forth in the Agreement.

(b) The Agreement with empanelled laboratories will remain valid up to 31.08.2024. This may be further extended for a further period of three months with mutual consent.

TERMINATION OF CONTRACT ON BREACH OF CONDITION

1. (a) In case the Service provider fails or neglects or refuse to faithfully perform any of the Covenants on his part herein contained, it shall be lawful for the Purchaser to forfeit the amount deposited by the Service provider as Performance Security and cancel the Contract.

(b) In case the Service provider fails, neglects, or refuse to observe, perform, fulfill and keep, all or any one or more or any part of any one of the Covenants, stipulation and provisions herein contained, it shall be lawful for the Purchaser on any such failure, neglect or refusal, to put an end to this Agreement and thereupon every article, cause and thing herein contained on the part of the Purchaser shall cease and be void, and in case of any damage, loss, expenses, difference in cost or other moneys from out of any moneys for the time being payable to the Service provider under this and/or any other Contract and in case such last mentioned moneys are insufficient to cover all such damages, losses, expenses, difference in cost and other moneys as aforesaid, it shall be lawful for the Purchaser to appropriate the Performance Security made by the Service provider as herein before mentioned to reimburse all such damages, losses, expenses, difference in cost and other sustained, incurred or been put to by reason of the Service provider having been guilty of any such failure, negligence or refusal as aforesaid or other breach in the performance of this Contract.



(c) If at any time during the course of the Contract, it is found that any information furnished by the Service provider to the Purchaser, either in his Tender or otherwise, is false, the Purchaser may put an end to the Contract/Agreement wholly or in part and thereupon the provisions of Clause (a) above shall apply.

2. The Purchaser reserves the right to terminate without assigning any reasons therefore the Contract/Agreement either wholly or in part without any notice to the Service provider. The Service provider will not be entitled for any compensation whatsoever in respect of such termination of the Contract/Agreement by the Purchaser.

NOTICE ETC, IN WRITING

3. All Certificates or Notice or orders for time or for extra, varied or altered supplies which are to be the subject of extra or varied charges whether so described in the Agreement or not, shall be in writing, and unless in writing, shall not be valid, binding or be of any effect whatsoever.

SERVICE PROVIDER NOT HAVE ANY INTEREST IN THE OFFICERS CONCERNED AND SUBORDINATES

4. The Service provider shall not be in any way interested in or concerned directly or indirectly with, any of the Officers, Subordinate or Servants of the Purchaser. In any trade, business or transactions nor shall the Service provider give or pay or promise to give or pay any such Officer, Subordinate or Servant directly or indirectly any money or fee or other consideration under designation of "Custom" or otherwise; nor shall the Service provider permit any person or persons whomsoever to interfere in the management or performance hereof under power of attorney or otherwise without the consent in writing the consent in writing of the Purchaser obtained in first hand.

BANKRUPTCY OF THE SERVICE PROVIDER

5. In case the Service provider at any time during the continuance of the Contract becomes bankrupt or insolvent or commits any act of bankruptcy or insolvency under the provisions of any law in that behalf for the time being in force, or should compound with his creditors, it shall be lawful for the Purchaser to put an end to the Agreement, and thereupon every article, clause and thing herein contained to be operative on the part of the Purchaser, shall cease and be void and the Purchaser shall have all the rights and remedies given to him under the preceding clauses.

SERVING OF NOTICE ON SERVICE PROVIDER

- 6. All notice or communication relating to or arising out of this Agreement or any of the terms thereof shall be considered duly served on or given to the Service provider if delivered to him or left at his premises, place of business or abode.
- 7. And it is hereby agreed and declared between the parties hereto that in case any question of dispute arises touching the construction or wording of any of clause herein contained on the rights, duties, liabilities of the parties hereto or any other way, touching or arising out of the presents, the decision of the Managing Director, Rajasthan Medical Services Corporation Ltd in the matter shall be final and binding.
- 8. All disputes arising out of this agreement and all questions relating to the interpretation of this agreement shall be decide by the Govt. and the decision of the Govt. shall be final.

SERVICER PROVIDER (Signature, Name & Full Address) Executive Director (Procurement), RAJASTHAN MEDICALSERVICES CORPORATION LTD.

Witness (Signature, Name & Full Address) 1.

2.